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ABSTRACT
TEMPORAL AND MOLECULAR INSIGHTS INTO THE PATHOPHYSIOLOGY OF CDKL5
DEFICIENCY DISORDER
Barbara Terzic
Zhaolan Zhou

CDKL5 deficiency disorder (CDD) is a severe, neurodevelopmental disorder associated
with lesions in the X-linked cyclin-dependent kinase-like 5 (CDKL5) gene. Despite the simple
genetic etiology of CDD its pathophysiology remains poorly understood, and the treatability of
specific CDD symptoms is untested. Using genetically modified mouse models of CDD, we
demonstrate that aberrant glutamatergic signaling through NMDA receptors underlies the
disrupted circuit hyperexcitability connected to several CDD-related deficits in mice. We also
temporally manipulated endogenous Cdkl5 expression, and find that post-developmental loss of
CDKL5 disrupts numerous behavioral domains, hippocampal circuit communication, and dendritic
spine morphology, demonstrating an indispensable role for CDKL5 in the adult brain. Accordingly,
adult restoration of Cdkl5 in knockout mice significantly ameliorates CDD-related behavioral
impairments and aberrant NMDA receptor signaling. These results demonstrate that adult neural
function requires CDKL5, and suggest chronic treatment may be required in CDD. Furthermore,
our results uncover a broad therapeutic time window for numerous CDD-related deficits, and
substantiate aberrant NMDA receptor signaling as underlying numerous CDD pathologies. These
discoveries expand upon our current understanding of CDKL5 in regulating neurological function,
and comprise a critical foundation for future studies aiming to develop therapeutics for CDD
patients, especially beyond the early developmental time window.
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CHAPTER 1 – INTRODUCTION

Overview
CDKL5 deficiency disorder (CDD) is a severe, childhood epileptic encephalopathy
associated with pathogenic variants in the X-linked cyclin-dependent kinase-like 5 (CDKL5)
gene(Fehr et al., 2013; Kalscheuer et al., 2003; Tao et al., 2004; Weaving et al., 2004). Currently,
CDD has a reported incidence of one in 40,000 to 50,000 live births, making it one of the most
common genetic causes of epilepsy in children(López-Rivera et al., 2020; H. E. Olson et al.,
2019). The majority of cases are heterozygous females who carry a constellation of debilitating
phenotypes including early-onset seizures, global neurodevelopmental delay, motor dysfunction,
intellectual disability, and several autonomic dysfunctions (e.g., feeding and gastrointestinal
problems, sleep disturbances, and breathing abnormalities)(H. E. Olson et al., 2019). Despite the
strong genetic link, the evolution of CDD pathophysiology and neurological impairments resulting
from disrupted CDKL5 function remain unclear.
Several animal models of CDD have been generated and characterized to date,
demonstrating a general overlap in phenotypic presentation and highlighting the importance of
CDKL5 in establishing proper brain development and neurological function(Amendola et al.,
2014; Okuda et al., 2018; I. T. Wang et al., 2012). Importantly, these animal models have also
provided an in vivo setting to discover and validate the molecular, cellular, and circuit disruptions
associated with loss of CDKL5 function. Despite this progress, the time course of CDD
pathogenesis, specific roles for CDKL5 in nervous system development versus maintenance, and
reversibility of CDD-related phenotypes remain undetermined. Thus, there remains a pressing
need to address these unknowns, and thereby support future examinations into CDKL5 function
as well as therapeutic efforts aimed towards treating CDD.
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The Genetics and Clinical Features of CDKL5 Deficiency Disorder
A history of the classification of CDKL5 Deficiency Disorder
CDKL5 Deficiency Disorder (CDD) only became recognized as an independent clinical
entity in 2013, however, clinical reports of patients presenting with an “atypical” pattern of Rett
syndrome date back as early as the 1980s(Fehr et al., 2013). In 1985, Dr. Folker Hanefeld
reported on a case in which a young girl presented with atypical infantile spasms in conjunction
with progressive Rett-like symptoms, now known to be characteristic of CDD(Hanefeld, 1985). As
early seizures are unusual in the evolution of Rett syndrome, and infantile spasms had yet to be
reported in these patients, this collection of phenotypes was hereafter referred to as the earlyonset-seizure, or “atypical,” variant of Rett syndrome. In 2003, Kalscheuer et al. reported an
association between lesions in the X-linked CDKL5 gene and severe infantile spasms coupled to
global neurodevelopmental delay(Kalscheuer et al., 2003). The two, severely affected, female
patients in this case report carried de novo X chromosome translocations, both of which disrupted
the (then named) serine-threonine kinase 9 gene, STK9 (since renamed CDKL5)(Montini et al.,
1998). The neurological impairments and infantile spasms presented by these two patients
carried characteristics of X-linked West syndrome, also referred to as X-linked infantile spasms
(ISSX), which presents with early-onset generalized seizures, hypsarrhythmia, and mental
retardation(Bienvenu, 2002). Thus, disruptions in STK9/CDKL5 were grouped with previouslyreported ARX mutations, and postulated to serve as a second X-chromosomal locus for
ISSX(Kalscheuer et al., 2003).
Independently, and shortly thereafter, Weaving et al. reported on two additional,
unrelated families carrying mutations in CDKL5 whose children (including one male) presented
with severe neurodevelopmental delay and infantile spasms(Weaving et al., 2004). This study,
published in 2004, also examined the CDKL5 locus within MECP2-mutation negative Rett
syndrome patients, and found an additional female patient reported to present with the earlyonset-seizure variant of Rett to carry a de novo CDKL5 splice-site mutation (CDKL5 IVS13-
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1GA). In this same 2004 issue of American Journal of Human Genetics, an independent clinical
report demonstrated further evidence linking de novo mutations in the CDKL5/STK9 gene to
early-onset infantile spasms, intellectual disability, and severe neurodevelopmental delay(Tao et
al., 2004). Although ~80% of Rett syndrome patients carry a mutation in the X-linked MECP2,
only ~20-40% of patients presenting with atypical Rett syndrome have reported MECP2
mutations. This study reported previously-unidentified CDKL5 mutations in several MECP2mutation negative atypical Rett syndrome patients, further linking lesions in CDKL5 to the atypical
clinical features associated with this subtype of Rett. Therefore, these early studies comprised a
seminal foundation for connecting lesions in CDKL5 to the etiology of this distinct constellation of
features characterized by early-onset seizures/infantile spasms, severe neurodevelopmental
delay, and autistic features. Although it would be another ten years before CDD became
classified as an independent clinical entity, distinct from Rett syndrome(Fehr et al., 2013).

Clinical presentations and phenotypic variations in CDKL5 Deficiency Disorder
The most updated reports of the clinical features of CDKL5 Deficiency Disorder (CDD)
currently classify it as a developmental encephalopathy(H. E. Olson et al., 2019). This class of
diseases share a common constellation of features beyond traditional autism spectrum disorders
or intellectual disability, most notably refractory epilepsy as well as motor and autonomic
dysfunctions(Paciorkowski, Seltzer, & Neul, 2018). The current incidence of reported pathogenic
variants in CDKL5 is one in 40,000 to 50,000 live births, making it only half as prevalent as
traditional Rett syndrome, and as an X-linked disorder CDD predominately afflicts young females
over males (~4:1)(López-Rivera et al., 2020; H. E. Olson et al., 2019).
One of the hallmark features of CDD, refractory epilepsy, significantly impacts patient and
family quality of life, with 80% of CDD patients presenting with daily seizures and fewer than half
reporting more than 2 months of sustained seizure freedom(Fehr et al., 2013; Fehr, Wong, et al.,
2016). Most families report a median age of onset at 6 weeks of age, with 90% of patients
developing seizures by three months of age. This severe, early-onset feature of CDD can also
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have profound impact on neurodevelopment and carries a high risk of behavioral and cognitive
comorbidities(Fehr et al., 2015; Fehr et al., 2013; Mangatt et al., 2016). Thus, seizure treatment in
CDD has been a central focus of recent therapeutic endeavors. The epilepsy of CDD typically
progresses in three stages across the first several years of life: 1) early-onset infantile spasms, 2)
epileptic encephalopathy with hypsarrhythmia, and finally 3) refractory multifocal and myoclonic
epilepsy. The evolving epilepsy phenotype in CDD appears to be mixed focal and generalized,
with spasms, tonic, and tonic-clonic seizures being the most common(Bahi-Buisson, Kaminska, et
al., 2008). The autonomic dysfunctions associated with CDD, such as irregular respirations and
apnea, can also arise during this time(H. E. Olson et al., 2019). Broad spectrum antiseizure
medications are most commonly prescribed including clobazam, valproate, topiramate,
levetiracetam, and vigabatrin in combination with a ketogenic diet(Fehr, Wong, et al., 2016; Muller
et al., 2016). Cannabidiol has been more recently explored with regards to the treatment of motor
seizure frequency, and is in phase 2 of clinical trials for use in CDD(Devinsky et al., 2018).
However, seizure management remains an issue for the majority patients, and the efficacy of
most therapies does not appear to extend beyond 12 months for most individuals(Muller et al.,
2016).
Unlike Rett syndrome, CDD patients do not typically carry a developmental regression,
and instead present with severe global developmental delays and intellectual disability(BahiBuisson, Nectoux, et al., 2008; Fehr et al., 2013; Liang et al., 2011; D. Mei et al., 2010; H.E.
Olson & Poduri, 2012). Only 22-23% of reported female patients can independently walk, and
26% of individuals could produce spoken language with only 7.5% speaking in sentences(Fehr,
Downs, et al., 2016; Fehr et al., 2015). However, microcephaly is only reported in fewer than 10%
of individuals(Fehr et al., 2013; H.E. Olson & Poduri, 2012). The cortical visual impairment
reported for CDD also limits the use of nonverbal communication and eye gaze(H. E. Olson et al.,
2019). Accordingly, although autistic features are commonly reported in CDD, a diagnosis of
autism spectrum disorder is infrequently provided given the significance of global developmental
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impairments(Bahi-Buisson, Nectoux, et al., 2008; Liang et al., 2011; D. Mei et al., 2010; Nemos et
al., 2009; H.E. Olson & Poduri, 2012).
Over 80% of CDD individuals also present with hand stereotypies such as selfstimulatory behavior as well as repetitive leg crossing, and hypotonia is a nearly universal feature
for most patients(Fehr et al., 2013; Fehr, Wong, et al., 2016; H. E. Olson et al., 2019),.
Gastrointestinal symptoms such as constipation, reflux, and air swallowing are reported in up to
86.5% of patients along with dysphagia, with only 5.3% able to eat and drink independently(Fehr
et al., 2013; Mangatt et al., 2016). Furthermore, sleep difficulties for CDD individuals are reported
by over 85% of parents often comorbid with breathing abnormalities and hyperventilation(Mangatt
et al., 2016).
Together, these clinical reports highlight a heterogeneous assortment of phenotypes,
including treatment-resistant epilepsy, autistic traits, and severe cognitive and motor
developmental delays, that can comprise CDD. However, significant phenotypic heterogeneity
has been reported, and growing efforts in diagnosis and variant mapping of CDD patients will
hopefully lead to better genotype-phenotype correlations(H. E. Olson et al., 2019). With further
clinical and preclinical studies, there is hope that future drug and therapy development will
ultimately provide more efficacious treatments for this devastating and debilitating disorder.

Genetic characteristics of CDKL5 Deficiency Disorder patients
CDD is associated with mutations, typically de novo, in the X-linked cyclin-dependent
kinase-like 5 (CDKL5) gene(Archer et al., 2006; Evans et al., 2005; Fehr et al., 2013; Kalscheuer
et al., 2003; H.E. Olson & Poduri, 2012). CDKL5 resides on the distal portion of the short arm of
the X chromosome (Xp22), and encodes a serine-threonine kinase of the same name,
CDKL5(Montini et al., 1998). Pathogenic missense variants mapped to date occur exclusively
within the catalytic domain of the protein, and deletion and truncating variants nearly universally
cause CDD(R.D. Hector et al., 2017). There have also been reports of patients carrying CDKL5
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duplications, which are typically associated with macrocephaly and learning disability without
epilepsy(Szafranski et al., 2015).
As mentioned, there is at times significant phenotypic heterogeneity amongst CDD
patients, however, genotype-phenotype correlations are limited. Individuals carrying early
truncating variants, compared with some pathogenic missense variants, appear to have a more
severe disorder(Bahi-Buisson et al., 2012; Fehr, Downs, et al., 2016; Fehr et al., 2015; Fehr,
Wong, et al., 2016). Being an X-linked disorder, some of the phenotypic heterogeneity observed
in CDD female patients may be due to variable X-chromosome inactivation (XCI), however, the
influence of somatic CDKL5 mosaicism on the clinical phenotype of CDD remains unknown(R.D.
Hector et al., 2017; H. E. Olson et al., 2019; Stosser et al., 2018). In the Weaving et al. clinical
reported discussed above, one female patient demonstrated slightly skewed XCI that favored
expression of the normal CDKL5 allele, however, the XCI pattern of blood leukocytes profiled in
this study may not accurately reflect XCI patterns in the brain(Weaving et al., 2004). In fact, the
same study reported twin sisters displaying similar XCI patterns in peripheral blood, yet
completely different clinical features. Furthermore, mosaic exon deletions and mosaic de novo
variants have been reported in both male and female CDD patients, and although their exact
incidence remains undetermined, they may be an underappreciated phenomenon in
CDD(Stosser et al., 2018).

Animal Models of CDKL5 Deficiency
In 2012, the first knockout mouse model of CDD was generated and found to recapitulate
several of the cardinal phenotypes of the human disease including learning and memory
impairments, motor deficits, and autistic-like behaviors but not overt seizures(I. T. Wang et al.,
2012). This line carries a deletion of Cdkl5 exon 6, mimicking a reported CDD patient splice site
mutation resulting in exon 6 skipping and loss of protein(Archer et al., 2006). The male mice
examined in this report exhibited normal growth, brain and body weight, and a lack of gross brain
pathology. Several additional knockout and knock-in lines have since been generated with
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behavioral assessments, despite a few discrepancies, highlighting a general overlap of
phenotype presentation across different Cdkl5 knockout models. These include three
independent Cdkl5 knockout lines (Cdkl5Δ4, Cdkl5Δ2, and Cdkl5STOP (first reported in this study;
Chapter 4)) as well as a knock-in line, Cdkl5R59X, modeling a reported patient nonsense mutation
resulting in early truncation and loss of CDKL5 protein(Amendola et al., 2014; Okuda et al., 2018;
Tang et al., 2019; Yennawar, White, & Jensen, 2019). A summary of the behavioral phenotypes
evaluated across various CDD mouse models is summarized in Table 1.
CDKL5 is expressed throughout various cell types in the heterologous brain highlighting
the importance of dissecting any cell type-specific and circuit-level network disruptions relevant to
CDD(Chen et al., 2010; Johnson et al., 2017; Rusconi et al., 2008; I. T. Wang et al., 2012; Zeisel
et al., 2015). There have accordingly been Cdkl5 conditional knockout studies wherein Cdkl5 was
ablated selectively from either forebrain glutamatergic (Nex-cKO) or forebrain GABAergic (DlxcKO; Chapter 2) neurons(Tang et al., 2019; Tang et al., 2017). These two studies, as discussed
further in Chapter 2 below, reflect a general segregation of Cdkl5 constitutive knockout
phenotypes with Nex-cKO mice selectively demonstrating impaired learning and memory
(reminiscent of the intellectual disability of CDD), and Dlx-cKO mice selectively demonstrating
autistic-like features. Prior to this work, Amendola et al. had also performed a conditional deletion
of Cdkl5 from forebrain glutamatergic neurons and glial cells (Emx1-cKO) versus GABAergic
(Dlx-cKO) neurons, but only evaluated general locomotion, finding a selective decrease in activity
in Dlx-cKO males(Amendola et al., 2014). Although the results of cell-type-specific loss of CDKL5
within different circuits and brain regions remain to be expanded upon, these data reveal that
distinct phenotypes in Cdkl5 knockout mouse models can be mapped to diverse forebrain
neuronal populations.
Interestingly, although early-onset epilepsy is one of the hallmark features of CDD, no
overt seizure phenotype or abnormal basal EEG pattern was reported in any of the hemizygous
knockout male mice observed in the above-mentioned studies. However, a recent finding by our
group suggests that spontaneous seizure activity in CDD mouse models is confined to aged,
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heterozygous knockout females (Chapter 5). This highlights X-linked mosaicism as a potential
driver for overt, spontaneous seizure activity and underscores why previous reports to date may
not have observed this phenotype. Further details on the EEG and network phenotypes reported
in Cdkl5-deficient animal models is discussed in the ‘Synaptic, Circuit, and Network Phenotypes
of CDKL5-Deficient Mice’ section below. Despite these multitude of behavioral and EEG
characterizations of various CDD mouse models, the endogenous function of CDKL5 and its role
in nervous system development, maintenance, and CDD pathogenesis remain undetermined.

Molecular Features and Signaling Pathways of the CDKL5 Protein
CDKL5 protein characteristics
The CDKL5 protein is serine-threonine kinase highly conserved among vertebrates,
carrying 99% identity within its 960 amino acids between mouse and human orthologues of
CDKL5(Montini et al., 1998). As mentioned, all pathogenic missense mutations appear to cluster
within the region of CDKL5 encoding the amino(N)-terminal kinase domain, suggesting that
disrupted kinase function likely underlies disease pathophysiology(R.D. Hector et al., 2017). The
CDKL5 kinase domain carries significant homology to those of the cyclin-dependent kinase
(CDK) and mitogen-activated protein (MAP) kinase families, however, it is distinct from these and
other cyclin-dependent kinase like (CDKL) family members in that it also possess a long, prolinerich carboxy(C)-terminal domain of about 700 amino acids(Canning et al., 2018; R. D. Hector et
al., 2016). Previous in vitro and heterologous cell line studies have suggested this C-terminal
domain to serve as a negative regulator of CDKL5 kinase activity as well as to affect protein subcellular localization(Bertani et al., 2006; Lin, Franco, & Rosner, 2005). In addition, the CDKL5
protein carries two predicted nuclear localization sequences (NLS) and a nuclear export
sequence (NES), suggesting that it may shuttle between the nuclear and cytoplasmic
compartments(Bertani et al., 2006; Rusconi et al., 2008). More recently, visualization of CDKL5 in
neuronal cultures as well as post-synaptic density fractionation from brain tissues has suggested
that CDKL5 is enriched at the post-synaptic density of neurons(Bayés et al., 2012; Reim et al.,
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2017; Ricciardi et al., 2012; Zhu et al., 2013). However, the in vivo relevance of these findings
has yet to be tested, and the limited availability of tools to visualize and tag the endogenous
CDKL5 make these results difficult to corroborate.

CDKL5 transcript isoforms and expression pattern
Analysis of the human and mouse CDKL5/Cdkl5 transcript sets has identified at least five
unique isoforms(R. D. Hector et al., 2016). hCDKL5_1/mCdkl5_1 is the predominant isoform in
the brains of humans and mice, respectively, with detectable levels in additional tissues
(particularly testis), albeit at significantly lower levels. Alternative CDKL5 mRNA isoforms
(hCDKL5_2-5; mCdkl5_2 & mCdkl5_6-8) arise from the inclusion of additional 3’ exons as well as
alternative splicing of exon 17, however, in mice, their expression pattern appears to be mostly
restricted to the testis. The human hCDKL5_2 (inclusion of exon 17) and hCDKL5_3 (alternative
splicing of exon 11) are also detectable in brain tissues, but are only predicted to constitute ~10%
of CDKL5 transcripts in brain(R. D. Hector et al., 2016). Therefore, the 960 amino acid protein
product of isoform 1 is thought to be the predominant product regulating neuronal function in both
mouse and human.
In rodents, the CDKL5 protein is most highly expressed in the central nervous system,
particularly within regions of the forebrain (e.g., cortex, striatum, amygdala, and
hippocampus)(Chen et al., 2010; Rusconi et al., 2008; I. T. Wang et al., 2012; Zeisel et al., 2015).
More recent findings have also demonstrated a role for CDKL5 within the peripheral nervous
system in the regulation of pain perception by sensory neurons of the dorsal root ganglia(Paolo
La Montanara et al., 2020). Our lab and others have also observed detectable, but significantly
lower, CDKL5 protein levels in additional tissues of mice such as lung, kidney, and testis(Lin et
al., 2005; Rusconi et al., 2008). Interestingly, a recent kinome-wide screen identified CDKL5 as a
critical regulator of a stress-response pathway in renal tubular epithelial cell death during acute
kidney injury, highlighting the potential importance of CDKL5 in additional tissues(Kim et al.,
2020). The role of CDKL5 and its various isoforms in additional tissues remains ripe for
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exploration, however, the remainder of this report will focus on its role in neurological function
with relation to CDD.
RNA-sequencing analysis of mouse embryonic brain tissue finds Cdkl5 transcripts
significantly detectable by embryonic day 15(Smith CM, 2019). This embryonic expression
pattern is supported by post-mortem, human brain transcriptome data reflecting a significant
expression of CDKL5 RNA within several brain regions by the second trimester of gestation(H. J.
Kang et al., 2011). Several groups have previously reported on the developmental expression
pattern of CDKL5 protein within the rodent brain, albeit with conflicting conclusions likely due to
the lack of a specific CDKL5 antibody. These reports range from suggesting the kinase to be
detectable in brain as early as embryonic day 7.5 to expression being restricted until the postnatal
period, and then usually peaking in expression during the critical period of synaptogenesis for
several brain regions in mice (i.e. postnatal day 10-14)(Lin et al., 2005; Rusconi et al., 2008; Zhu
et al., 2013). Despite slight embryonic discrepancies, our group and others have consistently
demonstrated that CDKL5 remains stably expressed throughout life in the forebrain of mice
(Chapter 3). These results ultimately motivated our exploration of the post-developmental role of
CDKL5 in neurological function (Chapter 3).

CDKL5 interacting proteins and signaling pathways
As mentioned above, CDKL5, unlike its family members CDKL1-4, is expressed
predominantly in post-mitotic neurons as opposed to dividing cells, likely conferring a distinct set
of signaling targets and pathways(Canning et al., 2018; Dubos, Pannetier, & Hanauer, 2008; He
et al., 2020; Li et al., 2014; Qin et al., 2017; Smith CM, 2019). To date, several in vitro and cell
culture studies have identified a variety of CDKL5 interacting proteins. Given the clinical overlap
between Rett syndrome and CDD, it was initially postulated that CDKL5 and MECP2 might
function within the same molecular pathway. In fact, it was shown in an in vitro kinase assay that
CDKL5 was capable of interacting with and phosphorylating MECP2(Mari et al., 2005). However,
this finding has yet to be replicated by other groups or in vivo, and more recent reports suggest
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the two proteins likely function within unique molecular signaling networks(Lin et al., 2005). Thus,
the clinical overlap between CDD and Rett syndrome may simply occur due to converging
disruptions at the cellular or network levels.
In line with the idea of a nuclear function for CDKL5, additional nuclear binding partners
and targets have been postulated, mainly identified via in vitro kinase assays or through work in
heterologous cell lines. These include the DNA methyltransferase 1 (DNMT1), as well as a role
for CDKL5 in regulating mRNA splicing activity via its association with the nuclear speckle
component SC35(Kameshita et al., 2008; Ricciardi et al., 2009). A more recent,
phosphoproteomic screen for direct CDKL5 substrates also highlighted proteins involved in the
DNA damage response, such as centrosomal protein 131 (CEP131)(Munoz et al., 2018). These
findings align with the increase in cell death and DNA damage-associated biomarkers reported
with CDKL5 deletion in mouse hippocampal cultures and human neuroblastoma (SH-SY5Y) cell
lines(Barbiero et al., 2017; Fuchs et al., 2019; Loi et al., 2020).
Additional hypotheses have focused on a synaptic role for CDKL5 within neurons. In rat
primary neuron cultures, knockdown of CDKL5 was found to disrupt neuronal morphogenesis and
neurite outgrowth upon BDNF-induced actin remodeling via its association with Rac1(Chen et al.,
2010). Similarly, two independent reports highlighted a role for CDKL5 in dendritic spine
morphology in cultured hippocampal neurons via its interaction with components of the
postsynaptic compartment such as phosphorylating netrin-G1 ligand (NGL-1) and co-localizing
with palmitoylated post synaptic density protein 95 (PSD-95)(Ricciardi et al., 2012; Zhu et al.,
2013). CDKL5 was also linked to the phosphorylation of amphiphysin 1 at the pre-synaptic
terminal, again, using an in vitro system(Katayama, Sueyoshi, & Kameshita, 2015; Sekiguchi et
al., 2013). Furthermore, a yeast two-hybrid screen identified an interaction of CDKL5 with
shootin1, a regulator of neuronal polarization during axon development(Nawaz et al., 2016).
Interestingly, a mind bomb 1 (Mib1) interactome screen that identified CDKL5 demonstrated that
CDKL5 is ubiquitinated by Mib1 and targeted for degradation by the proteasome(Mertz et al.,
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2015). The direct relevance of these synaptic and axonal targets in vivo has yet to be validated,
again likely due to the limitation of tools to visualize and tag the endogenous CDKL5.
More recently, a chemical-genetic approach was leveraged to identify direct CDKL5
kinase targets by harnessing an ATP analog-specific CDKL5 mutant in mouse brain tissue
lysates coupled with thiophosphopeptide-targeted mass spectrometry. This study reported that
CDKL5 directly phosphorylates peptides at the RPXS* motif that mapped to proteins associated
with the microtubule network of neurons(Lucas L. Baltussen et al., 2018). These targets included
the microtubule associated protein RP/EB family member 2 (MAPRE2/EB2), the microtubule
associated protein 1S (MAP1S), and Rho guanine nucleotide exchange factor 2 (ARHGEF2).
These results were corroborated by an independent group performing a global, TMT-based
phosphoproteomic screen for CDKL5 substrates. This second study confirm the enrichment of
CDKL5 phosphorylated proteins as involved in the actin cytoskeleton and microtubule-associated
proteins, including MAP1S(Munoz et al., 2018). Together, these findings highlight a novel,
activity‐dependent molecular pathway in dendritic microtubule regulation that may underlie the
pathology of CDD. These more recent results also align with some of the cellular and synaptic
phenotypes reported in CDKL5-deficient models (see ‘CDKL5 Loss-of-Function Cellular
Phenotypes’ section below). A summary of all reported CDKL5 interacting proteins and targets
identified to date is listed in Table 2.
Loss of CDKL5 was shown to disrupt signaling of the AKT-mammalian target of
rapamycin (mTOR) cascade within several brain region tissue lysates of the first Cdkl5 knockout
mouse (Cdkl5Δ6)(I. T. Wang et al., 2012). Similar findings were reported in whole brain extracts
of an independent knockout mouse line (Cdkl5Δ4) with reduced phosphorylation of AKT and
ribosomal protein S6 reflecting an overall disruption of neuronal growth/plasticity and protein
translation(Amendola et al., 2014). More specifically, altered AKT/GSK-3β signaling was also
reported within Cdkl5 knockout mouse hippocampal tissue, concomitant with a significant
reduction of dendritic arborization and length(Fuchs et al., 2014). However, the direct role of
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CDKL5 within the action of these pathways, as opposed to compensatory or non-specific
AKT/mTOR disruptions, has not been tested.

Cellular Phenotypes Resulting from CDKL5 Loss
At the cellular level, loss of CDKL5 has been reported to result in morphological deficits
such as reduced dendritic arborization and complexity as well as aberrant spine
morphology/stability in pyramidal neurons. In culture models, shRNA knockdown of CDKL5
impairs neurite outgrowth in rat primary hippocampal neurons, and several Cdkl5 knockout mice
have been reported to display reduced dendritic complexity in the hippocampus(Amendola et al.,
2014; Chen et al., 2010; Okuda et al., 2018; Tang et al., 2017). Our group recently demonstrated
little effect on dendritic morphology upon post-developmental deletion of CDKL5, bringing into
question the timing or specificity of this phenotype to CDKL5 loss. These results are discussed
further in Chapter 3.
The effects of CDKL5 loss on spine dynamics/stability, however, remain inconclusive.
Ricciardi et al. demonstrated that shRNA-mediated knockdown of CDKL5 in primary mouse
hippocampal neuron cultures leads to an increased density of filipodia-like, or immature, spine
protrusions that is corroborated by a decreased frequency of miniature excitatory postsynaptic
currents (mEPSCs), and this was recapitulated by Zhu et al. in 2013(Ricciardi et al., 2012; Zhu et
al., 2013). In line with these culture studies, Okuda et al. reported a significantly increased length
and density of spines on hippocampal pyramidal neurons of Cdkl5 knockout mice, and similarly,
conditional knockout of CDKL5 selectively from forebrain excitatory cells resulted in an increased
spine density and frequency of mEPSCs in this same region(Okuda et al., 2018; Tang et al.,
2017). However, additional studies have demonstrated that loss of CDKL5 in mice reduced
dendritic spine stability and density in somatosensory cortex and reduced excitatory synaptic
puncta markers in visual cortex(Della Sala et al., 2016; Pizzo et al., 2016). In the visual cortex,
loss of CDKL5 was associated with a decrease in excitatory puncta markers associated with
PSD-95 and Homer with a concomitant increase in parvalbumin-positive interneurons, suggestive
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of a disruptive synaptic organization within this region(Pizzo et al., 2016). Conflicting results on
these cellular phenotypes between groups is likely due to regional differences within the brain as
well as in vitro versus in vivo variability on circuit activity and spine dynamics. Furthermore, the in
vivo functional effects of these synaptic morphological abnormalities associated with CDKL5 loss
remain unresolved.
As mentioned, more recent molecular advances have begun to reveal a potential
mechanistic role for CDKL5 within the microtubule network of neurons, supporting the abovementioned morphological phenotypes. However, the in vivo relevance and cellular defects that
directly result from CDKL5-mediated disruption of microtubule dynamics remain poorly
understood. In particular, in vivo and genetic models such as knockout mice do not allow for a
mechanistic dissection of kinase roles in the brain that are direct versus a result of network and
developmental compensation.

Synaptic, Circuit, and Network Phenotypes of CDKL5-Deficient Mice
Synaptic phenotypes regulated by CDKL5
As highlighted above, several studies to date in both knockout mouse models and
knockdown cell culture systems have demonstrated an altered synaptic density and morphology
with loss of CDKL5. In hippocampal primary neurons and in vivo, CDKL5 knockout appears to
lead to an increased proportion of thin, filipodia-like, or morphologically immature, dendritic
spines(Della Sala et al., 2016; Ricciardi et al., 2012; Zhu et al., 2013). These have been
supported by a decreased frequency and amplitude of mEPSCs in hippocampal neuron cultures
and onto pyramidal neurons in vivo within somatosensory cortex(Della Sala et al., 2016; Ricciardi
et al., 2012; Zhu et al., 2013). Surprisingly, selective loss of CDKL5 from forebrain excitatory
neurons was reported to increase both spine density and the frequency of mEPSC in the
hippocampal CA1 region(Tang et al., 2017). In parallel, selective loss of CDKL5 from GABAergic
forebrain neurons also leads to an increased mEPSC frequency onto hippocampal pyramidal
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neurons coupled with circuit hyperexcitability in the form of aberrant paired-pulse facilitation(Tang
et al., 2019). Whether these varied results are the outcome of region-specific effects of CDKL5
loss, in vitro versus in vivo models, or the effects of conditional versus whole-network CDKL5
deletion remains to be confirmed, but highlight a potentially context-specific role for CDKL5.
Regardless, these previous findings have established precedence for altered synaptic signaling
with loss of CDKL5.
Okuda et al. reported an increased postsynaptic localization of GluN2B-containing NMDA
receptors in the hippocampus of Cdkl5 knockout mice. This finding was supported by an
increased ratio of NMDAR/AMPAR -mediated EPSCs, and in particular, a significantly larger
decay time constant of NMDA receptor-mediated EPSCs reflective of an increased contribution of
GluN2B-containing NMDARs. Accordingly, this aberrant NMDAR signaling activity was mitigated
by the GluN2B-selective antagonist ifenprodil, further highlighting NMDAR subunit mislocalization
within this circuit upon CDKL5 loss(Okuda et al., 2017).
In an independent study of Cdkl5 knock-in mice (Cdkl5R59X), there was no reported
alterations in the postsynaptic localization of NMDAR subunits measured by protein
quantification. Instead, this study reported a decrease in GluA2 protein within postsynaptic
density fractions of knockout mice, highlighting an increased contribution of GluA2-lacking AMPA
receptors that was accompanied by an increased rectification ratio of AMPAR-mediated EPSCs
within the CA1. Interestingly, a GluA2-lacking-specific AMPAR blocker (IEM-1460) was capable
of rescuing several behavioral deficits in this mouse model such as context-dependent
memory(Yennawar et al., 2019).
These synaptic phenotypes may arise through CDKL5’s regulation of postsynaptic
proteins such as NGL-1, SAP-102, or PSD-95, or alternatively, due to a disruption of microtubule
network-mediated receptor trafficking and synaptic maturation. However, the direct association
between CDKL5 loss, postsynaptic protein and receptor trafficking, and these synaptic
phenotypes has yet to be confirmed.
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Disrupted circuit activity with loss of CDKL5
Despite the lack of overt, behavioral seizures in animal models of CDD reported to date,
several groups have observed synaptic and circuit-level hyperexcitability in various brain regions
as well as altered sensitivity to specific chemoconvulsants. Constitutive loss of CDKL5 was found
to result in enhanced long-term potentiation in the hippocampus by a misregulation of
postsynaptic GluN2B-containing NMDA receptor localization(Okuda et al., 2017). In line with this,
Cdkl5 KO mice exhibit significant hyperexcitability to NMDA, and this NMDA-sensitivity phenotype
was recapitulated in an independent Cdkl5 knock-in line (Cdkl5R59X; reported in Chapter 2)(Tang
et al., 2019). In contrast, a different study demonstrated impaired long-term potentiation in
somatosensory cortex of Cdkl5 knockout mice coupled to decreased dendritic spine stability and
mEPSC frequency(Della Sala et al., 2016).
Furthermore, conditional deletion of CDKL5 from forebrain excitatory neurons was
reported to disrupt hippocampal microcircuitry with an increased frequency of both mEPSCs and
mIPSCs onto CA1 pyramidal neurons but no change in their amplitude(Tang et al., 2017).
Specifically, voltage-sensitive dye imaging (VSDI) demonstrated spatio-temporally-distinct
increases in depolarization and inhibition within the stratum radiatum and stratum
pyramidale/oriens highlighting a differential spatial distribution of aberrant excitation and inhibition
within the hippocampus. This disrupted hippocampal microcircuit was associated with the
impaired learning and memory phenotype selectively demonstrated by these conditional knockout
mice(Tang et al., 2017). A follow-up study of this conditional knockout line demonstrated overall
hippocampal circuit hypo-excitability in the form of aberrant paired-pulse depression(Tang et al.,
2019). In contrast, in the same study we demonstrate that conditional deletion of CDKL5 from
forebrain inhibitory neurons (Dlx-cKO; Chapter 2) leads to aberrant circuit hyperactivity within the
hippocampus in the form of aberrant paired-pulse facilitation(Tang et al., 2019). Intriguingly, these
Dlx-cKO mice also exhibited significantly enhanced frequency of mEPSCs onto pyramidal
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neurons of the hippocampus, highlighting a likely non cell-autonomous mechanisms for
disruptions of excitatory signaling via conditional CDKL5 loss from inhibitory neurons.

Network activity and epilepsy in models of CDKL5 deficiency
The drug-resistant, refractory, and high burden nature of the seizures associated with
CDD make them a particularly debilitating aspect of the disorder for both patients and their
families(H. E. Olson et al., 2019). However, until this year, no animal models to date had been
reported to recapitulate the spontaneous seizures that are a hallmark feature of the disorder.
Establishing animal models with stronger face validity for this epilepsy within CDD will be
imperative in order to dissect the nature of the seizures associated with mutations in Cdkl5 as
well as further preclinical development/screening of more targeted therapeutics to manage
seizure occurrence.

Hippocampal electroencephalographic (EEG) recordings in postnatal day (P) 70-90 male
Cdkl5Δ6 knockout mice demonstrated disruptions in event-related neuronal oscillations in
response to auditory stimuli, however, chronic video-EEG recordings revealed no spontaneous
seizure activity(I. T. Wang et al., 2012). Furthermore, basal EEG patterns and power distribution
across various oscillation frequencies were unchanged in these hemizygous male Cdkl5 knockout
mice versus littermate controls. Shortly afterwards, Amendola et al. developed and characterized
the Cdkl5Δ4 deletion mouse that also results in early reading frame truncation and loss of CDKL5
function(Amendola et al., 2014). Similarly to the exon 6 deletion mouse, EEG recordings in this
novel knockout line did not reveal spontaneous epileptiform activity in hemizygous male Cdkl5
knockout mice. More recently, an exon 2 deletion mouse of Cdkl5 (Cdkl5Δ2; also resulting in
constitutive knockout) was created, and although it was reported that these animals carried an
increased sensitivity to NMDA-induced seizures, no overt spontaneous seizure activity was
reported(Okuda et al., 2017). In summary, despite the presence of multiple behavioral and
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neurophysiological impairments, no spontaneous seizure activity has been reported across three,
independent constitutive Cdkl5 knockout mouse lines.

It was long purported that the lack of a robust seizure phenotype in CDD mouse models
was due to neural network differences between human and mouse brains. Despite this, several
groups have observed synaptic and circuit-level hyperexcitability in various brain regions
(described above) as well as altered sensitivity to specific chemoconvulsants. Although high-dose
kainic acid induces overt seizures in Cdkl5 hemizygous knockout males at similar latency to wildtype littermates, the mean duration of these epileptic EEG bursts is reported to be
longer(Amendola et al., 2014). Cdkl5 KO mice have also been reported to display decreased
latency to seizure upon low-dose pentylenetetrazol administration(Yennawar et al., 2019).
Although EGG recordings in loss-of-function models of CDD have not revealed spontaneous
seizures, the majority of these studies have been limited to hemizygous males or
young/adolescent animals. These early findings suggest that seizure susceptibility may in fact be
altered in the absence of CDKL5, but perhaps only under certain environmental conditions or
even specific periods of development and aging.
In Chapter 5, we describe the first report of overt, myoclonic behavioral seizures in two
distinct mouse models of CDD: the Cdkl5Δ6 and Cdkl5R59X. These events are specific to aged,
female mice heterozygous for mutations in Cdkl5, with no hemizygous knockout male mice,
homozygous knockout female mice, or wild-type mice displaying spontaneous seizure activity.
This suggests that X-linked mosaicism of Cdkl5 deficiency may be a driving factor of the seizure
phenotype in mouse models of CDD. A simultaneous report, in collaboration with our lab,
characterized the ictal and interictal EEG features of epileptic spasms in these female Cdkl5
heterozygous knockout mice, finding them to be most frequently associated with generalized
slow-wave activity during sleep(Mulcahey et al., 2020). The precise mechanisms driving this
mosaicism-linked seizure phenotype remain to be dissected. Nonetheless, these seminal findings
not only contribute to our understanding of the effects of CDKL5 loss on network hyperactivity in
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mice, but also strengthen the face validity of current CDD models for future therapeutic
development.
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Jhang et al.
2017
Male only

Male and
female

Male only

Male only

Tang et al.
2017

Tang et al.
2019

exon 6 deletion
(Cdkl5Δ6 )

exon 6 deletion
(Cdkl5Δ6 )

Conditional knockout
using Nex-Cre

Conditional knockout
using Dlx-Cre

Male only

Amendola et
al. 2014

Yennawar et
al. 2019

exon 4 deletion
(Cdkl5Δ4 )

R59X knock-in
(Cdkl5^R59X )

exon 6 deletion
PsychoGenics Male and
(Cdkl5Δ6 ; Wang et
female
2016
al. 2012)

exon 6 deletion
(Cdkl5Δ6 ; Wang et
al. 2012)

6-8 weeks

9-12 weeks

9-12 weeks

Normal gross physical
appearance, body weight,
and brain size

Normal gross physical
appearance, body weight,
and brain size

12-16 weeks

Normal gross physical
appearance and brain size

Normal body and brain
weight at 6 weeks of age

5-15 weeks

4-5 weeks

Decreased body weight at
5.5 weeks; reduced
respiration rate

Not assessed

8 weeks

Not assessed

Male and
female

Fuchs et al.
2014 & 2015

exon 4 deletion
(Cdkl5Δ4 )

6-8 weeks

Normal body and brain
weight at 6 weeks of age

Male and
female

Amendola et
al. 2014

exon 4 deletion
(Cdkl5Δ4 )

9-12 weeks

Normal gross physical
appearance and brain size

Male only

Wang et al.
2012

exon 6 deletion
(Cdkl5Δ6 )

Age upon
assessment

General physiology

Sex(es)
studied

Study

Allele

Conditional knockout
using Emx1-Cre &
Dlx5/6-Cre

Constitutive knockout

Model

Motor
Limb clasping and
gait abnormalities

Not assessed

Impaired motor
coordination
(Rotarod)

Hindlimb clasping

Hyperactivity (10min open
field assay)

normal locomotion

Context-dependent
hyperactivity (threechamber assay and Ymaze only)

No hindlimb
clasping

Hindlimb clasping

Unaltered odor
discrimination

Unaltered odor
discrimination

Unaltered
stereotyped
behavior
Increased
repetitive
behaviors
(grooming in a
homecage-like
environmnet)
Unaltered motor
coordination and
learning
(Rotarod)

Not assessed

Unaltered odor
discrimination

Not assessed

Not assessed

Unaltered odor
discrimination

Olfaction

Unaltered motor
coordination and
learning
(Rotarod)

Not assessed

Not assessed

Unaltered motor
coordination
(single-day
Rotarod)

Hindlimb clasping;
gait abnormalities
(NeuroCube)

Hypoactivity (24hr
PhenoCube assay)

Hypoactivity in home cage Hindlimb clasping in
(4day monitoring) in Dlx5/6- Emx1-cKO male
and female mice
cKO male mice

Increased
stereotyped
digging behavior

Not assessed

Not assessed

Impaired motor
coordination
(Rotarod)

Impaired motor
coordination
(Rotarod)

Not assessed

Hindlimb clasping

Stereotyped
behaviors

Motor
coordination
and learning

Not assessed

Hyperactivity (16min open
field assay)

Hypoactivity in home cage
(4day monitoring) but no
change in open-field arena
(30min assay)

Hindlimb and
Hyperactivity (60min beamforelimb clasping
break assay)

Locomotor activity

Table 1: Behavioral phenotyping of mouse models of CDKL5 deficiency
Sensory

Cognitive
Learning and memory

Anxiety and
aggression

Socio-emotional
Social behavior and
communication

Not assessed

Impaired optokinetic
response in Emx1cKO male mice

Not assessed

Not assessed

Not assessed

Not assessed

Not assessed

Increased anxiety
(open field periphery
time)

Not assessed

Unaltered anxiety
(open field assay), but
increased aggression
(resident-intruder test)

unaltered working memory
decreased sociability
(Y-Maze) and unaltered
during a 3-chambered Unaltered anxiety (zero
spatial learning (Barnes
maze)
social choice test and
Maze), but increased error
dyadic interaction test
probe

Unaltered social
Impaired spatial learning
Unaltered anxiety (zero
behavior (three(Barnes maze) and impaired
maze)
chamber assay) and
working memory (Y-maze)
nest-building

Not assessed

Reduced sociability
(three-chamber
assay)

Impaired context-dependent
learning (fear conditioning)
and working memory (YMaze)
Not assessed

Reduced social
interaction
(PhenoCube)
Impaired context- and cuedependent learning (fear
conditioning)

Reduced sociability
(three-chamber
assay); reduced
USVs in adult and
juvenile mice

Not assessed

Impaired working memory (Ymaze), impaired spatial
learning (Morris water maze)

Impaired spatial learning
(Barnes maze)

Not assessed
Not assessed

Reduced sociability
Impaired auditory eventImpaired context- and cueReduced anxiety
(three-chamber
related potential;
dependent learning (fear
assay); impaired nest- (elevated zero maze)
unaltered auditory
conditioning)
building
brainstem response

Hearing

Not assessed

Impaired optokinetic
response

Not assessed

Not assessed

Impaired optokinetic
response and
decreased visualevoked potentials

Not assessed

Vision

Tables

Table 2. Putative protein interactions and signaling pathways involving CDKL5 (results in
bold have been validated in vivo )
Putative Protein
Interaction

MeCP2

DNMT1
SC35
Rac 1
NGL-1
Amphiphysin 1
PSD-95

Mind Bomb 1
Shootin-1
HDAC4
MAP1S, EB2, and
ARHGEF2
MAP1S, CEP131,
and DLG5

Signaling Pathway
Alteration
Decreased AKT and
mTOR
phosphorylation
Decreased GSK3-β
phosphorylation
Increased levels of
GluN2B and
SAP102
Decreased levels of
GluA2

Experimental method
Co-immunoprecipitation of overexpressed GFP-CDKL5
and endogenous MeCP2 in HEK293T cells; GST pulldown assay of GST-MeCP2 with 35S-hCDKL5 & coimmunoprecipitation of GFP-CDKL5 with myc-MeCP2 in
293T cells
Pull-down assay using GST-DNMT1(1-290) incubated with
mouse brain extract, followed by fractionation and LCMS/MS
Co-immunoprecipitation of YFP-SC35 with GFP-CDKL5 in
NIH3T3 cells
Pull-down assay using GST-CDKL5(670-934) in COS-7
cells
Co-immunoprecipitation of NGL-1 using a CDKL5
antibody in P4 mouse brain synaptosome extract
Liquid-phase isoelectric focusing, followed by an in vitro
kinase assay using incubation with CDKL5(1-352)
Co-immunoprecipitation from rat brain
synaptosomes using CDKL5 and PSD-95 antibodies
Affinity purification of rat brain lysate using GSTMib1, followed by sequential elution and LC-MS/MS
analysis
Co-immunoprecipitation from P5-7 mouse brain
lysate using CDKL5 and Shootin-1 antibodies
Co-immunoprecipitation of overexpressed CDKL5-FLAG
with endogenous HDAC4 in SH-SY5Y cells
chemical-genetic identification of direct CDKL5
substrates, followed by validation of reduced
phosphorylation in Cdkl5 knockout mouse brain
TMT-based CDKL5 phosphoproteomic screening in U2OS
osteosarcoma cells followed by validation of reduced
phosphorylation in CDKL5 KD HEK293 cells

Reference(s)
Mari et al. 2005; Lin et al.
2005; Bertani et al. 2006;
Williamson et al. 2012

Kameshita et al. 2008
Ricciardi et al. 2009
Chen et al. 2010
Ricciardi et al. 2012
Sekiguchi et al. 2013
Zhu et al. 2013

Mertz et al. 2015
Nawaz et al. 2016
Trazzi et al. 2016
Baltussen et al. 2018

Muñoz et al. 2018

Experimental method

Reference(s)

Western blotting of whole mouse brain lysate;
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CHAPTER 2 – ALTERED NMDAR SIGNALING UNDERLIES AUTISTIC-LIKE
FEATURES IN MOUSE MODELS OF CDKL5 DEFICIENCY DISORDER
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Marsh ED, Zhou Z. Altered NMDAR signaling underlies autistic-like features in mouse
models of CDKL5 deficiency disorder. Nature Communications. 2019 Jun;10:2655
*these two authors contributed equally to this work

Abstract
CDKL5 deficiency disorder (CDD) is characterized by epilepsy, intellectual disability, and
autistic features, and CDKL5-deficient mice exhibit a constellation of behavioral phenotypes
reminiscent of the human disorder. We previously found that CDKL5 dysfunction in forebrain
glutamatergic neurons results in deficits in learning and memory. However, the pathogenic origin
of the autistic features of CDD remains unknown. Here, we find that selective loss of CDKL5 in
GABAergic neurons leads to autistic-like phenotypes in mice accompanied by excessive
glutamatergic transmission, hyperexcitability, and increased levels of postsynaptic NMDA
receptors. Acute, low-dose inhibition of NMDAR signaling ameliorates autistic-like behaviors in
GABAergic knockout mice, as well as a novel mouse model bearing a CDD-associated nonsense
mutation, CDKL5 R59X, implicating the translational potential of this mechanism. Together, our
findings suggest that enhanced NMDAR signaling and circuit hyperexcitability underlie autisticlike features in mouse models of CDD and provide a new therapeutic avenue to treat CDDrelated symptoms.
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Introduction
Mutations in cyclin-dependent kinase-like 5 (CDKL5) cause a severe
neurodevelopmental disorder characterized by early-onset seizures, intellectual disability, and
autistic features(Kalscheuer et al., 2003; Tao et al., 2004; Weaving et al., 2004). Mouse models
of CDD have recapitulated numerous aspects of the human disorder, and despite a subtle overall
degree of impairment, they show behavioral deficits such as impaired learning, reduced
sociability, motor dysfunction, and altered anxiety-related behaviors(Amendola et al., 2014;
Jhang, Huang, Hsueh, & Liao, 2017; Okuda et al., 2018; I. T. Wang et al., 2012). The extent to
which these behavioral deficits arise from common or distinct mechanisms, however, remains
unclear.
CDKL5 protein expression is enriched in the forebrain, primarily in glutamatergic and
GABAergic neurons(Chen et al., 2010; Johnson et al., 2017; Rusconi et al., 2008; I. T. Wang et
al., 2012; Zeisel et al., 2015). In glutamatergic neurons, CDKL5 has been found at the
postsynaptic density, where it interacts with PSD-95 and NGL-1(Ricciardi et al., 2012; Zhu et al.,
2013). In addition, loss of CDKL5, both in vitro and in vivo, is associated with changes in dendritic
morphology, spine density, excitatory synaptic transmission, and synaptic plasticity(Della Sala et
al., 2016; Okuda et al., 2017; Ricciardi et al., 2012; Tang et al., 2017). Mice lacking CDKL5
selectively in forebrain glutamatergic neurons (Nex-cKO) show impaired learning and memory,
reminiscent of the intellectual disability found in CDD(Tang et al., 2017). Interestingly, Nex-cKO
mice did not show other behavioral deficits found in Cdkl5 constitutive knockout mice, such as
alterations in sociability, stereotypic behavior, locomotion, motor coordination, and anxiety-related
behavior(Tang et al., 2017). These findings imply that distinct, cell-type specific etiologies
underlie CDD-related behavioral phenotypes in mice.
Mice lacking CDKL5 show numerous functional changes at the synaptic and circuit
levels. A recent study found that Cdkl5 constitutive knockout mice demonstrated increased
NMDA-dependent synaptic transmission and enhanced long-term potentiation at hippocampal
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synapses(Okuda et al., 2017). In contrast, long-term potentiation is decreased in the
somatosensory cortex of Cdkl5 knockout mice(Della Sala et al., 2016). Furthermore, selectively
ablating CDKL5 from glutamatergic neurons leads to increased glutamatergic and GABAergic
synaptic transmission, disrupted microcircuit dynamics, and learning and memory
impairment(Tang et al., 2017). While some of these differences are potentially attributable to
different genetic backgrounds of mouse models of CDD, the differences between Cdkl5
constitutive knockout mice and Nex-cKO mice suggest the existence of additional, nonglutamatergic mechanisms that may mediate CDD-related behavioral deficits. Notably, the
function of CDKL5 in forebrain GABAergic neurons, where CDKL5 is also highly expressed, has
yet to be elucidated(Johnson et al., 2017).
Here, we selectively ablate CDKL5 expression in forebrain GABAergic neurons (DlxcKO). We found that these mice exhibit an autistic-like phenotype, but, in contrast to Nex-cKO
mice, show preserved learning and memory(Tang et al., 2017). In addition, Dlx-cKO mice show
an enhancement of excitatory synaptic transmission and circuit-level hyperexcitability, coupled
with elevated levels of NMDA receptors. Reducing NMDAR activity using an uncompetitive
antagonist, memantine, significantly mitigated the behavioral deficits found in Dlx-cKO mice. To
examine the translational potential of these findings, we generated a novel CDD model bearing a
patient mutation and found that these mice, similarly to Dlx-cKO mice, show an elevation of
NMDA receptors. Importantly, acute, low-dose NMDAR blockade selectively ameliorates autisticlike features in this CDD model. Taken together, our findings support a novel mechanism by
which CDKL5 loss in GABAergic neurons leads to excessive NMDAR signaling and contribute to
the etiology of autistic-like behaviors in mouse models of CDD.
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Results
CDKL5 GABAergic deletion results in autistic-like features
Our previous findings showed that CDD-related learning and memory impairment has
origins in forebrain glutamatergic neurons in mice(Tang et al., 2017). Given that CDKL5 is also
highly expressed in forebrain GABAergic neurons, we generated conditional knockout mice
selectively lacking CDKL5 in this cell population (Dlx-cKO) using the Dlx-5/6 Cre driver (Figure
1A, B)(Monory et al., 2006). Dlx-cKO mice showed normal growth and body weight through
adulthood and no obvious physical abnormalities (Figure 2A). We then performed a battery of
behavioral assays, similar to those in previous studies of Cdkl5 constitutive KO and Nex-cKO
mice(Tang et al., 2017; I. T. Wang et al., 2012). Compared to WT controls, Dlx-cKO showed no
changes in locomotor activity, anxiety-related behaviors, and motor coordination (Fig. 2B–D).
In contrast, Dlx-cKO mice demonstrated significantly reduced social interaction on the
three-chamber social approach assay, showing diminished preference for investigating a social
stimulus as compared to an object (Fig. 3a, b). When allowed the opportunity for direct interaction
with a novel stimulus mouse, Dlx-cKO mice also spent significantly less time initiating contact in
comparison to wild-type controls (Fig. 3c). To rule out the involvement of an olfactory deficit
underlying reduced social preference, we conducted the olfactory habituation-dishabituation test.
Dlx-cKO mice showed an intact ability to discriminate between different scents but spent reduced
time sniffing a social scent, a feature consistent with a reduced interest in social stimuli (Fig. 3d).
In addition to social deficits, another defining feature of human autism spectrum disorders
(ASDs) is the presence of repetitive or stereotypic behaviors. We next assessed repetitive
behaviors in Dlx-cKO mice. In a home-cage like environment, Dlx-cKO mice showed significantly
increased time engaging in stereotypic behaviors such as grooming and digging (Fig. 3e), and
also exhibited a nesting deficit (considered by some to be a home-cage social behavior)
compared to littermate controls (Fig. 3f).
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We next assessed learning and memory, a behavioral domain significantly impaired in
both Cdkl5 constitutive knockout mice and Nex-cKO mice. Interestingly, Dlx-cKO showed no
impairment in spontaneous alternation behavior on the Y-maze, suggesting intact working
memory (Fig. 3g, h). On the Barnes maze, an assay of spatial learning and memory, Dlx-cKO did
not show a significant difference from wild-type controls in the number of errors made on probe
trials (Fig. 3i). However, when the target hole location was altered to the opposite side of the
maze after acquisition (reversal probe trials), Dlx-cKO mice demonstrated a significant
impairment in adjusting to this new target hole (Fig. 3j). In addition, Dlx-cKO mice show an
increased number of perseverations on reversal probe trials, or visits to the previous target hole
location (Fig. 3k). These results suggest that Dlx-cKO mice have intact learning and memory, but
impaired cognitive flexibility, another feature reminiscent of autism spectrum disorders.
Taken together, Dlx-cKO mice show a set of autistic-like features with relatively
preserved learning and memory that stand in contrast to previous findings in Nex-cKO mice,
which exclusively show impaired learning and memory(Tang et al., 2017). These results
demonstrate a segregation of behavioral deficits in Cdkl5 conditional knockout mice, suggesting
that impaired learning and autistic-like features have distinct cellular origins in CDD.

Dlx-cKO mice show aberrant circuit activation
In previously established mouse models of ASD, the finding of excitation-inhibition (E/I)
imbalance has emerged as a prominent theme underlying patterns of circuit and network
dysfunction(Bourgeron, 2015; Rubenstein & Merzenich, 2003). Specifically, hyperexcitability at
the circuit and network levels has been found to be associated with many of the autistic-like
features reported in these models. Importantly, reversal of hyperexcitability in these models is
often sufficient to ameliorate disease phenotypes, demonstrating a causal role for E/I imbalance
in generating the features of social impairment and stereotypy(Chung et al., 2015; Yizhar et al.,
2011).
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The exhibition of autistic-like features in Dlx-cKO mice, coupled to the previous findings
of E/I imbalance in other models of ASD, prompted us to investigate any circuit irregularities in
CDD mouse models. We first used voltage-sensitive dye imaging (VSDI), a technique that has
been consistently used in mouse models of neurologic disease to assess circuit function with high
spatiotemporal resolution(Ang, 2005; Ang, Carlson, & Coulter, 2006; Calfa, Hablitz, & PozzoMiller, 2011; Carlson & Coulter, 2008; Tang et al., 2017). We conducted our experiments with
WT, Dlx-cKO, and Nex-cKO mice, to facilitate a side-by-side comparison of circuit function in the
context of the distinct behavioral profiles of Dlx-cKO and Nex-cKO mice.
We began by interrogating the function of the perforant path-dentate gyrus pathway, a
hippocampal microcircuit often perturbated in disease states that critically relies on both excitation
and inhibition for proper function(Douglas A. Coulter et al., 2011; Dengler & Coulter, 2016;
Goldberg & Coulter, 2013). Using VSDI responses as a readout, we assessed the layer-specific
responses of the molecular layer, granule cell layer, as well as the downstream hilar region in
response to perforant path stimulation (Fig. 4a). We used a paired-pulse paradigm, which
assesses both the baseline excitability of the circuit and its short-term plasticity. We first focused
our analysis on the response of the granule cell layer (Fig. 4b–e), which contains the cell bodies
of the principal neurons of the dentate gyrus. WT mice showed comparable responses in the
granule cell layer to the first and second stimuli without significant facilitation or depression (Fig.
4b–d), showing a paired-pulse ratio that was not significantly different from one (Fig. 4e). Neither
Nex-cKO or Dlx-cKO mice showed a significant difference from WT in their peak responses to the
first stimulation, suggesting similar baseline excitability of the dentate gyrus (Fig. 4b, c).
Interestingly, Nex-cKO mice showed a diminished peak response to the second stimulus, with a
paired-pulse ratio significantly less than one (Fig. 4b, d, e). In contrast to Nex-cKO mice, Dlx-cKO
mice exhibited paired-pulse facilitation, evident by an increase in depolarization upon a second
successive stimulus and a peak ratio significantly greater than one (Fig. 4d, e). Importantly, this
aberrant paired-pulse facilitation in Dlx-cKO was also observed in an upstream input region
(molecular layer) and downstream output region (hilus) (Fig. 4f–k). Furthermore, we repeated this
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experiment at a second stimulation intensity and observed similar results (Fig. 5). Taken together,
our findings reveal that the distinct behavioral phenotypes of Cdkl5 conditional knockout mice are
accompanied by contrasting patterns of circuit dysfunction. Specifically, Dlx-cKO mice show
circuit hyperexcitability in the form of aberrant paired-pulse facilitation, whereas Nex-cKO mice
show circuit hypo-excitability in the form of aberrant paired-pulse depression.

Dlx-cKO mice show enhanced excitatory synaptic transmission
Given the finding of circuit hyperexcitability in Dlx-cKO mice, we next investigated the
synaptic origins of this E/I imbalance. Previous studies have found enhanced synaptic
transmission and long-term potentiation in the hippocampal CA1 region of Cdkl5 constitutive
knockout mice(Okuda et al., 2017). Interestingly, these changes were not fully recapitulated in the
glutamatergic conditional knockout mice, suggesting that CDKL5 function in other neuronal
populations, such as GABAergic neurons, may contribute to synaptic hyperexcitability(Tang et al.,
2017). Therefore, using whole-cell patch-clamp recordings, we assessed both excitatory and
inhibitory synaptic transmission in the hippocampal CA1 region in Dlx-cKO mice. We found that
Dlx-cKO mice exhibited significantly enhanced frequency of miniature spontaneous excitatory
postsynaptic currents (mEPSCs), but no changes in amplitude or kinetics of these events (Fig.
6a–e and Fig. 7A, B). In contrast, miniature spontaneous inhibitory postsynaptic currents
(mIPSCs) were not significantly different in either amplitude, frequency, or kinetics between DlxcKO and WT mice (Fig. 6f–j and Fig. 7C, D). This suggests that despite CDKL5 loss in
GABAergic neurons, adult Dlx-cKO mice do not show a significant alteration of inhibitory signaling
at CA1 pyramidal neurons. In turn, synaptic transmission between excitatory neurons is
enhanced upon selective loss of CDKL5 in GABAergic neurons. Taken together, our results
support a shift in E/I balance in Dlx-cKO mice toward hyperexcitability that is consistent with our
circuit findings.
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Dlx-cKO mice have an increase in postsynaptic NMDA receptors
The finding of excess glutamatergic synaptic transmission in Dlx-cKO mice suggests a
potential alteration in the molecular composition of postsynaptic receptors. Indeed, previous
studies have suggested a role for CDKL5 in regulating synaptic receptor composition and
homeostasis(P. La Montanara et al., 2015; Okuda et al., 2017). For example, excessive
glutamatergic synaptic transmission can result from an enhancement of postsynaptic AMPA
receptors (AMPAR), NMDA receptors (NMDAR), or both. We therefore examined the composition
of major ionotropic glutamate receptors in postsynaptic density membrane preparations from DlxcKO and WT mice, including GluA1, GluA2, GluN1, GluN2A, and GluN2B. Interestingly, we found
a selective increase in the protein level of NMDARs, but not AMPARs in Dlx-cKO mice (Fig. 8).
Specifically, the NMDAR subunits GluN1 and GluN2B were significantly elevated in Dlx-cKO
mice. (Fig. 8d, f). These findings are consistent with results from Cdkl5 constitutive knockout mice
and suggest a non-cell autonomous mechanism underlying the enhancement of glutamatergic
synaptic transmission through CDKL5 loss from GABAergic neurons(Okuda et al., 2017).

NMDAR blockade ameliorates autistic-like features in Dlx-cKO
Our findings in Dlx-cKO mice raised the possibility that enhanced NMDAR signaling may
underlie the autistic-like phenotype exhibited by these mice. We first investigated the extent to
which NMDAR signaling is responsible for the repetitive behavior phenotype in Dlx-cKO mice. We
used low doses of memantine, a non-competitive NMDA receptor blocker that has been
previously found to rescue behavioral deficits in numerous mouse models of neurodevelopmental
disorders(Chung et al., 2015; Figueiredo et al., 2013; J. Kang & Kim, 2015). We observed that
acute memantine administration (5 mg kg−1, intraperitoneal) ameliorated excessive grooming in
Dlx-cKO mice, significantly reducing both total time spent grooming and the duration of the
longest grooming bout (Fig. 9a, b). Next, we employed a modified dyadic interaction assay to
quantitatively assess social interactions in drug- and vehicle-treated Dlx-cKO mice. Whereas
vehicle-administered Dlx-cKO mice showed significantly reduced social interaction, memantine
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ameliorated this deficit, significantly increasing the time spent by Dlx-cKO mice in social
interaction (Fig. 9c). This effect was specific to Dlx-cKO mice, as memantine normalized the ratio
of time spent in social interaction in pairs of Dlx-cKO and WT control mice co-tested side-by-side
in identical cages (Fig. 9d). Taken together, these results suggest that enhanced NMDAR
signaling underlies, at least in part, the autistic-like features of Dlx-cKO mice, and that an acute
reduction of NMDAR activity can ameliorate these phenotypes.

NMDAR blockade improves autistic-like features in CDKL5 R59X
To investigate the translational potential of our findings in Dlx-cKO mice, we generated a
novel mouse model of CDD, Cdkl5R59X (referred to as R59X). R59X mice bear a knock-in
mutation mimicking a human CDD nonsense mutation at arginine 59, leading to the loss of
CDKL5 kinase function (Fig. 10a). We found that full-length CDKL5 protein expression was
abolished in R59X mice, similar to a knockout model we previously developed (Fig. 11)(I. T.
Wang et al., 2012). Similar to Dlx-cKO mice and other mouse models of CDD, R59X mice
demonstrate autistic-like features, including increased repetitive behaviors and diminished social
interaction (Fig. 12).
We next investigated the extent to which enhanced NMDAR signaling is also present in
R59X mice. Using a similar approach as for Dlx-cKO mice, we examined the protein levels of
NMDAR and AMPAR subunits in postsynaptic density fractions (Fig. 10b–g). In R59X mice, we
found an upregulation of NMDAR subunit levels, with a selective increase in GluN2B, mirroring
previous findings in Cdkl5 constitutive knockout mice (Fig. 10g)(Okuda et al., 2017).
Using R59X mice as a model of CDD, we next examined the extent to which enhanced
NMDA signaling is responsible for CDD-related behavioral deficits. We first tested the possibility
that enhanced NMDAR signaling may underlie impaired learning and memory in CDKL5-deficient
mice. Using the Y-maze assay, we found that R59X mice demonstrated a robust working memory
deficit, demonstrated by reduced spontaneous alternation behavior, similar to our previous
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findings in both Cdkl5 constitutive KO and Nex-cKO mice (Fig. 12a)(Tang et al., 2017; I. T. Wang
et al., 2012). Notably, acute memantine administration at a range of doses (1.25–10 mg kg−1,
intraperitoneal) did not ameliorate this behavioral deficit, suggesting that excess NMDAR
signaling is unlikely to be the major mechanism underlying learning and memory deficits in R59X
mice (Fig. 12a).
In contrast, we observed that acute memantine administration (5 mg kg−1, intraperitoneal)
rescued excessive stereotypic behaviors in R59X mice, significantly reducing both total time
spent grooming and the duration of the longest grooming bout to a level similar to that of WT mice
(Fig. 12b, c). Similarly, whereas vehicle-treated R59X mice showed significantly reduced social
interaction, memantine ameliorated this deficit, significantly increasing the time spent by R59X
mice in social interaction (Fig. 12d). This effect was specific to R59X mice, as memantine
normalized the ratio of time spent in social interaction in pairs of R59X and WT control mice cotested side-by-side in identical cages (Fig. 12e). Taken together, these results suggest that
enhanced NMDAR signaling underlies the autistic-like features, but not learning and memory
deficits, in CDKL5-deficient mice, and reveal the translational potential of this pathway in the
treatment of CDD.

Discussion
Our behavioral studies in Dlx-cKO mice revealed an autistic-like phenotype characterized
by reduced social preference and increased stereotypic behaviors, but relative preservation of
other behaviors such as learning and memory, motor coordination, and anxiety-related behaviors.
This behavioral profile stands in contrast to our previous findings in Nex-cKO mice, which exhibit
selectively impaired learning and memory. Our results delineate the distinct cellular origins of
CDD-related behavioral phenotypes: whereas impaired learning primarily originates from the loss
of CDKL5 in forebrain glutamatergic neurons, autistic-like features primarily originate from the
loss of CDKL5 in forebrain GABAergic neurons. Interestingly, anxiety-related behavior,
locomotion, and motor coordination were not altered in either Nex-cKO or Dlx-cKO mice. These
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additional phenotypes may be mediated by 1) CDKL5 function in other cell populations and brain
regions and/or 2) the synergistic functions of CDKL5 in forebrain glutamatergic and GABAergic
neurons.
Our findings in Cdkl5 conditional knockout mice support a model whereby CDKL5 loss in
glutamatergic and GABAergic neurons lead to divergent changes in E/I balance that generate
distinct behavioral deficits. We show that in Dlx-cKO mice, hippocampal circuit hyperexcitability is
coupled with autistic-like features, a finding corroborated in numerous other mouse models of
autism(Chung et al., 2015; Lee, Lee, & Kim, 2017; Sacha & Valakh, 2015; Yizhar et al., 2011). In
specific cases, autistic-like behaviors have been linked to a dysfunction of inhibitory neuronal
transmission(Chao et al., 2010; Han et al., 2012; Rothwell et al., 2014). In contrast, we show that
in Nex-cKO mice, hippocampal circuit hypo-excitability is linked to learning and memory deficits.
Interestingly, reduced E/I ratio has been demonstrated in numerous mouse models of intellectual
disability(Dierssen, 2012; Fernandez & Garner, 2007). Therefore, our studies reveal a novel
avenue toward treating specific CDD-related symptoms, but also suggest that modulation of E/I
balance in CDD may be a double-edged sword. To date, the majority of reported CDD patients
have been predicted to carry loss-of-function mutations, such as nonsense, indels, or missense
mutations abolishing CDKL5 kinase activity, suggesting that our knockout and R59X knockin
mouse models may carry a high translational relevance. In order to develop targeted therapies for
CDD, additional studies are needed to elucidate the specific signaling pathways and neural
circuits responsible for each of the behavioral symptoms.
In our VSDI studies of Nex- and Dlx-cKO mice, we employed a paired-pulse stimulation
paradigm, which assesses the integration of excitatory and inhibitory synaptic transmission in the
dentate gyrus. Interestingly, previous work has shown that NMDA signaling is a necessary
component for the paired-pulse facilitation response in the dentate gyrus, suggesting a potential
mechanism for circuit excitability in Dlx-cKO mice(Joy & Albertson, 1993). On the other hand, the
aberrant paired-pulse depression in Nex-cKO mice may result from enhanced inhibition, given

32

that feedforward and feedback inhibition play key roles in regulating the activity of the dentate
gyrus(Amaral, Scharfman, & Lavenex, 2007; D.A. Coulter & Carlson, 2007; Tang et al., 2017). In
our electrophysiologic studies of Dlx-cKO mice, the most prominent change was, surprisingly, an
enhancement in glutamatergic synaptic transmission. This change likely arises from a non-cell
autonomous mechanism, especially in the absence of a concomitant change in GABAergicglutamatergic inhibitory synaptic transmission. For example, the loss of CDKL5 in GABAergic
interneurons may lead to a modulation of presynaptic release probability at glutamatergic
synapses. Alternatively, enhanced excitatory synaptic transmission may be a homeostatic
response to a transient alteration of GABAergic signaling during early development. Supporting
this notion, a previous study has found that GABAergic transmission cooperates with NMDA
receptor activation during development for excitatory synapse formation(D. D. Wang & Kriegstein,
2008). Furthermore, the loss of CDKL5 may lead to different disruptions in distinct populations of
forebrain interneurons that as of yet we are unable to dissect from our Dlx5/6-Cre-driven
dissection. Future studies looking into the role of CDKL5 at specific sub-populations of
interneurons will provide clarity on its non-cell autonomous roles.
Interestingly, despite the findings of synaptic and circuit-level hyperexcitability, we did not
observe spontaneous seizure-like behaviors in Dlx-cKO mice during our routine assays, at least
in male mice and at the ages examined. This is similar to what has been observed in constitutive
loss-of-function models of CDD where EEG recordings have not revealed spontaneous
seizures(Amendola et al., 2014; Okuda et al., 2017; I. T. Wang et al., 2012). However, this does
not exclude the possibility that seizure susceptibility is altered in the absence of CDKL5 under
certain environmental conditions and during specific periods in development and aging. Thus far,
the lack of a robust seizure phenotype in CDD mouse models suggests that neural network
differences between human and mouse brains may prevent the development of overt seizures in
CDKL5-deficient mice. In addition, given the contrasting profiles of hypo- and hyperexcitability in
Nex-cKO and Dlx-cKO mice, respectively, the state of circuit excitability in constitutive loss-offunction models of CDD remains to be further characterized. Indeed, previous studies have
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revealed changes in synapse density, distribution, and plasticity of both excitatory and inhibitory
neurons(Della Sala et al., 2016; Okuda et al., 2017). Therefore, it is possible that both pro- and
anti-epileptogenic changes occur in the CDKL5-deficient brain, each playing a distinct role in
mediating the various behavioral deficits of CDD.
The finding of enhanced NMDAR signaling reveals a novel synaptic mechanism that may
potentially underlie the behavioral deficits of mouse models of CDD. Our results in Dlx-cKO mice
suggest that GABAergic dysfunction leads to an enhancement of NMDAR signaling, which in turn
is responsible for autistic-like features. We validate this mechanism in R59X mice, demonstrating
that the acute reduction of NMDAR signaling ameliorates select CDD-related behavioral deficits.
Whereas acute memantine administration specifically rescued repetitive behavior and
significantly improved social interaction in R59X mice, it did not positively affect the learning and
memory deficit in R59X mice. Altogether with our previous findings in Nex-cKO mice, our studies
suggest that distinct subsets of CDD-related phenotypes are mediated by distinct synaptic and
circuit mechanisms(Tang et al., 2017). Future studies are expected to refine these mechanisms
by testing brain region- and circuit-specific mechanisms for specific CDD-related phenotypes. For
example, given that we found enhanced NMDAR subunit levels in our postsynaptic density
membrane fractions, we cannot rule out the possibility that extra-synaptic NMDAR levels are also
altered in Dlx-cKO and R59X mice. Indeed, memantine is known to act at both synaptic and
extra-synaptic receptors in a dose-dependent manner, and its effects on behavior may be
mediated by both mechanisms(Beconi et al., 2011). Although it may be difficult to distinguish
between these two populations of NMDARs in vivo, further work in this direction can elucidate the
mechanism that underlies the enhancement of synaptic NMDAR signaling in mouse models of
CDD.
Taken together, our studies delineate the forebrain GABAergic origins of autistic-like
features in CDKL5-deficient mice, showing for the first time that CDKL5 is required in this diverse
population of neurons for proper neural development and function. At the synaptic level, we
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reveal an enhancement of NMDAR signaling that contributes to circuit hyperexcitability. Finally, in
a novel disease model of CDD, we show that acute reduction of NMDAR signaling can ameliorate
behavioral deficits, highlighting a potentially important mechanism for CDD-related phenotypes in
mice and supporting a novel therapeutic avenue for the treatment of these symptoms in CDD
patients.

Materials and Methods
Mouse strains. The Cdkl5 floxed mouse line with Cre-dependent excision of exon 6 was used for
the generation of conditional knockout mice(Tang et al., 2017). Dlx5/6-Cre, a mouse line
expressing Cre in forebrain inhibitory neurons, was obtained from Jackson Laboratories and
maintained in the C59BL/6J background (Stock No. 008199)(Monory et al., 2006). The CDKL5
R59X knock-in line was generated as follows: a targeting vector was designed to insert a frtflanked neomycin resistance (neo) cassette downstream of exon 5, and a single-nucleotide
change of C to T, leading to a nonsense mutation at arginine 59 (R59X) of the Cdkl5 gene. The
construct was electroporated into C57BL/6N embryonic stem (ES) cells. Correctly targeted ES
cells were injected into BALB/c blastocysts and resulting chimeric mice were bred with B6.CgTg(ACTFLPe)9205Dym/J (Jackson Laboratories, Stock No. 005703) to remove the neo cassette.
Resulting offspring were bred to C57BL/6J mice (Jackson Laboratories, Stock No. 000664) for at
least ten generations. The R59X knock-in mouse line has been deposited at Jackson
Laboratories (Stock No. 028856).

Mouse husbandry. Experiments were conducted in accordance with the ethical guidelines of the
National Institutes of Health and with the approval of the Institutional Animal Care and Use
Committee of the University of Pennsylvania. Cdkl5flox and R59X mice were backcrossed to
C57BL/6 for at least ten generations before breeding for experiments. Mouse lines were
genotyped using a PCR-based strategy, with their respective primer sequences and other details
found on the Jackson Laboratories website under the appropriate stock numbers listed above.
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Mice were group-housed in cages of three to five in a 12-h light/dark cycle with food and water
provided ad libitum.
For breeding of Dlx-cKO and wild-type control mice, each breeding cage consisted of two
homozygous female mice (genotype: Cdkl5flox/Cdkl5flox) and one male mouse (genotype: Dlx5/6Cre/+). Male littermates (genotypes: Cdkl5flox/y; +/+ and Cdkl5flox/y; Dlx5/6-Cre) were weaned at 3
weeks of age and housed together, with all experiments performed on age-matched adult mice
between 9 and 12 weeks of age. For behavioral experiments, wild-type control mice (genotype:
Cdkl5flox/y; +/+) from Nex-cKO breedings14 were pooled with wild-type control mice from Dlx-cKO
breedings (genotype: Cdkl5flox/y; +/+). Nex-cKO mice were generated using a similar strategy as
described previously. For breeding of R59X and wild-type control mice, each breeding cage
consistent of two heterozygous female mice (genotype: R59X/+) and one male mouse (genotype:
+/y). Male littermates (genotypes: R59X/y and +/y) were weaned at 3 weeks of age and housed
together, with all experiments performed on age-matched adult mice between 9-12 weeks of age.

Behavioral assays. All animal behavioral studies were carried out blinded to genotype. Mice
were allowed to habituate to the testing room for at least 1 h before the test, and testing was
performed at the same time of day. All animal behaviors were performed on adult male mice at 9–
12 weeks of age, and the analysis of behavioral data was carried out by a researcher blinded to
genotype.
Elevated zero maze. The elevated zero maze (Stoelting, Illinois, USA) consists of a circularshaped platform elevated above the floor. Two opposite quadrants of the maze are enclosed (wall
height, 12 inches), whereas the other two are open (wall height, 0.5 inches). Mice were placed in
one of the closed quadrants and their movement traced over the course of 5 min. Analysis,
including the quantification of percent of time spent in open arms and the number of entries, was
performed manually using a stopwatch. An entry was defined as a transition from a closed to
open arm, or vice versa, that involves all four paws.
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Three-chambered social approach assay. The social approach assay was performed as
previously described(Fairless et al., 2013; Sankoorikal, Kaercher, Boon, Lee, & Brodkin, 2006).
The social choice test was carried out in a three-chambered apparatus that consisted of a center
chamber and two end chambers. Before the start of the test and in a counter-balanced sequence,
one end chamber was designated the social chamber, into which a stimulus mouse would be
introduced, and the other end chamber was designed the nonsocial chamber. Two identical, clear
Plexiglas cylinders with multiple holes to allow for air exchange were placed in each end
chamber. In the habituation phase of the test, the test mouse was placed in the center chamber
and allowed to explore all three chambers for 10 min. During this acclimation period, baseline
measurements of how much time the mouse spent in each of the three chambers and the
distance traveled by the test mouse were collected. In the social choice phase of the test, a
stimulus mouse (adult gonadectomized A/J mice; The Jackson Laboratory) was placed in the
cylinder in the social chamber while a novel object was simultaneously placed into the other
cylinder in the nonsocial chamber. During the 5-min social choice period, chamber times and
numbers of transitions among chambers were again recorded. In the direct social interaction test,
the cylinders were removed simultaneously following the social choice test, and the amount of
time test and stimulus mice spent in direct contact (sniffing, allogrooming) was measured. If
fighting persisted for more than several seconds, the mice were removed from the apparatus and
excluded from the study.
Y-maze. Spontaneous alternation behavior was measured on a Y-maze apparatus (San Diego
Instruments, California, USA), composed of three arms (Arm A: 8in. x 5in. x 3in.; Arms B and C:
6in. x 5in. x 3in.). For habituation, the test mouse was placed in each of the three arms, facing the
center, and allowed to make one choice to enter another arm. For testing, the mouse was placed
in Arm C, facing the center, and allowed to freely explore the maze for 5 min. A spontaneous
alternation was defined an entry into the arm less recently explored. Percent spontaneous
alternation was calculated as the number of spontaneous alternations over the total number of
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entries. For example, the sequence C,B,A,B,C,B,A,C (starting in arm C) resulted in a percent
spontaneous alternation of 4/6 = 67%.
Barnes maze. Hippocampal-dependent memory was assessed on a Barnes Maze apparatus
(San Diego Instruments, California, USA), a circular platform with 36-inch diameter and 20
equally spaced escape holes along the perimeter, one of which leads to a “target” escape box.
Bright lighting was used as stimulus to complete the task. The assay consisted of five phases:
adaptation, forward acquisition training, forward probe trials, reversal training, and reversal probe
trials. For adaptation, each mouse was placed in a dark start chamber in the middle of the maze
for 10 s, then uncovered and guided gently to the escape box. Forward acquisition training
consisted of two trials per day for 4 days, with each mouse starting in the dark start chamber in
the middle of the maze and subsequently allowed to explore the maze for 3 min. The trial ends
when the mouse enters the target escape hole or after 3 min have elapsed, after which the
mouse is guided gently to the escape hole. After reaching the escape hole, the mouse is allowed
to remain there for 1 min. Forward probe trials were conducted on day 5, 24 h after the last
training day. During the probe trial, the maze is in the same position as the training days, and the
target hole is closed. Each trial lasted 90 s, during which the number of errors (pokes into nontarget holes) made prior to reaching the target hole is quantified. Days 6–10 consisted of reversal
training, conducted using a similar protocol as forward acquisition training, except that the target
was a stable escape hole moved 180° from its location during forward acquisition training.
Reversal probe trials were conducted on day 11 and identically to forward probe trials. In addition
to quantifying the number of total errors, the number of perseverations, defined as pokes into the
previous target hole during forward acquisition training, was counted.
Locomotor assay. Locomotor activity was measured by beam breaks in a photobeam frame (Med
Associates, Vermont, USA). Mice were individually placed into a clean home-cage like
environment lined with bedding and resting within a photobeam frame. The number of beam
breaks as a measure of locomotor activity was quantified over 30 min in 5-min bins.
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Accelerating Rotarod assay. Mice were placed on an accelerating Rotarod apparatus (Med
Associates) for 16 trials (four trials a day for 4 consecutive days) with at least 15 min of rest
between the trials. Each trial lasted for a maximum of 5 min, during which the rod accelerated
linearly from 4 to 40 rpm. The amount of time for each mouse to fall from the rod was recorded for
each trial.
Olfaction. Mice were tested for whether they could detect and differentiate odors in a habituation–
dishabituation protocol modified from Yang and Crawley. Mice were presented with cotton-tipped
wooden applicators dipped in water, vanilla, or swiped across the bottom of an unfamiliar social
cage. Each stimulus was presented for 2 min with a 1-min inter-trial interval. Time spent sniffing
was defined as when the animal was oriented with its nose 2 cm or closer toward the cotton tip.
Repetitive behavior. Mice were individually placed into a clean home-cage like environment lined
with bedding. After allowing 5 min for habituation, 10 min of activity was videotaped for each
mouse. The duration of repetitive behavior, defined as grooming or digging, was scored manually
using a stopwatch.
Nesting. Nesting behavior was scored in accordance with the standard protocol and rating scale
originally described by Deacon(Deacon, 2006). Four- to five-week old mice were assessed for
amount of cotton material used after 20 h and for the height and shape of the nest. Rating scale
as follows: (1) nestlet not noticeably touched (>90% intact); (2) nestlet partially torn (50–90%
remaining intact); (3) nestlet mostly shredded but often no identifiable nest site: <50% of the
Nestlet remains intact, but <90% is within a quarter of the cage floor area; (4) an identifiable but
flat nest: >90% of the Nestlet is torn and the material is gathered into a nest within a quarter of
the cage floor area, but the nest is flat, with walls higher than mouse body height (of a mouse
curled up on its side) for <50% of its circumference; (5) a (near) perfect nest: >90% of the Nestlet
is torn and the nest is a crater, with walls higher than mouse body height for >50% of its
circumference.
Dyadic interaction. The dyadic interaction test is an abbreviated version of the three-chambered
assay to quantitatively assess the duration of direct social interaction in two freely behaving mice.
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One week prior to the assay, male R59X and wild-type control mice were singly housed to
increase the motivation for social interaction and reduce aggression. Age-matched, novel, wildtype male stimulus mice were group-housed. On the day of the test, test and stimulus mice were
acclimated to the room for 1 h prior to the start of the assay. Following this period, each test
mouse is placed individually in a clear, round Plexiglass cage (Pinnacle Technology, Lawrence,
Kansas, USA) measuring 8 inches tall and 9.5 inches in diameter, with a thin layer of bedding.
Following 30 min of habituation in the cage, a novel, age-matched stimulus mouse was placed
into the cage, and the mice were allowed to freely interact under video monitoring for 10 min. The
total duration of social interaction initiated by the test mouse in the first 2 min was scored, and this
included oro-genital sniffing, oro-facial sniffing, close following, placing one or both paws on the
stimulus mouse, or allogrooming of the stimulus mouse. “Co-tested pairs” refer to side-by-side
tests involving two littermate R59X and wild-type control mice, each interacting with a novel
stimulus mouse in a separate cage.

Drug administration. Mice were acclimated to daily intraperitoneal (i.p.) injections of vehicle
(saline) for 3 days prior to each set of behavioral assays. For each behavioral cohort, the entire
cohort was administered either vehicle or drug, with the experimenter blinded to the genotypes of
mice throughout. All animal behaviors were performed on adult male mice at 9–12 weeks of age,
and the analysis of behavioral data was carried out by a researcher blinded to genotype. Vehicle
and drug (memantine hydrochloride, Tocris Biosciences, United Kingdom) were diluted in saline
at 10 μL per gram mouse body weight for administration. Vehicle or drug was administered 1 h
prior to the start of each behavioral assay, and during this period, mice were allowed to habituate
in the room where the assay would be carried out. Notably, we used doses of memantine similar
to those from studies in other mouse models of neurodevelopmental disorders, which are
expected to result in reversible blockade of a relatively small fraction of synaptic NMDA
receptors(Chung et al., 2015; Figueiredo et al., 2013).

40

Ex vivo slice preparation. All steps of electrophysiological experiments, including data collection
and analysis, were performed by a researcher blinded to genotype. Acute hippocampal slices
were prepared from mice 9 to 12 weeks of age. Animals were anesthetized with isoflurane and
transcardially perfused with ice-cold oxygenated (95% O2, 5% CO2) cutting artificial
cerebrospinal fluid (aCSF) solution (comprised of (mM): 2.5 KCl, 1.25 NaH2PO4, 5 MgSO4, 0.5
CaCl2, 200 sucrose, 25 NaHCO3, 25 glucose, ~300 mOsm, 7.2–7.4 pH). After decapitation,
brains were removed for sectioning in the same ice-cold cutting aCSF using a Vibratome (Leica
Microsystems 1200 s). For whole-cell patch-clamp recordings of mE/IPSCs and the measurement
of intrinsic membrane properties, 350-μm transverse hippocampal sections were prepared. For all
voltage-sensitive dye experiments, 400-μm transverse hippocampal sections were prepared.
Slices were recovered in the same cutting aCSF solution at 32 °C for 30 min and transferred to an
oxygenated room-temperature solution composed of 50% cutting aCSF and 50% regular aCSF
(comprised of (mM): 125 NaCl, 2.5 KCl, 1.25 NaH2PO4, 10 glucose, 26 NaHCO3, 2 CaCl2, 1
MgCl2, ~300 mOsm, 7.2–7.4 pH) for 30 min. Subsequently, slices were transferred to 100%
regular aCSF at room temperature for an additional 30 min before recording. All recordings were
performed at 34 °C.

Miniature spontaneous excitatory postsynaptic currents (mEPSCs). A pipette internal
solution comprised of (mM): 140 KCH3OSO3, 5 KCl, 0.5 EGTA, 1 MgCl2, 10 HEPES, 5 MgATP,
0.25 NaGTP, ~292 mOsm, ECl = −78.8 mV was used. Pipettes 4–6 MΩ in resistance were pulled
from borosilicate glass capillaries (World Precision Instruments, 1B150F-4) on a Sutter
Instruments P-1000 pipette puller. Voltage-clamp traces 5 min in duration were recorded at a
holding potential of −70 mV in the presence of 1 μM tetrodotoxin (Tocris). All recordings were
conducted with access resistance of <20 MΩ, leak current of <100 pA, and an applied series
resistance compensation of 80%. Cells that did not maintain these parameters for the duration of
the recording were eliminated. Analysis of mEPSCs was performed using pCLAMP10 (Axon
Instruments, Molecular Devices) using a variable-amplitude template method, generated from a
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stable recording of at least 50 mEPSC events. Each trace was first low-pass filtered at 1 kHz, and
negative-going mEPSCs were detected using a template match threshold of 4, without fitting.

Miniature spontaneous inhibitory postsynaptic currents (mIPSCs). In order to record
mIPSCs while maintaining a hyperpolarized membrane voltage, a high-chloride pipette internal
solution (comprised of (mM): 100 CsCH3O3S, 50 CsCl, 10 HEPES, 0.2 BAPTA, 3 KCl, 1 MgCl2,
0.25 GTP-Tris, 2.5 creatine phosphate disodium, 2 MgATP, ~296 mOsm, ECl = −23.7 mV) was
used. Pipettes 4–6 MΩ in resistance were pulled from borosilicate glass capillaries (World
Precision Instruments, 1B150F-4) on a Sutter Instruments P-1000 pipette puller. Voltage-clamp
traces 3 min in duration were recorded at a holding potential of −70 mV in the presence of 1 μM
tetrodotoxin (Tocris) and 2 mM kynurenic acid (Sigma Aldrich). All recordings were conducted
with access resistance of <20 MΩ, leak current of <100 pA, and an applied series resistance
compensation of 80%. Cells that did not maintain these parameters for the duration of the
recording were eliminated. Analysis of mIPSCs was performed using pCLAMP10 (Axon
Instruments, Molecular Devices) using a variable-amplitude template method, generated from a
stable recording of at least 50 mIPSC events. Each trace was first low-pass filtered at 1 kHz, and
negative-going mIPSCs were detected using a template match threshold of 4, without fitting.

Voltage-sensitive dye imaging. Following recovery, each slice was bulk-loaded with 100 μL of a
solution containing the voltage-sensitive dye di-2-ANEPEQ49,50 (JPW1114, Molecular Probes)
diluted at 0.05 mg/mL in aCSF(Antic & Zecevic, 1995; Habib-E-Rasul Mullah et al., 2013). Each
slice was stained for 14 min, washed with aCSF, and imaged in an interface chamber using an
80 x 80 CCD camera recording with a 1 kHz frame rate (NeuroCCD; RedShirt Imaging).
Illumination was provided by a 530 nm Green LED (Thor Labs, M530L3-C2). A filter set (Chroma
Technologies 11007v2 wide Green) was used to allow excitation at 510–560 nm and collection of
emitted fluorescence at a wavelength > 592 nm.

42

A concentric bipolar tungsten microelectrode was used for stimulation of the perforant path. Two
successive stimuli were applied with an inter-stimulus interval of 200 ms. Two stimulation
intensities (200 μA and 400 μA) were used. Imaging trials lasted a total of 1000 ms each, with a
20 s inter-trial interval. Interleaved trials without stimulation allowed for background subtraction.
All data analysis was performed in IGOR (Wavemetrics) on the average of 12 trials. Data
were displayed as the change in fluorescence divided by the resting fluorescence (ΔF/F).
Regions of interest (ROIs) were drawn for the molecular layer of the dentate gyrus, the dentate
granule cell layer, and the hilus. Like other dyes of the ANEPP family, di-2-ANEPEQ decreases in
fluorescence upon membrane depolarization. To be consistent with electrophysiological
conventions, depolarizing ΔF/F signals were displayed as upward signals (warmer colors) and
hyperpolarization ΔF/F signals were displayed as downward signals (colder colors). Snapshots of
VSDI represent an 80 × 80 pixel window, corresponding to an ~1.7 × 1.7 mm field of view.

Postsynaptic density protein purification. We adapted a widely used protocol for the
preparation of PSD fractions(Bermejo, Milenkovic, Salahpour, & Ramsey, 2014). Mice were
sacrificed via cervical dislocation, and their brains quickly extracted. Forebrain cortical tissues
were microdissected and Dounce-homogenized in 10 mL of homogenization buffer (0.32 M
sucrose, 4 mM HEPES, pH 7.4 with protease inhibitors). The homogenate was centrifuged at
1000 × g for 10 min at 4 °C to pellet cellular debris and nuclei (P1), and the subsequent
supernatant (S1) was centrifuged for another 15 min at 10,000 × g at 4 °C. The resulting pellet
(P2, “crude” synaptosomes) was resuspended in another 10 mL of homogenization buffer and
centrifuged at 10,000 × g for 15 min at 4 °C. The supernatant was discarded, and the resulting
pellet (P2’) was resuspended in 10 mL of 4 mM HEPES (pH 7.4) then homogenized on ice. The
lysate was incubated at 4 °C for 30 min while shaking to hypo-osmotically lyse the synaptosomes,
and then centrifuged for 20 min at 25,000 × g at 4 °C. The pellet (LP1) was resuspended in 1 mL
of homogenization buffer and layered on top of a discontinuous sucrose gradient (bottom to top:
1.5 mL of 1.2 M sucrose, 1 mL of 1.0 M sucrose, and 1 mL of 0.8 M sucrose). The gradient was
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ultracentrifuged at 150,000 × g for 1.5 h at 4 °C. The turbid layer between the 1.0/1.2 M sucrose
interphase containing the synaptic plasma membranes (~1 mL) was collected and resuspended in
5 mL of 4 mM HEPES to dilute out the sucrose. This fraction was ultracentrifuged again at
200,000 × g for 30 min at 4 °C. The resulting pellet was resuspended in 1 mL of 50 mM HEPES
with 2 mM EDTA (pH 7.4), and the membrane proteins extracted by adding Triton X-100 at a final
concentration of 0.5% and incubating at 4 °C while rotating for 15 min. The proteins were
centrifuged at 32,000 × g for 20 min at 4 °C, and the resulting pellet resuspended in 75 µL of
50 mM HEPES with 2 mM EDTA.

Brain microdissection. To assess CDKL5 protein expression in various brain regions, adult
male mice were sacrificed by cervical dislocation. After decapitation, brains were removed and
sectioned into 1 mm coronal slices using a mouse brain matrix. Tissue was dissected from the
somatosensory cortex, striatum, hippocampus, and cerebellum and homogenized in lysis buffer
containing 1% NP-40, pH 8.0.

Western blot. Protein concentration was measured using a Bradford assay. Purified synaptic
density membrane proteins or protein lysates were prepared for gel electrophoresis by adding 4X
LDS Sample Buffer (NuPAGE, NP0008) to a final concentration of 1x and β-mercaptoethanol to a
final concentration of 5%. Samples were heat-denatured at 75 °C for 20 min, and 7.5 µg of protein
was loaded into each well of a 4–12% Bis-Tris gradient gel (Invitrogen 10-well, 1.5 mm; NP0335).
Protein gels were run for 2 h at 125 V at room temperature on a ThermoFisher XCell SureLock
mini-cell electrophoresis box (EI001) using BioRad PowerPac HC High-Current Power Supply
(1645052), then transferred onto a nitrocellulose membrane (0.45 µm pore-size; Biorad 162–
0115) for 1 h and 10 min at 27 V at room temperature. The resulting membrane was blocked with
a 1:1 solution of LI-COR Odyssey blocking buffer (927–40100) and 1x PBS for 1 h at room
temperature.
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Primary antibodies used for CDKL5 detection are anti-N-terminal CDKL54 (in house;
diluted 1:500), anti-GAPDH (MA5–15738, Invitrogen; RRID: AB_10977387; diluted 1:1000), antiEB2 (AB45767, Abcam, diluted 1:1000). Secondary antibodies (Licor) are goat anti-rabbit IRDye
800CW and donkey anti-rabbit IRDye 680RD at dilutions of 1:10,000. Standard protocols were
used for the Odyssey Infrared Imaging System for visualization and quantification.
For postsynaptic density studies, the primary antibodies used were anti-N-terminal CDKL5, antiGluN1 (ThermoFisher, OMA1–04010; diluted 1:1000), anti-GluN2A (Frontier Institute,
AB_2571605; diluted 1:200), anti-GluN2B (Frontier Institute AB_2571761; diluted 1:200), antiGluA1 (Abcam, ab31232; diluted 1:1000), anti-GluA2 (Abcam, ab133477; diluted 1:2000), and
anti-ß-Actin (Abcam, ab8226; diluted 1:10,000). Secondary antibodies (LI-COR) were goat antirabbit IgG IRDye800CW and goat anti-mouse IgG IRDye680LT at dilutions of 1:10,000, and
incubated for 1 h at room temperature. Standard protocols were used for the Odyssey Infrared
Imaging System (LI-COR) for visualization and quantification.

Statistical analyses. For behavioral assays involving Dlx-cKO mice, we chose similar sample
sizes for all behavioral experiments based on previous published studies of Cdkl5 constitutive
knockout mice and Cdkl5 glutamatergic conditional knockout mice(Tang et al., 2017; I. T. Wang
et al., 2012). For behavioral assays involving drug administration, we used pilot behavioral
cohorts to estimate effect sizes required for detecting significant wild-type-mutant differences and
used similar samples sizes for saline- and drug-administered cohorts. Importantly, the number of
mice used were pre-determined prior to the start of each experiment.
For behavioral assays, statistical analyses were performed using Prism (GraphPad). All
data sets were analyzed using the Shapiro-Wilk test for normality. For one-sample comparisons,
data sets with normal distributions were analyzed for significance using the one-sample t-test,
whereas data sets with non-normal distributions were analyzed using the Wilcoxon signed-rank
test. For two-sample comparisons, data sets with normal distributions were analyzed for
significance using the unpaired Student’s t-test, whereas data sets with non-normal distributions
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were analyzed using the Mann–Whitney test. Two-way repeated measures ANOVA or the
Kruskal–Wallis test was conducted for the appropriate data sets with Holm-Sidak’s multiplecomparison test. All one-sample, two-sample, and multiple-comparison tests were two-tailed.
All other assays that involved sub-sampling of animals were analyzed using R (The R
Project for Statistical Computing). Each data set was analyzed using a linear mixed effect model,
where Genotype was modeled as a fixed effect term and Animal was modeled as a random effect
term. This model accounts for both between-animal and between-cell variation. For each assay,
null and alternative models were constructed using the lmer function in the lme4 package52 in the
following format(Bates, Machler, Bolker, & Walker, 2015):
m0=lmer(Outcome∼(1|Animal),REML=TRUE)
m1=lmer(Outcome∼Genotype+(1|Animal),REML=TRUE)

For data sets involving a third term (e.g., cumulative frequency bin), the following null and
alternative models were constructed, in order to test the significance of an interaction between
Genotype and the third term:
m0=lmer(Outcome∼Bin+Genotype+(1|Animal),REML=TRUE)
m1=lmer(Outcome∼Bin∗Genotype+(1|Animal),REML=TRUE)

To make statistical comparisons, the KRmodcomp function from the pbkrtest package
(Halekoh and Højsgaard, 2014) was used:
KRmodcomp (m0,m1)

The KRmodcomp function reports a modified F-test statistic based on the Kenward and
Roger approximation, which accounts for the small sample sizes in our study, modified numerator
and denominator degrees of freedom, and a p-value. The estimated effect of Genotype is
obtained from the alternative model constructed using the lmer function from lme4.
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Post-hoc testing for linear mixed effect models (e.g., at cumulative frequency bins) was
performed using the least-squares means method for multiple comparisons. The lsmeans
package was used53 on the alternative model generated by lmer(Lenth, 2016):
lsmeans(m1, pairwise ~ Genotype | Bin, mode = ‘kenward-roger’)
For the analysis of cumulative distributions (mEPSC and mIPSC inter-event intervals and
amplitudes), all samples from each individual cell was sorted, binned, and averaged at percent
intervals, effectively generating a binned cumulative distribution curve for each cell. Data from all
cells of a given genotype were plotted at these distinct binned percent intervals with the mean
and error bars indicating s.e.m. The results were analyzed using linear mixed effect models,
incorporating a third term, cumulative frequency bin.
All graphs are plotted using Prism (GraphPad). Boxplot limits indicate the minimum and
maximum, and boxplot center line indicates the median. In our figures, p-values between 0.05
and 0.1 are shown explicitly, * is used to denote all 0.01 < p < 0.05, ** for 0.001 < p < 0.01, *** for
0.0001 < p < 0.001, and **** for p < 0.0001.
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Figures

Figure 1. Generation and validation of mice lacking CDKL5 selectively in forebrain
GABAergic neurons (Dlx-cKO).
(A) Schematic representing the generation of Dlx-cKO mice using a conditional Cdkl5 exon 6floxed Cdkl5 mouse line (Tang et al., 2017) and the Dlx5/6-Cre driver (Monory et al., 2006). (B)
Validation of the cell type-specificity of CDKL5 protein knockout using microdissected brain
tissue. Two pairs of WT and Dlx-cKO littermates were used. In the cortex, a region enriched for
glutamatergic neurons, Dlx-cKO mice show comparable amounts of CDKL5 protein to WT. In the
striatum, a region enriched for GABAergic neurons, Dlx-cKO mice show reduced CDKL5 protein
in comparison to WT. The residual CDKL5 protein likely originates from non-GABAergic cells in
this brain region.
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Figure 2. Dlx-cKO mice show unaltered growth, locomotion, anxiety-related behavior, and
motor coordination.
(A) Unaltered body weight of Dlx-cKO mice at various ages (WT, n = 4-36 mice / time point; DlxcKO, 14-29 mice / time point; unpaired t-tests with Holm-Sidak’s correction for multiple
comparisons). (B) Dlx-cKO mice show unaltered home-cage locomotion on the beam break
assay (WT, n = 43, Dlx-cKO, n = 32; one-way repeated-measures ANOVA). (C) Dlx-cKO mice,
show unaltered anxiety-related behavior, as assessed by the percent time spent in open arms, on
the elevated zero maze assay (WT, n = 28, Dlx-cKO, n = 24; unpaired t-test). (D) Dlx-cKO mice
show unaltered motor coordination and learning on the Rotarod assay (WT, n = 39, Dlx-cKO, n =
23; one-way repeated-measures ANOVA).
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Figure 3. Dlx-cKO mice exhibit an autistic-like phenotype.
(A) Dlx-cKO mice showed similar times spent interacting with empty cylinders during the
habituation phase of the three-chambered social assay. Cyl1/Cyl2: empty cylinders 1 and 2. Soc:
social cylinder containing a stimulus mouse. Non-soc: non-social cylinder containing an object.
(WT, n = 28; Dlx-cKO, n = 26; paired t-test). (B) Wild-type mice showed a significant preference
for interacting with the cylinder containing a social stimulus, but Dlx-cKO mice did not show a
significant difference in time spent sniffing the social and non-social cylinders (paired t-test). (C)
Dlx-cKO mice also spent significantly reduced time initiating social contact during the direct
interaction phase (unpaired t-test). (D) Dlx-cKO mice showed unaltered ability to discriminate
between odors and habituation to the same odor upon repeated presentation. However, Dlx-cKO
mice show a reduced time sniffing a social scent compared to WT (WT, n = 20; Dlx-cKO, n = 14;
two-way ANOVA with Holm-Sidak’s multiple comparisons test; error bars demonstrate s.e.m.). (E)
Dlx-cKO mice spent significantly more time engaging in repetitive behaviors, including grooming
and digging, within a 10-minute period in a home cage-like environment (WT, n = 18; Dlx-cKO, n
= 16; unpaired t-test). (F) Dlx-cKO mice show significantly reduced nesting scores on the nesting
assay (WT, n = 9; Dlx-cKO, n = 8; Mann-Whitney test). (G) Dlx-cKO mice show unaltered
spontaneous alternation percentage in comparison to WT mice (WT, n = 20; Dlx-cKO: n = 12;
unpaired t-test). (H) The total number of entries made were not significantly different between
Dlx-cKO and WT mice (unpaired t-test). (I) Dlx-cKO mice did not show a significant difference in
the total number of errors made on forward probe trials of the Barnes maze (WT, n = 18; DlxcKO: n = 14; unpaired t-test). (J) Dlx-cKO mice made significantly more errors on the reversal
probe trials of the Barnes maze (unpaired t-test). (K) On the reversal probe trials, Dlx-cKO mice
also made significantly more perseverations, or visits to the original target hole location (MannWhitney test). *p<0.05, **p<0.01, ***p<0.001, and ****p<0.0001.
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Figure 4. Dlx-cKO mice show aberrant paired-pulse facilitation.
(A) Schematic of voltage-sensitive dye imaging (VSDI) showing the site of stimulation at the
perforant path and regions of interest used for quantitative analysis (GCL, granule cell layer; ML,
molecular layer; HIL, hilus). Snapshots of VSDI responses in a wild-type slice, from left to right:
baseline, peak response to first stimulus, baseline immediately prior to second stimulus, peak
response to second stimulus, 100 ms after second peak response (200 μA x 2 stimuli, with 200
ms inter-stimulus interval). (B) Averaged VSDI responses (ΔF/F) in the GCL for WT, Nex-cKO,
and Dlx-cKO mice in response to each of the two stimuli. Depolarization (decrease in ΔF/F) is
displayed as an upward signal, while hyperpolarization (increase in ΔF/F) is displayed as a
downward signal. Error envelopes represent mean +/- s.e.m. (C) Peak amplitudes of the GCL
response to the first stimulus were not different between WT, Nex-cKO, and Dlx-cKO mice (linear
mixed effect analysis). (D) Peak amplitudes of the GCL response to the second stimulus were
significantly different between Nex-cKO and Dlx-cKO mice (linear mixed effect analysis with
Tukey’s correction for multiple comparisons). (E) Ratios of peak responses in the GCL. Nex-cKO
slices showed significant paired-pulse depression, whereas Dlx-cKO slices showed significant
paired-pulse facilitation (one-sample t-tests for each of WT, Nex-cKO, and Dlx-cKO, two-tailed).
Dlx-cKO also showed significantly increased paired-pulse ratio in comparison to Nex-cKO (linear
mixed effect analysis with Tukey’s correction for multiple comparisons). (F-K) Averaged VSDI
responses (ΔF/F) in the ML and HIL for WT, Nex-cKO, and Dlx-cKO mice in response to each of
the two stimuli (linear mixed effect analysis). (H) Peak ratios in ML (one-sample t-test or Wilcoxon
signed-rank test, two-tailed). (K) Peak ratios in HIL (one-sample t-test or Wilcoxon signed-rank
test, two-tailed). For all experiments, n=20 slices/5 mice for WT, n=12 slices / 4 mice for NexcKO, and n=19 slices/5 mice for Dlx-cKO. *p<0.05, ****p<0.0001.
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Figure 5. VSDI responses in regions of the dentate gyrus at 400μA stimulation intensity.
(A-C) Peak responses are not significantly different between WT, Nex-cKO, and Dlx-cKO (linear
mixed effect analysis). In all three regions (ML, GCL, and HIL) at this higher stimulation intensity,
Dlx-cKO show significantly increased facilitation, whereas Nex-cKO shows no significant
facilitation or depression (one-sample t-test or Wilcoxon signed-rank test, two-tailed). In the GCL,
Dlx-cKO also showed significantly increased paired-pulse ratio in comparison to Nex-cKO (linear
mixed effect analysis with Tukey’s correction for multiple comparisons). *p<0.05, **p<0.01,
***p<0.001, and ****p<0.0001.
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Figure 6. Enhanced excitatory synaptic transmission but unaltered inhibitory synaptic
transmission in Dlx-cKO mice.
(A) Representative mEPSC traces for cells from WT and Dlx-cKO mice. (B) Dlx-cKO mice show
significantly enhanced mEPSC frequency at CA1 pyramidal neurons (linear mixed effect
analysis). (C) The cumulative frequency distribution of mEPSC inter-event intervals is also
significantly shifted in Dlx-cKO mice (linear mixed effect analysis with least-square means posthoc testing). (D) The mEPSC median amplitude is unaltered in Dlx-cKO mice (linear mixed effect
analysis). (E) The cumulative frequency distributions of mEPSC amplitudes are not significantly
different between Dlx-cKO and WT mice (linear mixed effect analysis). (F) Representative mIPSC
traces for cells from WT and Dlx-cKO mice. (G) Dlx-cKO mice show unaltered mIPSC frequency
at CA1 pyramidal neurons (linear mixed effect analysis). (H) The cumulative frequency
distributions of mIPSC inter-event intervals were not significantly different between Dlx-cKO and
WT mice (linear mixed effect analysis). (I) The median amplitude of mIPSCs is not significantly
different between Dlx-cKO and WT mice (linear mixed effect analysis). (J) The cumulative
frequency distributions of mIPSC amplitudes are not significantly different between Dlx-cKO and
WT mice (linear mixed effect analysis). For mEPSCs: WT, n = 18 cells / 3 mice; Dlx-cKO, n = 16
cells / 3 mice; for mIPSCs: WT, n = 18 cells / 3 mice; Dlx-cKO, n = 18 cells / 3 mice. *p<0.05.
Error bars s.e.m.
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Figure 7. Unaltered mEPSC and mIPSC kinetics in Dlx-cKO mice.
(A) The median 10-90% rise time of mEPSCs is unaltered in Dlx-cKO mice (linear mixed effect
analysis). (B) The median 90-10% decay times of mEPSCs is unaltered in Dlx-cKO mice (linear
mixed effect analysis). (C) The median 10-90% rise time of mIPSCs is unaltered in Dlx-cKO mice
(linear mixed effect analysis). (D) The median 90-10% decay times of mIPSCs is unaltered in DlxcKO mice (linear mixed effect analysis).
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Figure 8. Dlx-cKO mice have an upregulation of NMDA receptors at the postsynaptic
membrane.
(A) Representative western blot results for several major ionotropic glutamate receptor subunits
from postsynaptic density membrane fractions. Samples are from pairs of WT and Dlx-cKO
littermates. (B-F) Dlx-cKO mice show a selective increase in levels of GluN1 and GluN2B, two of
the major subunits that compose the NMDA receptor (WT, n = 10 mice; Dlx-cKO, n = 10 mice;
unpaired t-test or Mann-Whitney test). *p<0.05.
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Figure 9. Acute NMDAR blockade ameliorates autistic-like features in Dlx-cKO mice.
(A) Total grooming in a home cage-like environment is significantly increased in saline-treated
Dlx-cKO mice in comparison to WT, and memantine at 5 mg kg-1 significantly rescued the
increased grooming phenotype in Dlx-cKO mice (n = 8 for saline groups; n = 7 for memantine
groups; one-way ANOVA with Holm-Sidak’s multiple comparisons test). (B) Memantine
significantly reduces the duration of the longest grooming bout in Dlx-cKO mice. (C) On the
dyadic social assay, saline-treated Dlx-cKO mice spend significantly less time initiating social
interaction with a novel stimulus mouse in comparison to WT. Memantine at 5 mg kg -1 resulted in
a significant increase in time spent in social interaction (n = 8 for saline groups; n = 7 for WT memantine; n = 8 for Dlx-cKO - memantine; one-way ANOVA with Holm-Sidak’s multiple
comparisons test). (D) For co-tested pairs of Dlx-cKO and WT mice, the ratio of time spent in
direct interaction was significantly reduced in saline-treated mice. Memantine normalized this
ratio, indicating a differential effect of this drug on social interaction in WT and Dlx-cKO mice (n=7
for all groups; unpaired t-test). *p<0.05, **p<0.01, and ***p<0.001.

58

Figure 10. R59X mice have an upregulation of NMDA receptors at the postsynaptic
membrane.
(A) Schematic of the R59X non-sense mutation at arginine 59, which results in early truncation of
the catalytic domain of CDKL5. (B) Representative western blot results for several major
ionotropic glutamate receptor subunits from postsynaptic density membrane fractions. Samples
are from pairs of WT and R59X littermates. (C-G) R59X mice show a selective increase in level of
GluN2B, a major subunit of the NMDA receptor (WT, n = 8 mice; R59X, n = 8 mice; unpaired ttest or Mann-Whitney test). *p<0.05
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Figure 11. Loss of full-length CDKL5 protein in R59X knock-in mice.
Loss of full-length CDKL5 protein in R59X mice, shown with western blots of dissected whole
cortex lysate in four pairs of WT and R59X littermates. Green arrow indicates band corresponding
to CDKL5 (note a non-specific band running at approximately the same size). Total EB2 protein
was used as a loading control.

60

Figure 12. Acute NMDAR blockade ameliorates autistic-like features, but not learning and
memory, in CDKL5-deficient mice.
(A) Spontaneous alternation percentage is significantly reduced in saline-treated R59X mice in
comparison to WT mice. However, acute memantine administration at either 2.5 or 5 mg kg -1
doses did not significantly rescue the spontaneous alternation deficit (WT-saline, n = 9; R59Xsaline, n = 11; WT-memantine (5 mg kg-1), n = 6; R59X-memantine (5 mg kg-1), n = 6; WTmemantine (2.5 mg kg-1), n = 6; R59X-memantine (2.5 mg kg-1), n = 6; Kruskal-Wallis test with
Dunn’s multiple comparisons test). (B) Total grooming in a home cage-like environment is
significantly increased in saline-treated R59X mice in comparison to WT, and memantine at 5 mg
kg-1 significantly ameliorated the increased grooming phenotype in R59X mice (n = 8 for all
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groups; one-way ANOVA with Holm-Sidak’s multiple comparisons test). (C) The duration of the
longest grooming bout is significantly increased in saline-treated R59X mice in comparison to
WT, and memantine also ameliorated this aspect of repetitive behavior (n = 8 for all groups; oneway ANOVA with Holm-Sidak’s multiple comparisons test). (D) On the dyadic social assay,
saline-treated R59X mice spend significantly less time initiating social interaction with a novel
stimulus mouse in comparison to WT. Memantine at 5 mg kg-1 resulted in a significant increase in
time spent in social interaction (n = 7 for all groups; one-way ANOVA with Holm-Sidak’s multiple
comparisons test). (E) For co-tested pairs of R59X and WT mice, the ratio of time spent in direct
interaction was significantly reduced in saline-treated mice. Memantine normalized this ratio,
indicating a differential effect of this drug on social interaction in WT and R59X mice (n=7 for all
groups; unpaired t-test). *p<0.05, **p<0.01, ***p<0.001, and ****p<0.0001.
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CHAPTER 3 – CDKL5 IS ESSENTIAL IN THE POST-DEVELOPED BRAIN TO
MAINTAIN MULTIPLE BEHAVIORAL DOMAINS, HIPPOCAMPAL CIRCUIT
COMMUNICATION, AND SYNAPTIC MORPHOLOGY

Contributions: Barbara Terzic led this study with help from Sheng Tang and Yu-Ting Liu
for cellular morphology experiments, and Zhaolan Zhou for the review and interpretation
of data. Yue Cui managed all mouse husbandry, genotyping, and breeding. Barbara
Terzic wrote this chapter with input from all authors.

Abstract
CDKL5 deficiency disorder (CDD) is an early-onset, neurodevelopmental syndrome
characterized by intractable seizures, intellectual disability, hypotonia, and autistic features. It is
associated with pathogenic variants in the gene encoding cyclin-dependent kinase-like 5
(CDKL5), but the specific action of CDKL5 in neuronal development and maintenance remains
unclear. Although CDD is an early-onset disorder, from both a basic science and therapeutic
perspective it will be imperative to understand whether CDKL5 also serves a critical role in the
nervous system after development. In this study, we address this uncertainty by employing a
conditional adult knockout of Cdkl5 in mice to examine the post-developmental requirement of
CDKL5. We present, for the first time, that CDKL5 function is required in adult mice to maintain
proper performance within several behavioral domains, hippocampal circuit communication, and
dendritic spine morphology. We also demonstrate that CDKL5 continuously regulates
phosphorylation of the microtubule-associate protein EB2, highlighting disrupted microtubule
networks as a potential node in CDD pathogenesis. Collectively, these results demonstrate that
adult neural function requires CDKL5, and expand upon our current understanding of CDKL5 in
regulating neurological function. Importantly, our results also suggest that chronic treatment may
be needed for effective mitigation of CDD.
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Introduction
Mutations in the X-linked gene encoding cyclin-dependent kinase-like 5 (CDKL5) are
associated with a devastating neurodevelopmental syndrome known as CDKL5 deficiency
disorder (CDD)(Fehr et al., 2013; Kalscheuer et al., 2003; Tao et al., 2004; Weaving et al., 2004).
CDD is characterized by a constellation of phenotypes including intractable seizures, severe
neurodevelopmental delay, intellectual disability, hypotonia, and autistic features(S. T. Demarest
et al., 2019; H. E. Olson et al., 2019). The disorder predominantly afflicts young females
heterozygous for mutations in CDKL5, but hemizygous male cases have also been reported
(albeit at a significantly lower prevalence)(S. T. Demarest et al., 2019; Liang, Huang, Wang, & Lu,
2019). With an overall incidence of one per forty-two thousand live births, mutations in CDKL5
currently comprise one of the most common genetic causes of epilepsy in children(Symonds et
al., 2019). Despite this strong genetic link, the pathogenesis of CDD remains unclear. Presently,
there is no cure, and the limited treatment options available have focused on mitigating seizure
burden using a variety of non-specific anticonvulsants(H. E. Olson et al., 2019).
In 2012, the first knockout mouse model of CDD was generated and found to recapitulate
several of the cardinal phenotypes of the human disease including learning and memory
impairments, motor deficits, and autistic-like behaviors(I. T. Wang et al., 2012). This line carries a
deletion of Cdkl5 exon 6, mimicking a reported CDD patient splice site mutation resulting in exon
6 skipping and loss of full-length protein(Archer et al., 2006). Several additional knockout and
knock-in lines have since been generated with similar behavioral deficits, highlighting the
reproducibility of CDD-related phenotypes in mice(Amendola et al., 2014; Okuda et al., 2018;
Tang et al., 2019). Despite the multitude of CDD models, the time course of CDD pathogenesis,
specific roles for CDKL5 in nervous system development versus maintenance, and reversibility of
CDD-related phenotypes remain undetermined.
CDKL5 is a serine-threonine kinase most highly expressed in forebrain neurons and
enriched at the neuronal post-synaptic density(Kilstrup-Nielsen et al., 2012; Ricciardi et al., 2012;
Zhu et al., 2013). Recent work has identified microtubule-associated proteins as targets of the
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kinase, revealing a potential role for CDKL5 in regulating the microtubule network and
morphology of neurons(Lucas L. Baltussen et al., 2018; Muñoz et al., 2018). Indeed, previous
studies have reported that shRNA-mediated knockdown of CDKL5 leads to an increased density
of filipodia-like, or immature, spine protrusions, consistent with observed reductions in the
frequency of miniature excitatory postsynaptic currents (mEPSCs) in cultured hippocampal
neurons(Ricciardi et al., 2012). Loss of CDKL5 in vivo in mice results in reduced dendritic spine
stability and density in somatosensory cortex and visual cortex, but increased spine density in the
hippocampus. Conditional knockout of CDKL5 selectively from forebrain excitatory neurons also
results in an increased spine density and frequency of mEPSCs within the hippocampal
CA1(Della Sala et al., 2016; Lupori L, 2019; Okuda et al., 2018; Tang et al., 2017). Conflicting
results on these cellular phenotypes are likely due to regional differences within the brain as well
as in vitro versus in vivo variability on neuronal activity and spine dynamics. Furthermore, the cellautonomous versus non cell-autonomous effects of CDKL5 loss on these reported phenotypes,
particularly in light of developmental compensation that may occur with germline or cell typespecific Cdkl5 deletion, remain unaddressed.
Clinical reports illustrating the early, postnatal onset of CDD symptomology support a
critical role for CDKL5 in the developing nervous system(H. E. Olson et al., 2019; Y. C. Zhu & Z.
Q. Xiong, 2019). However, from a treatment perspective, it will be important to determine whether
CDKL5 is also required for the maintenance of neurological function after development. Would
transient treatment of CDKL5-related functional pathways during early postnatal life be sufficient
to permanently mitigate disease? With recent advances in precision medicine highlighting
promising treatment options for CDD patients in the future, it is imperative to establish the
temporal role of CDKL5 in neuronal development versus maintenance in order to inform
treatment time windows.
To address these questions, we have employed a genetic strategy to ablate Cdkl5
expression in adult mice and evaluate the functional significance of CDKL5 in the mature brain.
We find that post-developmental deletion of Cdkl5 results in behavioral and circuit deficits in adult
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mice similar to germline knockout mice, suggesting that CDKL5 is indispensable in adulthood. We
also demonstrate that adult loss of CDKL5 alters neuronal dendritic spine morphology, but not
dendrite complexity, in a cell autonomous manner, highlighting a critical role for this kinase in
synaptic maintenance. These findings are the first to delineate a post-developmental requirement
for CDKL5, providing critical insight into the endogenous requirements of CDLK5 and informing
future therapeutic efforts aimed towards the treatment of CDD.

Results
Post-developmental loss of CDKL5 results in behavioral deficits similar to germline
knockout mice
Several groups have previously reported on the early-developmental expression of
CDKL5 across different tissues, demonstrating it to be mostly highly enriched in forebrain
neurons(Kilstrup-Nielsen et al., 2012; Y. C. Zhu & Z. Q. Xiong, 2019). We extended these studies
by quantifying CDKL5 protein expression in the forebrain at different developmental timepoints,
using knockout littermates to corroborate antibody specificity. We found that CDKL5 protein was
detectable in forebrain tissues at postnatal day (P)0, followed by a gradual increase and peak in
expression around P14 (Figure 1a). After this postnatal peak, CDKL5 remained stably expressed
in the forebrain throughout adulthood, suggesting that its function may not be exclusively limited
to developmental processes (Figure 1a). This prompted us to investigate the necessity of CDKL5
in the maintenance of proper neurological function after development.
We crossed our previously-reported Cdkl5 floxed mouse line (Cdkl5flox) to transgenic
mice expressing a Cre-ERT2 fusion gene under the control of the human ubiquitin C promoter
(UBC-Cre-ERT2, hereafter referred to as CreER)(Tang et al., 2017). This line drives ubiquitous
Cre-ER expression, and thereby allows for temporal control of gene deletion using
tamoxifen(Ruzankina et al., 2007). We delivered tamoxifen via oral gavage (0.3mg∙kg-1 every
other day for a total of 5 doses) to mice beginning at P42, the end of adolescence in C57BL/6
mice and well after the closure of developmental critical periods in the mouse brain(Hensch,
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2004). This regiment resulted in successful ablation of CDKL5 protein expression to <5% of wildtype levels one week after tamoxifen delivery (Figure 2). We then waited approximately two
months before beginning a battery of behavioral assessments, similar to those examined in
germline knockout animals, to determine the functional impact of adult loss of CDKL5(I. T. Wang
et al., 2012). All experiments were performed on the following three groups: Cdkl5flox/y; +/+ (Flx),
Cdkl5+/y; CreER/+ (Cre), and Cdkl5flox/y; CreER/+ (AKO) where all genotypes received tamoxifen
in order to minimize potential variability introduced upon tamoxifen administration. Post-hoc
CDKL5 protein quantification in all experimental mice confirmed a nearly complete loss of CDKL5
protein in the brains of AKO animals but not Flx or Cre littermate controls (Figure 1b).
We found that AKO mice exhibit motor and anxiety-related impairments similar to Cdkl5
germline knockout animals. AKO mice spent significantly more time in the open arm of the
elevated zeromaze suggestive of decreased anxiety-related behaviors (Figure 1c, Figure 3a), and
displayed hyperactivity during an open field test (Figure 1d, Figure 3b). They also recapitulate
several of the autistic-like features observed in germline knockout models of CDD, namely,
reduced time sniffing and directly interacting with a novel stimulus mouse in the 3-chambered
social choice test (Figure 1e-f, Figure 3f-g) as well as increased repetitive grooming and digging
behaviors (Figure 1g) when compared to littermate Flx and Cre controls. Moreover, AKO mice
displayed significantly impaired contextual- and cue-dependent memory in a Pavlovian fear
conditioning paradigm when compared to Flx and Cre controls, though working memory
measured by the Y-Maze assay appeared unaffected (Figure 1h, Figure 3c-e). Interestingly, AKO
mice show enhanced motor coordination on the rotarod assay, with a significantly increased
latency to fall from an accelerating, rotating rod, and show no hindlimb clasping when compared
to Flx and Cre controls (Figure 1i, Figure 3h). This is contrary to Cdkl5 germline knockout mice
that exhibit significantly impaired motor coordination and a penetrant hindlimb clasping
phenotype. Importantly, we did not find any significant differences across all examined behavioral
domains between Flx and Cre controls, suggesting that the presence of the Cre allele alone does
not induce any abnormal phenotypes. In summary, although two documented germline knockout
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phenotypes were not recapitulated in AKO mice, our results highlight several major behavioral
domains disrupted upon adult loss of CDKL5, supporting an indispensable role for CDKL5 in the
post-developed brain.

Adult loss of CDKL5 disrupts hippocampal, low-frequency event-related neuronal
oscillations similar to germline knockout mice
Auditory or visual event-related potentials (ERPs) have been increasingly leveraged as a
biomarker for sensory information processing deficits in both patients and animal models of
various neurodevelopmental disorders(Saby, Peters, Roberts, Nelson, & Marsh, 2020). We
previously reported that germline loss of CDKL5 resulted in disrupted auditory-evoked ERPs
recorded from the hippocampus, reflecting an impairment in neural circuit activity(I. T. Wang et
al., 2012). We thus measured sensory-evoked ERPs in the hippocampus of AKO mice in
response to an auditory cue. These assessments were performed on nonanesthetized, freely
mobile mice and are not confounded by the motor and cognitive deficits observed in our CDD
models. We found that AKO animals displayed an aberrant ERP waveform with a significantly
decreased amplitude of the canonical N1 (negative) and P2 (positive) polarity peaks as well as a
significantly increased latency in the P2 polarity peak, similar to Cdkl5 germline knockout animals
(Figure 4a). The amplitude and latency of these ERP polarity peaks are thought to reflect the
strength and timing of cognitive processes, thereby suggesting that adult loss of CDKL5 also
impairs sensory information processing in conjunction with compromised behavioral functions.
Time-frequency analysis of these ERPs in the hippocampus also demonstrated reduced
oscillatory strength specifically in the low-frequency delta (δ, 2-4Hz), theta (θ, 4-8Hz), and alpha
(α, 8-12Hz) oscillations, but no differences in the high-frequency beta (β, 12-30Hz), low gamma
(γlow, 30-50Hz), and high gamma (γhigh, 70-140Hz) oscillations in AKO mice relative to Flx
littermate controls (Figure 4b-c). Similarly, event-related phase locking (measured by the phaselocking factor, PLF), which reflects the reliability and sensitivity of the circuit communication, was
also significantly decreased in AKO mice compared to Flx littermate controls but selectively in the
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low-frequency δ and θ (Figure 4b-c). Notably, EEG studies in ASD children have reported
selective deficits in low-frequency δ, θ, and α oscillations, suggesting similar neural network
defects in CDD and related syndromic ASDs(Saby et al., 2020). Together, these results indicate
that adult loss of CDKL5 leads to similar hippocampal network alterations as reported in germline
knockout animals, and that CDKL5 is required for the maintenance of proper signaling within this
circuit throughout life.

Germline, but not adult, loss of CDKL5 disrupts dendritic complexity of hippocampal CA1
pyramidal neurons
We next sought to investigate any cellular deficits that may be underlying the circuit and
behavioral abnormalities that emerge upon loss of CDKL5. In culture models, shRNA knockdown
of CDKL5 impairs neurite outgrowth in rat primary hippocampal neurons, and several Cdkl5
knockout mice have been reported to display reduced dendritic complexity in the
hippocampus(Amendola et al., 2014; Chen et al., 2010; Okuda et al., 2018; Tang et al., 2017).
However, the direct impact of CDKL5 loss on pyramidal neuron morphology remains
undetermined. Ablating CDKL5 selectively in adulthood provided us with a unique opportunity to
examine the consequences of CDKL5 loss independent of developmental confounds or any
homeostatic compensatory mechanisms that may be occurring. Our present EEG recordings, as
well as previous studies in various mouse models of CDD, have repeatedly revealed hippocampal
circuit abnormalities coupled to deficits in hippocampal-dependent learning and memory(Okuda
et al., 2017; Tang et al., 2019; Tang et al., 2017; I. T. Wang et al., 2012). These data, along with
the fact that CDKL5 is highly enriched in excitatory cells of this circuit, directed our initial studies
to pyramidal neurons of the hippocampal CA1(Zeisel et al., 2015).
We initially examined the effects of germline loss of CDKL5 on dendritic complexity of
hippocampal pyramidal neurons by crossing Cdkl5 constitutive knock-in mice (Cdkl5R59X, which
results in early truncation and loss of protein) to Thy1-GFPm transgenic mice. This reporter allele
allows for in vivo visualization of pyramidal neurons in their entirety, and subsequent analysis of
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dendritic arborization and complexity(Feng et al., 2000). In comparison to wild-type littermate
controls (Cdkl5+/y; Thy1-GFPm/+), WT, germline knockout mice (Cdkl5R59X/y; Thy1-GFPm/+), KO,
displayed a significant decrease in the complexity of both the basal and proximal apical dendrites
of their CA1 pyramidal neurons as shown by Sholl analysis (Figure 5a & 5c). These data are in
line with previous studies describing the effects of CDKL5 knockdown and knockout in vitro and in
vivo. Furthermore, both basal and proximal apical dendrite length were significantly reduced in
germline knockout mice in comparison to wild-type littermates (Figure 5b & 5d).
We next wanted to evaluate whether similar morphological deficits might be recapitulated
upon adult loss of CDKL5. We crossed our AKO mice (Cdkl5flox/y; CreER/+) and Flx littermate
controls (Cdkl5flox/y; +/+) to mice carrying the Thy1-GFPm reporter allele and delivered tamoxifen
to all animals at the previously described dosage and regiment beginning at P42. We then
evaluated cellular morphology at the same age we had previously assessed behavioral
impairments in AKO mice (P120). Interestingly, dendritic complexity at either the proximal apical
or basal dendritic tree, measured via Sholl analysis, was not altered between Cdkl5flox/y; CreER/+;
Thy1-GFPm/+ (AKO) mice and Cdkl5flox/y; +/+; Thy1-GFPm/+ (Flx) littermates at this age (Figure
5e & 5g). In fact, there were very subtle but significant increases in basal dendrite complexity at
the 120-150μm distances from the soma. These minor morphological shifts were in stark contrast
to the reduction in dendrite complexity seen in germline knockout animals. We also saw no
significant differences in average basal or apical dendrite length (Figure 5f & 5h). These findings
argue that germline, but not adult, loss of CDKL5 is capable of modulating pyramidal neuron
dendrite complexity and length in the hippocampal CA1, and suggest a specific developmental
window for the emergence of this phenotype.

CDKL5 is required for the maintenance of dendritic spine morphology on hippocampal
CA1 pyramidal neurons
Previous studies have also reported that loss of CDKL5 leads to aberrant dendritic spine
stability/morphology and perturbed miniature excitatory post-synaptic currents (mEPSCs),
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suggesting an important role for CDKL5 in neuronal synapse maturation(Della Sala et al., 2016;
Lupori L, 2019; Okuda et al., 2018; Ricciardi et al., 2012; Tang et al., 2017; Zhu et al., 2013). The
extent to which CDKL5 regulates the formation and/or maintenance of these highly dynamic
compartments, however, remains inconclusive.
We examined the effects of germline and adult loss of CDKL5 on dendritic spines of
pyramidal neurons in the hippocampal CA1 by utilizing the same Thy1-GFPm reporter line
described above, allowing us to evaluate dendritic spine density and morphology in vivo. We
found that dendritic spine density was not significantly altered on either basal or proximal apical
dendritic trees of CA1 pyramidal neurons between germline knockout (Cdkl5R59X/y; Thy1-GFPm/+)
and wild-type littermate (Cdkl5+/y; Thy1-GFPm/+) animals, or between AKO (Cdkl5flox/y; CreER/+;
Thy1-GFPm/+) mice and Flx littermate controls (Cdkl5flox/y; +/+; Thy1-GFPm/+). These results
argue that loss of CDKL5 during either germline or adulthood does not significantly alter dendritic
spine density in the hippocampal CA1 (Figure 6).
Aside from spine density and turnover, previous work in cultured neurons and Cdkl5
knockout animals has also proposed an altered spine morphology in CDD models(Della Sala et
al., 2016; Lupori L, 2019; Okuda et al., 2018; Ricciardi et al., 2012; Tang et al., 2017). We thus
evaluated various components of dendritic spine morphology in an in vivo setting using
reconstruction and analysis of the three-dimensional confocal image stacks taken for spine
density quantifications. We found that, on average, spine length was significantly increased on
both basal and apical dendrites of pyramidal CA1 neurons of AKO mice compared to Flx controls
(Figure 7a,d). This phenotype, coupled to a trending decrease in spine head diameter, is
reflective of a filipodia-like state typically associated with immature spines(Harris KM, 1989).
Given that the total density of dendritic spines remained unchanged, these findings suggest a
significantly increased representation of morphologically immature spines on both apical and
basal trees of CA1 pyramidal neurons in AKO mice, resembling similar findings seen upon loss of
CDKL5 in cultured hippocampal neurons(Ricciardi et al., 2012).
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Our adult knockout allows for an evaluation of neuronal morphological deficits resulting
from CDKL5 loss in vivo independent of developmental confounds, yet, it remained uncertain
whether this spine phenotype was indeed a cell autonomous effect of CDKL5 loss or a
compensatory phenotype due to ablation of CDKL5 in every cell. Sparse, conditional deletion
isolates the single-neuron consequences of CDKL5 loss while also bypassing pre- versus postsynaptic effects of mutant cells on spine dynamics. We therefore performed a conditional, sparse
deletion of CDKL5 in adult mice by crossing Cdkl5 floxed mice to SLICK transgenic mice. The
Single-neuron Labeling with Inducible Cre-mediate Knockout technique (or SLICK) utilizes two
copies of the Thy1 promoter to simultaneously drive sparse expression CreER and yellow
fluorescent protein (YFP), thereby allowing for conditional knockout and simultaneous labeling of
individual neurons to assess cell autonomous-driven morphology(Young et al., 2008). Cdkl5flox/y;
SLICK/+ mice and wild-type controls (Cdkl5+/y; SLICK/+) received tamoxifen beginning at P42,
and their spine morphology was subsequently analyzed at P70. We found that sparse, conditional
deletion of CDKL5 in adulthood amplified the increased spine length of both apical and basal
dendritic spines on CA1 pyramidal neurons seen in AKO animals (Figure 8b & 8f). Remarkably,
we also observed a significantly decreased spine head diameter and decreased spine volume, on
average, of basal and apical CA1 dendritic spines on knockout neurons in comparison to wildtype control neurons (Figure 8c-d, 8g-h). Again, there was no change in spine density on both
apical and basal dendritic arbors between Cdkl5 sparse knockout and wild-type control neurons
(Figure 8a & 8e).
Taken together, these results demonstrate an increased proportion of filipodia-like, or
morphologically immature, dendritic spines on CA1 pyramidal neurons of the hippocampus with
loss of Cdkl5, and highlight a key role for CDKL5 in the maintenance of dendritic spine
morphology in a cell autonomous manner.
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CDKL5 continuously regulates phosphorylation of the microtubule end-binding 2 protein
Previous work in Cdkl5 knockout mice has reported disruptions of AKT–mTOR signaling
with reduced phosphorylation of AKT Ser473 and mTOR Ser2448, specifically, but no
concomitant alteration in total AKT or mTOR protein levels(I. T. Wang et al., 2012).
Phosphorylation of these residues normally promotes AKT activation and mTOR complex 1
(mTORC1) assembly, respectively, likely reflecting decreased AKT and mTORC1 activity upon
Cdkl5 loss-of-function(Bhaskar & Hay, 2007; Rosner, Siegel, Valli, Fuchs, & Hengstschläger,
2010). To profile whether similar molecular signaling disruptions were also occurring upon postdevelopmental deletion of CDKL5, we harvested forebrain cortical tissues from AKO mice and
FLX littermate controls and evaluated the phosphorylation of key AKT pathway members,
including AKT, mTOR, S6, GSK-3β, and β-catenin. In contrast to what is reported in germline
Cdkl5 knockout mice, adult loss of CDKL5 did not lead to any significant changes in the
phosphorylation of pAKT Ser473, pmTOR Ser2448, pS6 Ser240/244, pGSK-3β Ser9, and βcatenin compared to their respective total protein levels (Figure 9). These results raise the
possibility that loss of CDKL5 may indirectly disrupt these cell growth/proliferation transduction
cascades during a critical time window in development, or that they are simply a compensatory
by-product of germline loss of CDKL5. Regardless, our findings highlight the potential for CDKL5
loss-of-function behavioral, circuit, and cellular phenotypes to emerge without a concomitant
disruption of AKT/mTOR signaling.
Notably, recent studies have suggested a role for CDKL5 in microtubule dynamics
through its direct phosphorylation of microtubule-associated proteins such as end-binding 2 (EB2)
protein(Lucas L. Baltussen et al., 2018; Muñoz et al., 2018). Interestingly, we found that
phosphorylation of endogenous EB2 Ser222 (pS222) was significantly reduced in forebrain
tissues of AKO mice to a similar magnitude as observed in germline knockout mice (Figure 10).
This suggests that this microtubule-associated substrate remains modulated by CDKL5 in
adulthood, and highlights that similar microtubule network disruptions may occur upon post-
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developmental loss of CDKL5. Given the expression pattern of CDKL5 is developmentally
regulated (Figure 1a), it will be informative to determine whether EB2 phosphorylation is also
dynamically regulated with CDKL5 throughout critical periods of brain development.
To investigate this, we harvested forebrain cortical tissues from wild-type mice at various
developmental and adult ages: postnatal day (P)0, P7, P14, P21, P30, and P60 and subsequently
examined the protein levels of CDKL5, phospho-EB2 (Ser22), and total EB2. CDKL5 protein
expression was developmentally regulated as previously shown (Figure 1a), with a postnatal
peak in expression ~P14 (Figure 11a-b). Interestingly, we found pEB2 Ser222 levels to also be
developmentally regulated and correlating with CDKL5, with phosphorylation levels peaking ~P14
and subsequently declining into adult ages (>P21) (Figure 11a, c). Total levels of EB2 protein
remained unchanged throughout the time points examined, and CDKL5 and pEB Ser222 levels
were significantly ablated in Cdkl5 knockout brain tissues (Figure 11a). These findings suggest
that phosphorylation of EB2 at Ser222 correlates with the expression levels of CDKL5.
We next profiled CDKL5, phospho-EB2 (Ser22), and total EB2 protein levels across the
same ages in Cdkl5 knockout forebrain cortical tissues (P0-P60). As expected, CDKL5 protein
levels were undetectable at every age in Cdkl5 knockout cortices, however, phosphorylation of
EB2 Ser22 was still detectable at each age (Figure 11a, d). We examined the relative
developmental progression of EB2 phosphorylation in Cdkl5 knockout brain tissues across
various ages. Intriguingly, pEB2 Ser222 levels still reflected a developmental regulation: peaking
early postnatally and subsequently declining into adulthood (Figure 11a, d). However, the peak
pEB2 level occurred at P7, rather than at P14 as observed in Cdkl5 wild-type animals (Figure
11a, e). A comparison of EB2 phosphorylation across all ages between Cdkl5 wild-type and
Cdkl5 knockout brains reflects an overall reduction in pEB2 as previously shown (Figure 10), but
also demonstrates this shift in the peak levels of pEB2 Ser222 to an earlier age (Figure 11e).
These results highlight that CDKL5 dynamically regulates phosphorylation of EB2 throughout
development and adulthood, and perhaps plays a role in continuously regulating microtubule
dynamics via its regulation of microtubule-associated proteins such as EB2. The synaptic
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morphological deficits reported in our AKO, coupled with an impaired regulation of EB2, represent
a potential cellular basis for the behavioral and circuit phenotypes exhibited by AKO animals.

Discussion
Several mouse models of CDD have been characterized to date, and although they
recapitulate many of the hallmark phenotypes of the human disorder, it remains unclear whether
these deficits are solely a consequence of detrimental changes occurring in the developing
nervous system or also due to loss of CDKL5 function in mature neurons(Amendola et al., 2014;
Okuda et al., 2018; I. T. Wang et al., 2012; Yennawar et al., 2019). Furthermore, from a
therapeutic perspective, it will be imperative to delineate the temporal requirement of CDKL5
action needed to establish as well as maintain proper neurological function. Prior to this study, it
was uncertain if providing CDKL5 function, or abrogating kinase pathway dysfunction, exclusively
during critical periods of development would be sufficient to significantly mitigate disease
pathology for life or whether chronic treatment would be required in CDD. Along this line, our
adult knockout experiments comprise a seminal foundation for future studies aiming to dissect the
temporal requirement of CDKL5 in various circuits and behavioral domains, informing future
therapeutic endeavors aimed at treating CDD.

Adult neural function requires CDKL5
Our results demonstrate that multiple features of disease-associated behavioral and
circuit phenotypes in mouse models of CDD can be recapitulated following adult deletion of
Cdkl5. Since Cdkl5 germline knockout mice have been reported to present with a constellation of
behavioral deficits, we began by testing various behavioral domains in our adult knockout
animals. We found that adult loss of CDKL5 resulted in similar deficits in anxiety-related
behaviors, locomotion, sociability, repetitive behaviors, and context- and cue-dependent fear
conditioning as previously reported in germline knockout mice(I. T. Wang et al., 2012). Adult
knockout of Cdkl5 also resulted in perturbation of auditory-evoked ERPs recorded from the
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hippocampus, reflective of gross circuit abnormalities that can arise even upon postdevelopmental CDKL5 loss. Specifically, auditory-evoked ERP recordings in the hippocampus of
these AKO mice displayed significant decreases in amplitude and increases in latency of the
canonically-elicited polarity peaks, suggesting perturbed sensory processing in these animals (a
hallmark feature of several ASDs in both humans and mouse models)(Gandal et al., 2010; Jeste
& Nelson, 2009; Riva et al., 2018; Roberts et al., 2010). Furthermore, our expression data reflect
a peak in CDKL5 protein levels during the critical period of synaptogenesis for several brain
regions followed by stable expression throughout adulthood, further highlighting that the kinase’s
functional roles are likely not sequestered to developmental processes. Collectively, these results
demonstrate that adult neural function still requires CDKL5, and suggest that early postnatal
expression of the kinase, or transient, early-developmental treatments, would offer little protection
against the disease. Rather, our findings argue that either chronic treatment of CDD or genereplacement therapy will comprise viable avenues(Gao et al., 2020). These data also contend
that many of the phenotypes associated with CDD may be unrelated to any stage-restricted
functions of CDKL5, at least in mice. Notably, similar results have been highlighted with loss of
MECP2 in Rett syndrome as well as postnatal deletion of various synaptic proteins, and may
reflect a unifying theme for synaptopathies and related ASDs(Chabbert et al., 2019; Djurisic,
Brott, Saw, Shamloo, & Shatz, 2018; Huang et al., 2019; McGraw, Samaco, & Zoghbi, 2011;
Spratt et al., 2019; X. Wang et al., 2016).
Interestingly, working memory (measured via spontaneous alternations in a Y-Maze
assay) was not significantly affected by adult loss of CDKL5. This effect could be governed by
specific circuits that, after proper establishment, are resilient to later loss of CDKL5 or carry the
ability to more readily compensate to kinase loss at these later ages. The dorsolateral prefrontal
cortex plays a known role in working memory functions thought to be executed by the basal
ganglia. The fact that working memory was not affected in AKO mice in spite of concomitant
motor and anxiety-related deficits suggests that the working memory impairment reported in
germline Cdkl5 knockout animals is not simply a byproduct of other phenotypic confounds.
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Rather, loss of CDKL5 may directly modulate this circuitry during a critical time window in
development. In contrast, context- and cue-dependent memory retrieval were both sensitive to
adult loss of CDKL5, further emphasizing these hippocampal-mediated memory domains as
distinct in their circuit-origins from working memory. Furthermore, the sensitivity of hippocampalmediated behaviors and hippocampal circuit function to loss of CDKL5 at both ages reflects a
likely critical maintenance role for the kinase in this brain region throughout life. In the future, it
will be interesting to dissect the temporal role of CDKL5 in the various circuits that underlie these
behavioral domains, and to perhaps delineate a critical time window of CDKL5 action in
regulating these behaviors.
Surprisingly, adult knockout of Cdkl5 resulted in a significantly enhanced motor
coordination phenotype in contrast to the deficit in motor coordination typically reported in
germline knockout animals and severe hypotonia reported in CDD patients(S. Demarest et al.,
2019). It is unlikely that the concomitant hyperactivity or repetitive behavior phenotypes present in
AKO animals influence this enhanced motor coordination given germline knockout mice mirror
similar deficits yet still carry impaired motor coordination. Although motor coordination and
learning are strongly associated with proper cerebellar functioning, CDKL5 is minimally
expressed in this brain region suggesting additional circuitry may drive this phenotype(Lein et al.,
2007; I. T. Wang et al., 2012). Furthermore, a recent, pilot gene therapy study in Cdkl5 knockout
mice utilizing AAV-CDKL5 vectors revealed only partial rescue of motor coordination deficits on
the rotarod assay. This is likely due to the fact that vector expression was mostly limited to the
hindbrain regions of treated mice (including cerebellum) but not forebrain or midbrain regions
where CDKL5 is most highly expressed(Gao et al., 2020). This incomplete rescue further
highlights the importance of additional, extra-cerebellar circuitry to the motor phenotypes
regulated by CDKL5. Notably, the basal ganglia (where CDKL5 is highly expressed) also play a
known role in motor control and learning, and have been highlighted as common node for ASD
pathophysiology(Fuccillo, 2016). We previously reported that loss of CDKL5 exclusively from
forebrain GABAergic neurons (including the striatum) selectively recapitulates the autistic-like
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features present in Cdkl5 constitutive knockout models, including aberrant repetitive behaviors.
However, this conditional deletion of CDKL5 from forebrain inhibitory neurons did not elicit any
changes in locomotor activity, anxiety-related behaviors, or motor coordination(Tang et al., 2019).
This may suggest that aberrant striatal circuitry does not autonomously drive the motor
coordination phenotypes seen across CDD mouse models, including our AKO mice, yet it is
important to highlight that the Dlx5/6 Cre driver used in this study does not encompass the
entirety of basal ganglia circuitry. Namely, the midbrain and subthalamic nuclei of the
diencephalon are not targeted in this conditional knockout(Monory et al., 2006). Thus, loss of
CDKL5 may still be affecting proper motor output of this circuitry via 1) a critical function in basal
ganglia subregions not affected upon Dlx5/6 conditional knockout or 2) the synergistic action of
CDKL5 across the basal ganglia and additional forebrain circuits not modeled by conditional
deletion. Alternatively, CDKL5 may regulate motor coordination and learning through a different
circuit or mechanism including contributions from the spinal cord (where CDKL5 expression is
detectable). How loss of CDKL5 in adulthood leads to improved motor coordination and learning
remains uncertain, but represents an interesting future avenue to investigate temporally-distinct
influences of CDKL5 loss of the same behavioral output.

Loss of CDKL5 influences dendritic arborization of CA1 pyramidal neurons during a
critical time window in development
Impaired dendritic arborization and complexity, particularly within the hippocampus, has
been reported across multiple Cdkl5 knockout models(Amendola et al., 2014; Okuda et al., 2018;
Tang et al., 2017). These morphological deficits were initially postulated to contribute to the
impaired hippocampal-dependent memory phenotypes robustly seen in various CDD mouse
models. Thus, we were surprised when we saw no significant alterations in dendrite length or
complexity with post-developmental deletion of Cdkl5, yet observed similar behavioral
phenotypes such as impaired context-dependent memory retrieval. These findings suggest that
impaired dendrite arborization or outgrowth of hippocampal CA1 neurons is not necessary for the
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impaired learning and memory phenotypes seen with CDKL5 loss. In fact, the majority of
behavioral impairments reported for germline Cdkl5 knockout animals were recapitulated upon
post-developmental deletion of CDKL5, highlighting alternative cellular mechanisms as likely
driving loss-of-function behavioral impairments.
Our findings argue that CDKL5 either modulates dendritic complexity during a specific
time window during development, or that this phenotype is a compensatory mechanism in
response to loss of CDKL5. For example, the reduction in dendritic complexity reported in
germline Cdkl5 knockout models could be a secondary, homeostatic response to altered spine
morphology and synaptic activity. Activity-dependent dendritic retraction is known to occur both in
vivo and in vitro, and elevated GSK-3 activity, which is associated with activity-dependent
shrinkage of dendrites, has been reported in mouse models of CDKL5 deficiency(Fuchs et al.,
2014; Krey et al., 2013; Rui et al., 2013; Wong & Ghosh, 2002). Alternatively, CDKL5 may simply
regulate dendrite and synapse formation through distinct mechanisms at distinct periods of
development. This idea is consistent with recent findings in which neuronal activity in immature
neurons leads to the induction of CDKL5 protein levels, whereas neuronal activity in mature
neurons leads to the degradation of CDKL5(P. La Montanara et al., 2015). CDKL5 may therefore
have distinct functions during stages of development that uniquely affects the processes of
dendrite growth, spine generation, and activity-dependent pruning. One such example of a family
of kinases that serve two contrasting cellular functions is the doublecortin-like kinases (DLCKs),
which promote dendrite growth but suppress synapse maturation(Shin et al., 2013).
Concomitant with a significant reduction of dendritic arborization and length of pyramidal
neurons, germline Cdkl5 knockout mouse models also have reported AKT/mTOR/GSK-3β
signaling disruptions(Amendola et al., 2014; I. T. Wang et al., 2012). These findings aligned with
the known importance of mTOR as a regulator of cell growth, proliferation, and neuronal
plasticity, and motivated a subsequent study to administer IGF-1 to juvenile Cdkl5 knockout mice
as a treatment for dendritic spine instability(Della Sala et al., 2016). However, the efficacy of this
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therapy in CDD patients remains uncertain, especially since these signaling changes may be an
indirect effect of Cdkl5 loss(Costales & Kolevzon, 2016).
Surprisingly, adult loss of CDKL5 did not lead to significant disruption of AKT-mTOR
signaling in spite of recapitulated germline knockout behavioral, circuit, and synaptic deficits.
These data suggest that disrupted AKT-mTOR signaling is not required for the emergence of
several CDD-related phenotypes, but may be a compensatory, or developmentally-specific
outcome of CDKL5 loss. The two, germline knockout-specific phenotypes highlighted in this
chapter (dendritic arborization and AKT/mTOR signaling) may be regulated by a developmentalspecific function of CDKL5 on neuronal outgrowth and arborization, and align with the known
importance of AKT/mTOR signaling in cell growth and proliferation.

CDKL5 is required for the maintenance of hippocampal dendritic spine morphology
The direct impact of CDKL5 loss on pyramidal neuron morphology has been contentious,
likely due to context-dependent variability. In our initial findings, we observed no significant
differences in dendritic spine density upon CDKL5 loss on either the basal or apical dendritic
arbors of hippocampal CA1 pyramidal neurons. This is in contrast to previous studies that have
reported either increased dendritic spine density with CDKL5 shRNA-mediated knockdown in
vitro, or decreased dendritic spine density in somatosensory and visual cortex of Cdkl5 knockout
mice(Della Sala et al., 2016; Ricciardi et al., 2012). These discrepancies are likely due to in vitro
versus in vivo circuit differences that can alter spine signaling and dynamics, as well as potential
regional differences of CDKL5 action across different circuits. We sought to overcome these
confounds by harnessing an adult deletion of CDKL5 to observe more direct effects of kinase
loss. However, adult knockout of CDKL5 did not result in significant changes in dendritic spine
density on pyramidal cells within the hippocampal CA1. Taken together, we suggest that there
are likely not significant effects on dendritic spine density within the hippocampal CA1 with loss of
CDKL5.
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Interestingly, however, we did notice significant morphological changes for the dendritic
spines we imaged upon adult deletion of Cdkl5. Overall, dendritic spines on both the apical and
basal dendritic trees of hippocampal CA1 pyramidal neurons were significantly longer upon adult
knockout of Cdkl5. We found that sparse, conditional deletion of CDKL5 in adulthood
recapitulated this increased spine length phenotype we saw in our constitutive AKO, and also
resulted in a significantly decreased head diameter and decreased total volume of analyzed
spines. Taken together, these filipodia-like structures are suggestive of a more morphologically
immature spine state that, when combined with no change in overall spine density, reflect a
greater proportion of morphologically immature spines on hippocampal CA1 pyramidal
neurons(Arellano, 2007). Collectively, these results suggest that CDKL5 is required for the
maintenance of dendritic spine maturation or morphology within the hippocampal CA1, and align
with the deficits in hippocampal-dependent behavioral domains and hippocampal circuit
communication presented in our AKO model. Future work will aim to dissect the causal role of
these spine phenotypes in relation to the hippocampal behavioral and circuit abnormalities
resulting from CDKL5 loss. It will also be relevant to examine whether CDKL5 plays a similar
spine maintenance role across various brain regions, particularly those implicated in the
behavioral domains disrupted in our AKO mice.
Our sparse, conditional deletion addresses the cell-autonomous effects of CDKL5 loss on
pyramidal neuron spines, however, it is still possible that these results are a compensatory or
secondary effect of CDKL5 loss within excitatory neurons of the hippocampus. We show that
CDKL5 is capable of regulating EB2 phosphorylation, a member of the end-binding protein family,
even during adulthood. End-binding proteins are plus-end-tracking proteins that accumulate at
the growing microtubule end, and play pivotal roles in microtubule dynamics that mediate cellular
architecture, cargo trafficking, and spine stability. Thus, it is appealing to hypothesis that CDKL5
may play a role in continuously regulating microtubule dynamics, particularly those related to
receptor trafficking at the post-synaptic density, via its continuous regulation of microtubuleassociated proteins such as EB2(Baltussen, Rosianu, & Ultanir, 2018; Barbiero, De Rosa, &
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Kilstrup-Nielsen, 2019; Jaworski et al., 2009; Merriam et al., 2013). However, the extent to which
CDKL5 regulation of EB2 activity, specifically, can affect cellular morphology and synaptic
maturation remains uncertain. This target’s well-characterized family member, EB3, has
previously been implicated in regulating dendritic spine morphology within hippocampal neurons,
but whether EB2 itself is essential for similar functions remains undetermined(Leterrier et al.,
2011; Pchitskaya et al., 2017; Straube & Merdes, 2007). In our future work, we are focused on
delineating the specific role of CDKL5 in regulating synaptic turnover and maturation through the
microtubule network.

Materials and Methods
Regulatory approval. Experiments were conducted in accordance with the ethical guidelines of
the National Institutes of Health and with the approval of the Institutional Animal Care and Use
Committee of the University of Pennsylvania. Mice were group-housed in cages of two to five in a
twelve-hour light/dark cycle with food and water provided ad libitum.

Mouse strains and genotyping. The Cdkl5 conditional (Cdkl5flox) and R59X knock-in (Cdkl5R59X)
lines were generated as previously described, and are available from the Jackson Laboratories
(Cdkl5flox: Stock No. 030523; R59X: Stock No. 028856)(Tang et al., 2019; Tang et al., 2017).
UBC-CreER (Stock No. 007001), Thy1-GFP line M (Thy1-GFPm; Stock No. 007788), and SLICK
(Stock No. 007610) mice were all obtained from the Jackson Laboratories. All lines have been
maintained in the C57BL/6J background.
Experimental cohorts were all weaned at 3 weeks of age and littermates housed
together. Cdkl5flox, Cdkl5R59X, and Thy1-GFPm mice were genotyped using previously-reported
PCR-based strategy or with qPCR by Transnetyx, Inc. For genotyping of UBC-CreER and SLICK
transgenics, primers and genotyping strategy were identical to that used by Jackson
Laboratories.
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Tamoxifen preparation and administration. Tamoxifen (Sigma, T5648) was dissolved in corn
oil (Sigma, C8267) at a concentration of 20mg∙ml-1 by vortexing and slowly heating the solution at
40°C for approximately one hour. Freshly prepared tamoxifen was protected from light by
aluminum foil and stored at 4°C for a maximum of one week. Animal feeding needles from Roboz
Surgical Store (20 gauge, 1.5” length, curved; FN-7910) were used for oral gavage delivery of
0.3mg∙kg-1 of tamoxifen every other day for a total of five doses. All genotypes received tamoxifen
within each experimental cohort.

Behavioral assessments. All animal behavioral studies were carried out blinded to genotype.
Mice were allowed to habituate to the testing room for at least 1 hr before the test, and testing
was performed at the same time of day. All animal behaviors were performed on adult male mice
between postnatal days 120-160, and the analysis of behavioral data was carried out by a
researcher blinded to genotype.
Elevated zeromaze. The elevated zeromaze (San Diego Instruments; California, USA) consists of
a circular-shaped platform elevated 3 feet above the floor. Two opposite quadrants of the maze
are enclosed (wall height, 12 inches), whereas the other two are open (wall height, 0.5 inches).
Mice were placed in one of the closed quadrants and their movement traced over the course of 5
min. Analysis, including the quantification of percent of time spent in open arms and the number
of entries, was performed manually using a stopwatch. An entry was defined as a transition from
a closed to open arm, or vice versa, that involves all four paws. Total distance traveled over the
entire assay was measured by a ceiling-mounted camera coupled to a video-tracking software
(SmartScan 3.0), allowing for real-time analysis of all movements.
Open-field test. Locomotor activity was measured via an open-field test where mice were
individually placed into, and allowed to explore, a 15” x 15” arena for a total of 60 min. A ceilingmounted camera allowed for a video-tracking software (SmartScan 3.0) to real-time analyze the
total distance traveled as well as the percent time spent in the center of the arena (defined as the
central 25% of the total area).

83

Y-maze. Spontaneous alternation behavior was measured on a Y-maze apparatus (San Diego
Instruments; California, USA), composed of three arms (Arm A: 8in. x 5in. x 3in.; Arms B and C:
6in. x 5in. x 3in.). For testing, the mouse was placed in Arm C, facing the center, and allowed to
freely explore the maze for 5 min. A spontaneous alternation was defined an entry into the arm
less recently explored. Percent spontaneous alternation was calculated as the number of
spontaneous alternations over the total number of entries. For example, the sequence
C,B,A,B,C,B,A,C (starting in arm C) resulted in a percent spontaneous alternation of 4/6 = 67%.
Three-chambered social approach assay. The social choice test was carried out in a threechambered apparatus that consisted of a center chamber and two end chambers. Before the start
of the test and in a counter-balanced sequence, one end chamber was designated the social
chamber, into which a stimulus mouse would be introduced, and the other end chamber was
designed the nonsocial chamber. Two identical, clear Plexiglas cylinders with multiple holes to
allow for air exchange were placed in each end chamber. In the habituation phase of the test
(Phase I), the test mouse was placed in the center chamber and allowed to explore all three
chambers for 10 min. During this acclimation period, baseline measurements of how much time
the mouse spent in each of the three chambers and the distance traveled by the test mouse were
collected. In the social choice phase of the test (Phase II), an age-matched stimulus mouse
(adult, gonadectomized A/J mice) was placed in the cylinder in the social chamber while a novel
object was simultaneously placed into the other cylinder in the nonsocial chamber. During the
subsequent 10 min social choice period, chamber times and numbers of transitions among
chambers were again recorded as well as the percent time spent sniffing the social cylinder. In
the direct social interaction test, the cylinders were removed simultaneously following the social
choice test, and the amount of time test and stimulus mice spent in direct contact (sniffing,
allogrooming) was measured for a total of 5 min. If fighting persisted for more than several
seconds, the mice were removed from the apparatus and excluded from the study.
Accelerating rotarod assay. Mice were placed on an accelerating rotarod apparatus (Harvard
Apparatus) for 16 trials (four trials a day for four consecutive days) with at least 15 min of rest
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between the trials. Each trial lasted for a maximum of 5 min, during which the rod accelerated
linearly from 4 to 40 rpm. The amount of time for each mouse to fall from the rod was recorded for
each trial.
Context- and cue-dependent fear conditioning. For the training day, mice were placed in
individual chambers (Med Associates) for 2 min followed by a loud tone (85 dB, 2 kHz) lasting 30
s that coterminated with a 2-s, 1.25-mA foot shock. Mice were left undisturbed for an additional
30 s in the chamber and then immediately placed back into their home cage. Freezing behavior,
defined as no movement except for respiration, was determined before and after the tone-shock
pairings and scored by FreezeScan NI version 2.00. To test for context-dependent learning, we
placed mice back into the same testing boxes 24 hr later for a total of 5 min without any tone or
shock, and again measured the total time spent freezing. After 4 hrs, we tested for cuedependent fear memory by placing the mice into a novel chamber consisting of altered flooring,
wall-panel inserts, and vanilla scent. After 2 min in the chamber, the cue tone (85 dB, 2 kHz) was
played for a total of 3 min, and the total time spent freezing during the presentation of this cue
tone was recorded.
Olfaction. Mice were tested for whether they could detect and differentiate odors in a habituationdishabituation protocol modified from Yang and Crawley(Yang & Crawley, 2009). Mice were
presented with cotton-tipped wooden applicators dipped in either water, vanilla, or swiped across
the bottom of an unfamiliar social cage. Each stimulus was presented for 2 min with a 1-min intertrial interval. Time spent sniffing was defined as when the animal was oriented with its nose 2 cm
or closer toward the cotton tip.
Repetitive behavior. Mice were individually placed into a clean, home-cage like environment lined
with bedding. After allowing 5 min for habituation, 10 min of activity was videotaped for each
mouse. The duration of repetitive behavior, defined as grooming or digging, was scored manually
using a stopwatch.
Hindlimb clasping. Mice were suspended by the base of their tail at least 6 inches above a flat
surface for up to 1 min. If the hindlimbs were consistently splayed outward, away from the
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abdomen, the mouse was assigned a score of 0. If one hindlimb was retracted towards the
abdomen for more than 50% of the time, the score was 1. If both hindlimbs were partially
retracted for greater than 50% of the time, the score was 2. Finally, if both hindlimbs were entirely
retracted and touching the abdomen for more than 50% of the time suspended, the mouse
received a score of 3.

Event-related potentials. ERP surgeries, recordings, and analyses were performed as
previously described(Goffin et al., 2012; I. T. Wang et al., 2012).
Surgery. Mice underwent stereotaxic implantation of tripolar electrode assemblies (PlasticsOne)
for nonanesthetized recording of auditory ERPs. Mice were anesthetized with isoflurane (4% for
induction (vol/vol), 1.5-2% for surgery with 1 L·min−1 O2). Three stainless steel electrodes,
mounted in a single pedestal were aligned to the sagittal axis of the skull. A stainless steel
recording electrode was placed 2.0 mm posterior, 2.0 mm left lateral relative to bregma, and at 1.8 mm depth. Ground and reference electrodes were placed posterior of the hippocampal
electrode at 1.0 mm and 2.0 mm distances, respectively. The electrode pedestal was secured to
the skull with ethyl cyanoacrylate and dental cement. Postoperative analgesia was supplied using
the opioid analgesic, buprenorphine (buprenex, subcutaneous, 0.1 μg ∙ gram-1 of body weight).
Mice were allowed to recover for 7 days before EEG recordings.
Recordings. EEG recordings were performed on freely mobile, nonanesthetized mice in their
home cage environment after a 20 min acclimation to the recording room. Recordings were
performed using Spike2 software connected to a Power 1401 II interface module (CED) and high
impedance differential AC amplifier (A-M Systems). Signals were acquired at 1,667 Hz and bandpass filtered between 1 and 500 Hz with a 60-Hz notch filter and gain of 1,000.
Event-related potentials (ERPs) were recorded by presentation of auditory stimuli
consisting of a series of 250 white-noise clicks of 10 ms duration, 85 dB sound pressure, and 4 s
interstimulus intervals. Stimuli were presented through speakers on the recording chamber ceiling
(model 19-318A, 700-10,000 Hz frequency response; Radio Shack) connected to a digital audio
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amplifier (RCA model STAV3870; Radio Shack). ERP traces were generated by averaging
across single trial epochs centered at t = 0 ± 2 s. Single trials were baseline corrected by
subtracting the temporal mean at t = −1 s to t = 0.5 s. Altering the baseline closer to sound
presentation had no effect on the results shown. The mean ERP amplitudes were subsequently
calculated across 250 trials.
Time-frequency analysis of EEG. For each recording in which mice were presented with 250
white-noise clicks (10 ms duration, 85 dB sound pressure, 4 s interstimulus intervals), we
computed event-related power and phase as a function of frequency and time. Time-frequency
calculations were performed as previously described(Goffin et al., 2012; I. T. Wang et al., 2012).

Brain microdissection. To assess CDKL5 protein expression in various brain regions, adult
male mice were sacrificed by cervical dislocation. After decapitation, brains were removed and
sectioned into 1mm coronal slices using a mouse brain matrix. Tissue was dissected from the
somatosensory cortex, striatum, hippocampus, and cerebellum and homogenized in RIPA lysis
buffer (150mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate [DOC], 0.1% sodium dodecyl
sulfate [SDS], 25mM Tris [pH7.4] with protease inhibitors [Roche, cOmplete, EDTA-free protease
inhibitor cocktail tablets; 5056489001]). To prepare protein extracts, homogenized lysates were
incubated on ice for 15 min, and then centrifuged at 21,000 x g for 15min at 4°C. The supernatant
fraction was removed and sonicated using a Biorupter for 3 alternating session at max frequency
for 15 sec, each followed by a 60 sec cooldown period. The lysate was then centrifuged at 21,000
x g for 15min at 4°C, and the top aqueous layer carefully removed and collected as the total
protein fraction.

Western blot. Protein concentration was measured using a Bradford assay. Purified synaptic
density membrane proteins or protein lysates were prepared for gel electrophoresis by adding 4X
LDS Sample Buffer (NuPAGE, NP0008) to a final concentration of 1X and β-mercaptoethanol to
a final concentration of 5%. Samples were heat-denatured at 75°C for 20 min, and 25 µg of
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protein was loaded into each well of a 4–12% Bis-Tris gradient gel (Invitrogen, 10-well, 1.5mm;
NP0335) for brain lysate quantification, respectively. Protein gels were run for 2hr at 125V at
room temperature on a XCell SureLock mini-cell electrophoresis box (ThermoFisher; EI001)
using a PowerPac HC High-Current Power Supply (BioRad; 1645052), then transferred onto a
polyvinylidene fluoride (PVDF) membrane (0.45µm pore-size; Biorad 162–0115) at 27V for 1hr
and 10min at room temperature. The resulting membrane was blocked with a 1:1 solution of
Odyssey blocking buffer (LICOR; 927-40100) and 1X PBS for 1hr at room temperature.
Primary antibodies used were rabbit anti-N-terminal CDKL5 (in house; diluted 1:500),
mouse anti-β-Actin (Abcam; ab8226; diluted 1:10,000), rat anti-EB2[K52] (Abcam, ab45767;
diluted 1:10,000), and rabbit anti-phospho-EB2[S222] (generously shared by Dr. Sila Ultanir at
the Francis Crick Institute; London, UK; diluted 1:1000). For AKT/mTOR signaling studies, the
primary antibodies used were rabbit anti-AKT (CST4691P), rabbit anti-pAKT S473 (CST4060),
rabbit anti-mTOR (CST2983), rabbit anti-p-mTOR S2448 (ab109268), rabbit anti-S6 (CST2217),
rabbit anti-pS6 S240/244 (CST5364), rabbit anti-GSK-3β (CST9315), rabbit anti-pGSK-3β S9
(CST5558), rabbit anti-β-Catenin (CST9562), and anti-β-Actin. Secondary antibodies (LI-COR)
used were goat anti-rabbit IgG IRDye800CW, rabbit anti-mouse IgG IRDye680LT, and goat antirat IRDye680LT, all incubated for 50min at room temperature at dilutions of 1:10,000. Standard
protocols were used for the Odyssey Infrared Imaging System (LI-COR) for protein visualization
and quantification.

Dendritic branching and dendritic spine analysis. All steps of sectioning, imaging, and data
analysis were performed by a researcher blinded to genotype. Adult male mice at postnatal day
120 (Cdkl5R59X/y; Thy1-GFPm/+ versus Cdkl5R59X/y; +/+ or Cdkl5flox/y; +/+ ; Thy1-GFPm/+ versus
Cdkl5flox/y; UBC-CreER; Thy1-GFPm/+ or Cdkl5flox/y; SLICK/+ versus Cdkl5+/y; SLICK/+) were
transcardially perfused with 4% paraformaldehyde. Brains were extracted and postfixed
additionally for 1hr (for dendritic branching analysis) or overnight at 4°C (for dendritic spine
analysis). For dendritic branching analysis, brains were embedded in 2% agar and sectioned
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coronally at 200μm on a Leica VT1000S vibratome. For dendritic spine analysis, brains were
cryoprotected upon overnight fixation by sinking in 15% sucrose and subsequently 30% sucrose
in PBS, and then frozen in OCT (Sakura Finetek). Frozen brains were sectioned coronally at
50μm on a Leica CM3050S cryostat. For both dendrite and spine imaging, unstained sections
were mounted with ProLong™ Glass Antifade Mountant (Thermo Fisher; P36982).
GFP-positive pyramidal neurons located in the hippocampal CA1 region (approximately
between bregma coordinates -1.34 to -1.94) with well-preserved morphology were chosen for
imaging. For dendritic branching, confocal image stacks were taken on a laser scanning confocal
microscope (Leica TCS SP8, 488 laser) with a 20X/0.75 NA immersion objective at 1X zoom.
Each neuron was oriented diagonally and centered in a field of view with dimensions 553.57 X
553.57 μm, with a step size of 0.5 μm. For dendritic spines, secondary and tertiary dendritic
branches of basal and proximal apical dendrites, excluding the apical tuft, of CA1 pyramidal
neurons were imaged. Image stacks were taken with a 63X/ 1.40 NA oil-immersion objective at
4X zoom. Each dendritic segment was centered in a field of view with dimensions 43.93 X 10.95
μm, with a step size of 0.22 μm and total depth spanning a depth of <7 μm.
All image analysis was performed by a researcher blinded to genotype. For dendritic
branching analysis, the dendrites of each neuron were traced in a supervised manner using
Imaris FilamentTracer (Bitplane; RRID: SCR_007366). Each branch was individually traced using
a combination of the Autopath and Autodepth functions, with the center of the soma designated
as the dendrite beginning point. The basal and apical dendritic trees were separately traced. Sholl
analysis was automatically performed by Imaris, and the statistics were exported for analysis.
For spine analysis, three-dimensional blind deconvolution was first performed on
confocal image stacks with an iterative constrained Tikhonov-Miller algorithm (DeconvolutionLab,
ImageJ) using a pointspread function generated from the imaging parameters (PSF Generator,
ImageJ). The deconvolved image stack was imported into Imaris and analyzed. The dendritic
backbone of each segment was first traced using the Autopath function and a cone-type dendrite
diameter was built using a contrast threshold of 0.2 and dendrite maximum diameter of 1 μm.
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Spines were manually traced on each dendrite using the Autopath function, with a cutoff of a
maximum distance of 3 μm from the dendritic backbone. Automated spine reconstruction of
manually-traced spines was performed using the Imaris Bitplane Wizard builder. Imaris performed
automated computation of spine density and estimation of morphometric parameters for individual
spines, including spine length, terminal point (head) diameter, and volume.

Statistical Analysis. For behavioral assays, we chose similar sample sizes for all behavioral
experiments based on previous published studies of Cdkl5 constitutive knockout mice and Cdkl5
conditional knockout mice(Tang et al., 2019; Tang et al., 2017; I. T. Wang et al., 2012).
Importantly, the number of mice used was pre-determined prior to the start of each experiment.
Statistical analyses were performed using Prism (GraphPad). All data sets were analyzed using
the Shapiro-Wilk test for normality. For one-sample comparisons, data sets with normal
distributions were analyzed for significance using the one-sample t-test, whereas data sets with
non-normal distributions were analyzed using the Wilcoxon signed-rank test. For two-sample
comparisons, data sets with normal distributions were analyzed for significance using the
unpaired Student’s t-test, whereas data sets with non-normal distributions were analyzed using
the Mann-Whitney test. Two-way repeated measures ANOVA or the Kruskal-Wallis test was
conducted for the appropriate data sets with post hoc Sidak’s or Dunn’s multiple-comparisons
tests. All one-sample, two-sample, and multiple-comparison tests were two-tailed.
All other assays that involved sub-sampling of animals were analyzed using R (The R
Project for Statistical Computing). Each data set was analyzed using a linear mixed effect model,
where Genotype was modeled as a fixed effect term and Animal was modeled as a random effect
term. This model accounts for both between-animal and between-cell variation. For each assay,
null and alternative models were constructed using the lmer function in the lme4 package in the
following format:
m0 = lmer(Outcome ~ (1|Animal), REML = TRUE)
m1 = lmer(Outcome ~ Genotype + (1|Animal), REML = TRUE)
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To make statistical comparisons, the KRmodcomp function from the pbkrtest package
(Halekoh and Højsgaard, 2014) was used:
KRmodcomp(m0, m1)
The KRmodcomp function reports a modified F-test statistic based on the Kenward and
Roger approximation, which accounts for the small sample sizes in our study, modified numerator
and denominator degrees of freedom, and a p-value. The estimated effect of Genotype is
obtained from the alternative model constructed using the lmer function from lme4.
All graphs are plotted using Prism (GraphPad). Bolded center lines reflect the mean, and
all error bars indicate s.e.m. For boxplots, the limits indicate the minimum and maximum with
boxplot center line indicating the median. In our figures, p-values between 0.05 and 0.1 are
shown explicitly, * is used to denote all 0.01 < p < 0.05, ** for 0.001 < p < 0.01, *** for 0.0001 < p
< 0.001, and **** for p < 0.0001.
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Figures
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Figure 1: Post-developmental loss of CDKL5 disrupts multiple behavioral domains in mice
(a) Top: Representative western blot showing CDKL5 protein expression from forebrain tissues of
wild-type mice across multiple ages (Postnatal Day (P)0, P4, P7, P10, P14, P21, P60, P120) with
Actin protein as a loading control and forebrain tissue from Cdkl5 knockout mice as a reference
for antibody specificity; Bottom: Quantification of western blot results for CDKL5 protein
expression across multiple ages demonstrates a postnatal increase in CDKL5 forebrain
expression and peak ~P14, with stable expression detectable into adulthood. Normalized to Actin
loading control and plotted relative to P0 levels (n=4). (b) Top: Tamoxifen administration scheme
and experimental schedule; Bottom: Representative western blot and quantification for CDKL5
protein expression in all experimental mice demonstrates significant reduction of CDKL5 protein
in AKO over Flx and Cre forebrain tissues collected after undergoing behavioral evaluation. Actin
protein served as a loading control, and Cdkl5 knockout and wild-type brain tissues were used as
a reference for antibody specificity with all values normalized to Cre-only control CDKL5 levels.
(c) AKO mice spent significantly more time in the open arm of the elevated Zeromaze assay over
Flx and Cre littermate controls suggestive of decreased anxiety. (d) AKO mice travel significantly
more distance than Flx littermates in the open-field assay suggesting hyperactivity. (e) AKO mice
spent significantly less time than Flx and Cre littermates sniffing and (f) directly interacting with a
novel stimulus mouse during the 3-chambered social choice test, suggestive of deceased
sociability. (g) AKO mice carry aberrant repetitive behaviors demonstrated by increased time
spent grooming or digging in a homecage-like environment when compared to Flx and Cre
littermates. (h) AKO mice freeze in response to a mild footshock similarly to Flx and Cre
littermates, but show decreased percent time freezing compared to Flx and Cre littermates when
returned to the testing chamber (contextual) and upon hearing the testing tone (cue),
demonstrating impaired learning and memory. (i) AKO mice take significantly more time to fall
from an accelerating, rotating rod than Flx and Cre littermates, indicating enhanced motor
coordination. For all panels: Flx, n=13; Cre, n=19; AKO, n=23 where all genotypes received
tamoxifen; Kruskal-Wallis test with Dunn’s multiple comparisons test (except Open-field: MannWhitney test & Rotarod: 2-way repeated measures ANOVA with Sidak’s multiple comparisons
test). *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. Bars represent mean ± SEM.
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Figure 2. Timecourse of CDKL5 protein knockdown with tamoxifen
Top: tamoxifen administration scheme and experimental schedule; Bottom: representative
western blot results and quantification demonstrating significant reduction in CDKL5 protein in
forebrain tissues of Cdkl5flox/y; CreER/+ (AKO) mice compared to Cdkl5flox/y; +/+ (Flx) littermate
controls after tamoxifen administration. Forebrain tissues were collected and analyzed for CDKL5
protein 9, 13 and 16 days after the first tamoxifen dose, and all experimental mice were sacrificed
after behavioral assessment for post-hoc protein quantification. Actin protein was a loading
control, and AKO CDKL5 protein was normalized to Flx levels.
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Figure 3. Additional behavioral domains analyzed upon adult deletion of Cdkl5
(a) Total distance traveled in the elevated Zeromaze assay was similar between AKO and Flx
mice (Mann-Whitney test). (b) AKO mice traveled significantly more in an open-field assay
relative to Flx littermates over the course of one hour (distance traveled binned in 5min intervals;
two-way, repeated measures ANOVA with Sidak’s multiple comparisons test). (c) AKO mice
showed no difference in percentage of spontaneous alternations in a Y-Maze assay, and no
difference in the (d) total number of alternations or (e) total difference traveled when compared to
Flx and Cre littermate controls (Kruskal-Wallis test). (f) Flx, Cre, and AKO mice all spent
significantly more time in the chamber containing a social stimulus (S; novel mouse) over a nonsocial stimulus (NS; rock) during the 3-chambered social choice test (paired t test). (g) Flx, Cre,
and AKO mice all spent significantly more time sniffing a social scent over either water or almond
scents, with no significant difference detected between genotypes (two-way ANOVA with
Dunnett’s multiple comparisons test). (h) No Flx, Cre, or AKO animals displayed any hindlimb
clasping phenotypes (Kruskal-Wallis test). For all panels: Flx, n=13; Cre, n=19; AKO, n=23 where
all genotypes received tamoxifen; *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. Bars represent
mean ± SEM.
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Figure 4: Post-developmental loss of Cdkl5 disrupts hippocampal event-related potentials.
(a) Top: grand-average hippocampal CA1 ERP waveform following presentation of auditory
stimuli in Cdkl5flox/y; +/+ (Flx) and Cdkl5flox/y; CreER/+ (AKO) mice demonstrates abnormal ERP
waveform in AKO mice. Traces represent mean amplitude ± SEM. Characteristic polarity peaks
P1, N1, and P2 in Flx control are labeled (scale bar: 100ms [horizontal] and 20mV [vertical]);
Bottom: quantification of the amplitude and latency of ERP peaks shows significantly decreased
amplitude of the canonical N1 and P2 peaks and increased latency in the P2 polarity peak
(unpaired, two-tailed t test). (b) Time-frequency plots showing changes in event-related power
(top) and phase-locking factor (PLF; bottom) following auditory stimulus. Color represents mean
power/PLF, where warmer colors correspond to increased power/PLF and cooler colors
correspond to decreased power/PLF relative to prestimulus baseline. (c) Changes in eventrelated mean power (top) and PLF (bottom) averaged across δ (2-4Hz), θ (4-8Hz), α (8-12Hz), β
(12-30Hz), γlow (30-50Hz), and γhigh (70-140Hz) oscillation frequencies demonstrate a selective
disruption of power and phase-locking in the low-frequency oscillations in AKO mice over Flx
littermate controls (unpaired, two-tailed t test). Bars represent mean ± SEM; n=7 Flx and n=7
AKO for all ERP experiments.

97

98

Figure 5: Germline, but not adult, loss of Cdkl5 results in decreased dendrite length and
complexity of CA1 pyramidal neurons.
(a) Reduced complexity of the basal dendritic tree of hippocampal CA1 neurons in Cdkl5R59X/y;
Thy1-GFPm (KO) mice compared to Cdkl5+/y; Thy1-GFPm (WT) littermate control mice measured
via Sholl analysis. (b) Total basal dendrite length is significantly decreased in KO animal CA1
neurons compared to WT neurons. (c) Reduced complexity of the apical dendritic tree of
hippocampal CA1 neurons in KO mice compared to WT littermate control mice measured via
Sholl analysis. (d) Total apical dendrite length is significantly decreased in KO animal CA1
neurons compared to WT neurons. (n=18 cells/3 mice for WT; n=21 cells/3 mice for KO). (e)
There was no significant difference in basal tree dendritic complexity of hippocampal CA1
neurons between Cdkl5flox/y; CreER/+; Thy1-GFPm (AKO) mice and Cdkl5flox/y; +/+; Thy1-GFPm
(Flx) littermate control mice measured via Sholl analysis. (f) Total basal dendrite length was
unchanged in AKO animal neurons compared to Flx littermate controls. (g) There was no
significant difference in apical tree dendritic complexity of hippocampal CA1 neurons between
AKO mice and Flx littermate control mice measured via Sholl analysis. (h) Total apical dendrite
length was unchanged in AKO animal neurons compared to Flx littermate controls. Basal: n= 24
cells/6 mice for WT, n= 40 cells/8 mice for cKO; Apical: n=23 cells/6 mice for WT, n=26 cells/8
mice for AKO. Linear mixed effects analysis, *p<0.05.
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Figure 6. Germline or post-developmental deletion of Cdkl5 does not alter dendritic spine
density on hippocampal CA1 neurons.
(a) Cdkl5 germline knock-in mice (Cdkl5R59X/y; Thy1-GFPm/+), KO, show no significant difference
in spine density compared to wild-type littermate controls (Cdkl5+/y; Thy1-GFPm/+), WT, on either
basal or (b) apical dendritic arbors of hippocampal CA1 pyramidal neurons (Basal: n=23 cells/5
mice for WT; n=32 cells/5 mice for KO. Apical: n=23 cells/5 mice for WT; n=28 cells/5 mice for
KO). (c) Cdkl5flox/y; CreER/+; Thy1-GFPm/+ (AKO) mice similarly show no significant change in
spine density compared to Cdkl5flox/y; +/+; Thy1-GFPm/+ (Flx) littermate controls on either basal
or (d) apical dendritic arbors of hippocampal CA1 pyramidal neurons (Basal: n= 22 cells/8 mice
for Flx, n= 30 cells/7 mice for AKO. Apical: n=25 cells/8 mice for Flx; n=36 cells/7 mice for AKO).
Linear mixed effects analysis.
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Figure 7. Post-developmental deletion of Cdkl5 disrupts hippocampal CA1 dendritic spine
morphology.
(a) Cdkl5flox/y; CreER/+; Thy1-GFPm/+ (AKO) neurons have increased spine length compared to
Cdkl5flox/y; +/+; Thy1-GFPm/+ (Flx) littermate control neurons on both basal and (d) apical
dendritic arbors. Spine head diameter [(b) basal; (e) apical] and spine volume [(c) basal; (f)
apical] were not significantly different between AKO neurons and Flx neurons. For all spine
analyses: Basal: n= 22 cells/8 mice for Flx; n= 30 cells/7 mice for AKO. Apical: n=25 cells/8 mice
for Flx; n=36 cells/7 mice for AKO. Linear mixed effects analysis, *p<0.05.
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Figure 8: Post-developmental loss of Cdkl5 results in cell-autonomous disruption of
dendritic spine morphology on CA1 pyramidal neurons.
(a) Cdkl5flox/y; SLICK/+ (cKO) mice show no significant change in spine density on (a) basal or (e)
apical dendritic arbors of CA1 pyramidal neurons compared to Cdkl5+/y; SLICK/+ (WT) littermate
control neurons. cKO neurons have increased spine length compared to WT controls on both (b)
basal and (f) apical dendritic arbors as well as significantly reduced head diameter [(c) basal; (g)
apical] and reduced volume [(d) basal; (h) apical]. Basal: n= 24 cells/6 mice for WT, n= 40 cells/8
mice for cKO; Apical: n=19 cells/6 mice for WT, n=33 cells/8 mice for cKO. Linear mixed effects
analysis. *p<0.05, **p<0.01.
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Figure 9. AKO mice do not demonstrate disrupted AKT-mTOR pathway signaling
(a) Representative western blot results for several major proteins within the AKT-mTOR signal
cascade including phospho-protein levels and total protein levels for each. Samples are from
pairs of Cdkl5flox/y; +/+ (FLX) and Cdkl5flox/y; CreER/+ (AKO) littermates. (b-f) AKO mice do not
show significant changes in levels of pAKT S473, p-mTOR S2446, pS6 S240/244, and pGSK-3β
S9 over respective total protein levels, or changes in total levels of β-catenin compared to FLX
littermate controls. (FLX, n = 10 mice; AKO, n = 10 mice; unpaired Mann-Whitney test).
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Figure 10. Germline and post-developmental deletion of Cdkl5 abrogate EB2
phosphorylation.
(a) Left: representative western blot demonstrating CDKL5, phospho-EB2 (S222), and total EB2
protein levels in wild-type (WT) versus Cdkl5 germline knock-in (Cdkl5R59X/y; KO) forebrain
tissues. Two bands present for EB2 represent two isoforms detectable in brain tissue (both
containing Ser222); Right: quantification of phospho-EB2 (S222) western blot results
demonstrates a nearly total loss of EB2 phosphorylation at Ser222 in KO forebrains compared to
WT, normalized to total EB2 protein levels (n=4 per genotype). (b) Left: representative western
blot demonstrating CDKL5, phospho-EB2 (S222), and total EB2 protein levels in Cdkl5flox/y; +/+
(Flx) versus Cdkl5flox/y; CreER/+ (AKO) forebrain tissues (both genotypes receiving tamoxifen);
Right: quantification of phospho-EB2 (S222) western blot results demonstrates a nearly total loss
of EB2 phosphorylation at Ser222 in AKO forebrains compared to Flx, normalized to total EB2
protein levels (n=8 per genotype). For all panels: Mann-Whitney test; *p<0.05, **p<0.01,
***p<0.001.
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Figure 11. EB2 phosphorylation is developmentally regulated and correlates with CDKL5.
(a) Representative western blot results for CDKL5, pEB2 Ser222, and total EB2 protein levels
from forebrain cortices of Cdkl5 wild-type (left) and Cdkl5 knockout (right) mice at various ages
(Postnatal Day (P)0, P7, P14, P21, P30, P60). Two bands present for EB2 represent two
isoforms detectable in brain tissue (both containing Ser222). (b) Quantification of total CDKL5
protein levels in wild-type mice across various ages, normalized to Cdkl5 knockout, demonstrates
a postnatal increase and expression peak ~P14. (c) Quantification of phospho-EB2 Ser222
levels, normalized to total EB2 levels, in Cdkl5 wild-type mice across various ages demonstrate a
developmental regulation that correlates with CDKL5 expression, including a peak ~P14. (d)
Quantification of phospho-EB2 Ser222 levels, normalized to total EB2 levels, in Cdkl5 knockout
mice across various ages reflects a shift in the peak phosphorylation levels of EB2 from P14 to
P7. (e) Overlay of pEB2 Ser222 protein quantifications from Cdkl5 wild-type and knockout mice
demonstrates the overall reduction in EB2 phosphorylation in knockout mice at each timepoint,
and highlights the shifted peak phosphorylation age.
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CHAPTER 4 – LATE RESTORATION OF CDKL5 EXPRESSION IS SUFFICIENT TO
RESCUE CDD-RELATED BEHAVIORAL IMPAIRMENTS AND ABBERANT NMDARECEPTOR SIGNALING

Contributions: Barbara Terzic led this study with help from M. Felicia Davatolhagh for
electrophysiological experiments, Joshua Ross for data analysis, and Marc V. Fuccillo
and Zhaolan Zhou for the review and interpretation of data. Yue Cui and Erin Nugent
managed all mouse husbandry, genotyping, and breeding. Barbara Terzic wrote this
chapter with input from all authors.

Abstract
CDKL5 deficiency disorder (CDD) is an early-onset, neurodevelopmental syndrome
associated with pathogenic variants in the gene encoding cyclin-dependent kinase-like 5
(CDKL5). CDKL5 has been implicated in neuronal synapse maturation and NMDA receptor
subunit trafficking at the post-synaptic membrane, however, the reversibility of these and other
CDD-associated impairments remain unknown. We genetically manipulated endogenous Cdkl5
expression in mice, and found adult restoration of CDKL5 in hemizygous male knockout mice
significantly ameliorates CDD-related behavioral impairments, NMDA-induced seizure
susceptibility, and aberrant NMDA receptor signaling. We have further extended these findings
into a novel, independent conditional rescue line to corroborate that late rescue of CDKL5 also
reverses several behavioral deficits in heterozygous female models of CDD. These findings
underscore the potential for disease reversal in both male and female CDD patients, and suggest
a broad therapeutic time window exists for numerous CDD-related deficits.
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Introduction
Mutations in the X-linked gene encoding cyclin-dependent kinase-like 5 (CDKL5) are
associated with a devastating neurodevelopmental syndrome known as CDKL5 deficiency
disorder (CDD)(Fehr et al., 2013; Kalscheuer et al., 2003; Tao et al., 2004; Weaving et al., 2004).
CDD is characterized by a constellation of phenotypes including intractable seizures, severe
neurodevelopmental delay, intellectual disability, hypotonia, and autistic features(S. T. Demarest
et al., 2019; H. E. Olson et al., 2019). The disorder predominantly afflicts young females
heterozygous for mutations in CDKL5, but hemizygous male cases have also been reported
(albeit at a significantly lower prevalence)(S. T. Demarest et al., 2019; Liang et al., 2019). Despite
this strong genetic link, the pathogenesis and treatability of CDD remains unclear. Presently,
there is no cure, and the limited treatment options available have focused on mitigating seizure
burden using a variety of non-specific anticonvulsants(H. E. Olson et al., 2019).
In 2012, the first knockout mouse model of CDD was generated and found to recapitulate
several of the cardinal phenotypes of the human disease including learning and memory
impairments, motor deficits, and autistic-like behaviors(I. T. Wang et al., 2012). Several additional
knockout and knock-in lines have since been generated with similar behavioral deficits,
highlighting the reproducibility of CDD-related phenotypes in mice(Amendola et al., 2014; Okuda
et al., 2018; Yennawar et al., 2019). Intriguingly, Cdkl5 knockout mouse models have also
demonstrated a robust sensitivity to NMDA-induced seizures concomitant with an increased
postsynaptic localization of NMDA receptors (NMDARs), specifically GluN2B-containing
NMDARs(Okuda et al., 2017). These results were supported by our recent study which
demonstrated that acute, NMDAR blockade was capable of selectively ameliorating autistic-like
phenotypes in CDKL5-deficient mice (see Chapter 2)(Tang et al., 2019). Despite these multitude
of CDD models, however, the extent of reversibility of the remaining heterogeneous constellation
of CDD-related phenotypes, particularly at later ages, remains undetermined.
Clinical reports illustrating the early, postnatal onset of CDD symptomology support a
critical role for CDKL5 in the developing nervous system(H. E. Olson et al., 2019; Y. C. Zhu & Z.
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Q. Xiong, 2019). However, it remains unknown whether restoration of the kinase after critical
periods of brain development can reverse any CDD-related deficits. With recent advances in
precision medicine highlighting promising treatment options for CDD patients in the future, it is
imperative to establish the temporal role of CDKL5 in neuronal development versus maintenance,
and the potential for symptom amelioration in patients who may have already passed a specific
developmental time window(Benke & Kind, 2020).
To address these questions, we have employed a genetic strategy to investigate the
reversibility of CDD-associated symptoms by generating conditional rescue mice enabling
temporal control of Cdkl5 re-expression at its endogenous locus. We find that the majority of
CDD-related behavioral deficits, as well as aberrant NMDA receptor signaling, are significantly
mitigated with late restoration of CDKL5 expression. We corroborate these findings an
independent conditional rescue model, demonstrating that several CDD-related behavioral
impairments are also reversible in heterozygous female Cdkl5 knockout mice with late Cdkl5 reexpression. These findings, in conjunction with our adult knockout studies highlighted in Chapter
3, are the first to delineate a post-developmental requirement for CDKL5, and the first to
demonstrate the potential for disease reversal in CDD. Importantly, our results also uncover a
broad therapeutic time window for numerous CDD-related deficits, supporting future therapeutic
efforts aimed towards the treatment of CDD.

Results
Adult restoration of CDKL5 rescues numerous CDD-related behavioral deficits in
hemizygous male knockout mice
Our previous findings support that post-developmental loss of CDKL5 induces similar
phenotypes as germline knockout (see Chapter 3). However, the reversibility of CDD-associated
symptoms remains a long-standing question in the field, especially since the disorder presents
very early in life. Given that CDD patients do not normally experience neurodegeneration, the
viability of mutant neurons in CDD patients opens up the prospect that re-expression of CDKL5
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(or therapeutic intervention) may restore CDKL5-dependent signaling pathways and thereby
alleviate some of the disorder phenotypes(H. E. Olson et al., 2019). If a critical time window of
CDKL5 function does exist, then delayed treatment (or gene replacement) may have little effect
or even contravening outcomes in a system that has partially compensated for its loss.
To address this, we created a mouse line in which the endogenous Cdkl5 gene is
conditionally silenced by the insertion of a loxP-flanked transcriptional STOP cassette, and where
physiological levels of Cdkl5 expression can be restored upon Cre-mediated cassette deletion
(Cdkl5STOP, hereafter referred to as STOP; Figure 1a). This is particularly relevant as human
genetic studies have reported that duplication of CDKL5 is associated with neurological
impairments(Szafranski et al., 2015). A preliminary characterization of STOP mice demonstrated
that they do not express detectable levels of CDKL5 protein and display similar phenotypes to
Cdkl5 germline knockout mice by P42 when we began tamoxifen administration (Figure 2). We
delivered tamoxifen to four experimental groups of mice: Cdkl5+/y; +/+ (WT), Cdkl5+/y; CreER/+
(Cre), Cdkl5STOP/y; +/+ (STOP), and Cdkl5STOP/y; CreER/+ (rescue, Res) beginning at P42 using
the same regiment applied in our adult knockout experiments (0.3mg∙kg-1 every other day for a
total of 5 doses). We observed significant restoration of CDKL5 protein expression in forebrain
tissues of Res mice, but not STOP mice, that was comparable to WT and Cre-only littermate
controls within two weeks of tamoxifen delivery. Unexpectedly, however, we noticed significant
lethality at this dosage selectively in Res mice, but not WT, Cre, or STOP animals (Figure 3a).
These findings suggest there may be toxicity associated with rapid Cdkl5 reactivation, even at
endogenous levels of CDKL5 expression. We therefore optimized our tamoxifen administration
protocol and found that a more gradual Cdkl5 re-expression (1 tamoxifen dose of 0.3mg∙kg-1
every week for a total of 3 weeks, followed by 2 booster treatments) was able to eliminate this
toxicity while restoring CDKL5 expression to nearly WT levels (Figure 1b, Figure 3b).
Consequently, we adhered to this gradual Cdkl5 activation protocol for subsequent rescue
experiments. Remarkably, phosphorylation of EB2 Ser222 was also restored to control levels
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upon adult reversal of Cdkl5 expression, highlighting that CDKL5-dependent signaling pathways
are likely rescued with Cdkl5 re-expression (Figure 1b).
Using this gradual gene reversal strategy, we next examined the extent to which late
restoration of CDKL5 expression could mitigate CDD-related behavioral deficits. We again
administered tamoxifen to a cohort of Cre, STOP, and Res littermates beginning at P42 (the age
at which most behavioral deficits have arisen in STOP mice, Figure 2) and then beginning at
P140 evaluated multiple behavioral domains known to be disrupted in Cdkl5 germline and adult
knockout animals. We found that Res animals showed significant improvement over STOP
littermates in hyperactivity and anxiety-related behaviors. STOP mice spent significantly more
time exploring the open arm of the elevated zeromaze in comparison to Cre-only controls,
suggestive of decreased anxiety (Figure 1c). However, adult restoration of Cdkl5 resulted in a
significant decrease in open-arm time compared to STOP mice, with Res animals behaving
comparable to Cre controls (Figure 1c, Figure 4a). STOP mice also moved significantly more over
the course of one hour in an open field test when compared to Cre-only controls, whereas Res
mice exhibited activity levels closer to Cre control littermates (Figure 1d, Figure 4b). Adult
restoration of CDKL5 also ameliorated several of the autistic-like phenotypes frequently reported
upon Cdkl5 deletion. During the three-chambered social choice assay, Res animals spent similar
amounts of time to Cre-only controls sniffing the social cylinder and directly interacting with a
novel stimulus mouse, while STOP mice spent significantly less time sniffing the social cylinder
and directly interacting with a novel stimulus mouse, suggestive of decreased sociability (Figure
1e-f, Figure 4f-h). STOP mice also exhibited aberrant repetitive behaviors, illustrated by an
increased time spent grooming/digging in a home cage-like environment when compared to Cre
controls, whereas Res mice displayed control-level grooming/digging behaviors (Figure 1g).
Similar to other Cdkl5 knockout models, STOP mice recapitulate impaired motor learning
on the rotarod assay, as demonstrated by a decreased latency to fall from an accelerating,
rotating rod as well as a penetrant hindlimb clasping phenotype. Adult rescue of CDKL5
significantly ameliorated these motor deficits, with Res mice performance on the rotarod assay
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comparable to littermate Cre-only controls and no hindlimb clasping present in any of the 17 Res
animals tested (Figure 1h-i). Finally, normal context- and cue-dependent learning and memory
were also restored to nearly control levels in Res animals, while STOP mice displayed significant
impairment in both of these memory domains (Figure 1j). Interestingly, working memory, as
measured by spontaneous alternations during the Y-Maze assay, was not significantly improved
in Res animals when compared to STOP-only littermate mice (Figure 4c). However, total activity
during the Y-Maze assay (measured by the total number of alternations) was significantly
restored to Cre control levels in Res animals which aligns with the ameliorated hyperactivity
phenotype illustrated by the open field test (Figure 4d-e). Collectively, these findings support that
adult restoration of CDKL5 is sufficient to reverse or ameliorate the majority of loss-of-function
behavioral impairments; namely, the hyperactivity, anxiety-related phenotypes, autistic-like
behaviors, motor impairments, and learning and memory deficits appear to remain amenable to
post-developmental restoration of CDKL5 expression. Additionally, post-hoc examination of
CDKL5 restoration revealed that several rescue mice showed only 20-50% of wild-type protein
expression (Figure 5). The rescue of numerous behavioral domains in these mice underscores
the potential that even partial restoration of CDKL5 expression may show notable therapeutic
benefit, at least in mice.

Adult restoration of CDKL5 abrogates NMDA-induced hyperexcitability and aberrant
NMDAR-mediated synaptic responses
The significant rescue of behavioral phenotypes upon re-expression of endogenous
Cdkl5 in adult mice raises the possibility that the molecular and cellular deficits caused by loss of
CDKL5 are also reversible. To investigate this, we focused on the aberrant NMDA receptor
(NMDAR) signaling phenotypes previously found to be altered in Cdkl5 knockout and knock-in
mice. Specifically, CDD mouse models display an increase in the ratio of NMDA-mediated to
AMPA-mediated synaptic responses (NMDA/AMPA EPSC ratio) in the CA1 region of the
hippocampus that correlates with an increased susceptibility to NMDA-induced seizures(Okuda et
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al., 2017; Tang et al., 2019). The NMDA-mediated synaptic responses in CDD mouse models
also display significantly larger decay times, suggestive of a higher contribution of GluN2Bcontaining NMDARs.
Consistent with our previous studies in Cdkl5 knockout and knock-in models, we found
that the levels of membrane-associated GluN2B in postsynaptic density fractions purified from
STOP mice were significantly elevated compared to littermate controls, but detected no change in
several other major ionotropic glutamate receptor subunits such as GluA1, GluA2, and GluN2A
(Figure 6a-e). Correspondingly, STOP mice also recapitulated the enhanced susceptibility to
NMDA-induced seizures as shown in other Cdkl5 knockout lines (Figure 6f)(Okuda et al., 2017;
Tang et al., 2019). These phenotypes were further supported by an increase in the NMDA/AMPA
ratio onto CA1 pyramidal neurons of the hippocampus. Additionally, the NMDA-mediated currents
displayed a significantly larger decay time constant, highlighting that our STOP mice carry similar
NMDAR signaling deficits to other CDD models (Figure 6g-i)(Okuda et al., 2017). Remarkably, we
found that late restoration of Cdkl5 expression was able to reverse these NMDAR synaptic
phenotypes. Adult reversal of Cdkl5 expression, using our established tamoxifen regiment
beginning at P42, restored GluN2B expression to Cre-only levels, and consistently attenuated the
enhanced susceptibility to NMDA-induced seizures exhibited by STOP-only mice (Figure 6a-f).
Furthermore, the ratio of NMDA/AMPA currents and NMDAR-current kinetics were rescued as a
result of restoring Cdkl5, suggesting reestablishment of control-level NMDAR subunit composition
(Figure 6g-i). Together, these findings demonstrate that late restoration of CDKL5 expression
attenuates the aberrant NMDAR signaling deficits in the hippocampus that result from CDKL5
loss, underscoring the reversibility of molecular and synaptic signaling deficits present in CDD
models.
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Adult restoration of Cdkl5 expression ameliorates CDD-related behavioral deficits in
heterozygous female mouse models of CDD
Given the variability introduced from X-chromosome inactivation and mosaic Cdkl5
expression in females, we confined our initial experiments to hemizygous male knockout animals.
However, the majority of carriers for this X-linked disorder are heterozygous females(H. E. Olson
et al., 2019). Thus, we expanded upon our initial findings to also examine the reversibility of CDDrelated deficits in adult, heterozygous female mouse models of CDD. We generated an
independent conditional rescue line, Cdkl5FLEX, that, similar to our Cdkl5STOP animals allows for
temporal control of Cdkl5 re-expression at its endogenous locus upon Cre-mediated
recombination. Cdkl5FLEX mice carry an inverted Cdkl5 exon 4 flanked by two pairs of loxP sites
that allow for proper cassette re-orientation and gene expression upon tamoxifen delivery (Figure
7a). We crossed this novel conditional rescue line to a second, inducible Cre allele, CAG-CreER.
We next delivered tamoxifen to three experimental groups of mice: Cdkl5+/+; CreER/+ (Cre),
Cdkl5FLEX/+; +/+ (FLEX), and Cdkl5FLEX/+; CreER/+ (rescue, Res) beginning at P90 using the same
regiment applied in our adult knockout experiments (0.3mg∙kg -1 every other day for a total of 5
doses). We subsequently assayed a similar battery of behavioral test as in our male rescue
studies 3 months later.
An open-field test demonstrated significant hyperactivity of FLEX heterozygous
knockouts compared to Cre littermate controls, similar to what is reported for hemizygous Cdkl5
knockout male mice (Figure 7b). Interestingly, although Res females appeared to also be slightly
hyperactive, there was no significant activity change between Cre-only controls and Res mice,
suggesting reduced hyperactivity with late Cdkl5 re-expression (Figure 7b). We also examined
sociability behaviors, known to be disrupted in Cdkl5 knockout male mice, using a 3-chambered
social choice test. FLEX female mice spent significantly less time sniffing and directly interacting
with a novel stimulus mouse compared to Cre littermate controls, reflecting impaired sociability
upon heterozygous Cdkl5 loss similar to male knockouts (Figure 7c-d). In contrast, Res mice
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spent similar amounts of time sniffing and directly interacting with a stimulus mouse as their Cre
littermate controls, demonstrating rescued sociability with late Cdkl5 restoration (Figure 7c-d).
FLEX heterozygous females also carry impaired context-dependent memory retrieval in a
Pavlovian fear-conditioning paradigm highlighted by reduced time spent freezing upon return to
the foot-shock chamber (Figure 7e). Res mice show significantly increased time freezing
compared to FLEX knockouts, suggesting improved contextual memory retrieval (Figure 7e).
These results suggest that the hyperactivity, sociability, and learning and memory deficits
exhibited by hemizygous Cdkl5 knockout male mice are also recapitulated upon heterozygous
loss of Cdkl5. More importantly, we demonstrate that these domains appear to be amenable to
late kinase rescue in female models of CDD, similar to what we report for hemizygous male mice.

Discussion
Adult restoration of CDKL5 ameliorates several loss-of-function deficits
Several models have been putatively proposed for CDKL5’s role in nervous system
function, including neuronal signaling, PSD stability, and microtubule dynamics(Lucas L.
Baltussen et al., 2018; Fuchs et al., 2014; Ricciardi et al., 2012). However, the absence of a
unifying hypothesis likely explains the scarcity of effective therapeutics currently available to
reverse or ameliorate CDD. Therefore, gene replacement has been recently explored as a viable
strategy for treatment(Gao et al., 2020). A key question along this avenue, however, is whether
later restoration of CDKL5 is sufficient to restore normal neurological function or if the absence of
CDKL5 results in irreversible abnormalities. If a critical time window of CDKL5 does exist, then
later treatment (or gene replacement) may have little effect or even contravening outcomes in a
system that has partially compensated for its loss.
Our adult rescue study of CDKL5 highlights the capability of late reversal of Cdkl5
expression in ameliorating several loss-of-function deficits in mice. Namely, we see significant
rescue of anxiety-related behaviors, hyperactivity, autistic-related phenotypes, motor
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coordination, hindlimb clasping, and learning and memory impairments, suggesting that the
underlying circuitry essential for these behavioral domains is amenable to later kinase restoration.
Notably, working memory was not rescued with adult restoration of CDKL5, which aligns with our
adult knockout study (Chapter 3) where we accordingly saw no impairment of this behavior upon
adult loss of CDKL5. This further reinforces that this behavioral domain and its underlying circuitry
may be modulated by CDKL5 during a critical developmental time widow in development.
Importantly, rescue mice exhibited working memory deficits in spite of their ameliorated
hyperactivity phenotype (demonstrated both by the open-field test and total number of
alternations on the Y-Maze assay), again suggesting that this behavioral domain is impaired upon
loss of CDKL5 independent of motor confounds. These findings also suggest that the reported
working memory phenotypes in germline Cdkl5 knockout animals likely exist independent of any
motor activity confounds. Regardless, the promise of late restoration of CDKL5 mitigating several
CDD-associated deficits in patients represents an exciting development for the field.
In 2016, IGF-1 treatment in juvenile Cdkl5 knockout mice was shown to partially rescue
dendritic spine instability, and although preliminary clinical trials have demonstrated some
success for this therapy in Rett syndrome, its efficacy in CDD patients remains
undetermined(Costales & Kolevzon, 2016). CDKL5 protein substitution therapy in knockout mice
was also reported to rescue neurological phenotypes, but only with continuous administration.
Furthermore, this study exclusively reported on short-term outcomes, and, analogous to IGF-1
therapies, its feasibility and efficacy in CDD patients is untested(Trazzi et al., 2018). Finally, as
the majority of these studies were performed in juvenile animals, the reversibility of CDKL5 lossof-function phenotypes at later ages remains to be addressed. These results, combined with the
monogenetic nature of CDD, highlight the pertinence of gene replacement therapy for viable
treatment in this highly heterogeneous disease. Previous studies have applied the concept of late
gene reversal in rodents to attempt phenotypic rescue in various disease models(Chandran et al.,
2017; Guy, Gan, Selfridge, Cobb, & Bird, 2007; James et al., 2012; Y. Mei et al., 2016). Notably,
late restoration of Mecp2 expression in knockout mouse models has been reported to alleviate
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impairments associated with Rett syndrome, and adult restoration of Shank3 is capable of
rescuing selective autistic-like phenotypes(Guy et al., 2007; Y. Mei et al., 2016). However, no
study to date in rodent models of neurodevelopmental disorders other than CDD has reported
rescue of autistic phenotypes using AAV gene therapy(Gadalla et al., 2017; Garg et al., 2013;
Gholizadeh, Arsenault, Xuan, Pacey, & Hampson, 2014). This pernicious lack of effective gene
therapy treatments for neurodevelopmental syndromes highlights the potential for gene
replacement in CDD to set the stage for future attempts at widespread CNS delivery of gene
vectors to treat the heterogeneous assortment of symptoms associated with these disorders. As
mentioned, a preliminary gene therapy study in Cdkl5 knockout mice achieved successful AAVhCDKL5 development and expression of CDKL5, but only in hindbrain regions(Gao et al., 2020).
Although this was capable of partially restoring some motor coordination deficits in this model,
further work is needed to improve upon forebrain and CNS-wide delivery of CDKL5. Nevertheless
this study, together with our findings, highlights the promise of late gene restoration in
successfully alleviating CDD-associated impairments.

CDKL5 and NMDA receptor signaling
Our results suggest that loss of CDKL5 is capable of regulating post-synaptic localization
of NMDA receptor subunits, namely GluN2B, with resultant behavioral effects on NMDA-induced
hyperexcitability. During development, the canonical switch from predominantly GluN2Bcontaining to GluN2A-containing NMDA receptors across the CNS is thought to be a regulatory
mechanism involved in shaping circuit plasticity during the critical period of synaptogenesis for
several brain regions(Paoletti, Bellone, & Zhou, 2013). Interestingly, the peak expression of
CDKL5 in mouse forebrain appears to coincide with this subunit composition switch during a time
window also associated with circuit refinement and acquisition of learning abilities(Shipton &
Paulsen, 2014). Our results in STOP mice are unable to demonstrate whether this phenotype is a
result of a failed switch from GluN2B to GluN2A early in development, or a continual role of
CDKL5 in maintaining receptor subunit composition at the post-synaptic membrane. Our gene
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reversal study demonstrates that this aberrant GluN2B expression and NMDA hyperexcitability
phenotype is reversible upon late restoration of CDKL5, arguing that CDKL5 may continuously
regulate NMDA receptor composition rather than carry a specific function early in development.
However, the direct role of the kinase within this domain remains to be dissected. Interestingly,
CDKL5 has been reported to target EB2 pS222 via an NMDAR-dependent mechanism, providing
a potential link between disrupted NMDAR signaling, microtubule dynamics, and CDKL5 loss-offunction phenotypes(Lucas L. Baltussen et al., 2018). While we see a significant reduction in EB2
phosphorylation at Ser222 in STOP mice, this reduction is restored to nearly Cre control levels
upon adult rescue of CDKL5. Still, a more mechanistic examination of the role of EB2
phosphorylation, and its effects on synaptic maturation, is needed before a direct role for CDKL5
in this pathway can be corroborated.

Modeling and treating CDD-related phenotypes in heterozygous female mice
The final component of this study demonstrates that several behavioral domains
disrupted in hemizygous knockout mouse models of CDD are also impaired in heterozygous
females of our second, novel knockout line (Cdkl5FLEX). These findings further confirm that
heterozygous Cdkl5 knockout female mice can serve as a viable pre-clinical model for CDD.
Importantly, we also demonstrate that late restoration of Cdkl5 expression in these females
ameliorates several CDD-related deficits, similar to what we reported in hemizygous male rescue
mice. Our future work aims to provide a more in-depth analysis on the reversibility of additional
CDKL5 loss-of-function phenotypes in this female model, however, these initial results provide
promising evidence that the findings of our hemizygous male studies may also extend to female
CDD models.
In contrast to the pervasive epilepsy in CDD patients, the absence of an overt seizure
phenotype in Cdkl5 knockout male mice could contribute to the success of phenotypic reversibility
found in this study. This is particularly pertinent given that in the subsequent chapter (Chapter 5),
we report the occurrence of spontaneous and disturbance-associated seizures exclusively in
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heterozygous Cdkl5 knockout female mice. This epilepsy phenotype appears to increase in
frequency and severity with age, with a median age of onset around 28-30 weeks. Although our
behavioral testing was confined to heterozygous females within 21-25 weeks of age (prior to
seizure development), we cannot exclude the fact that an altered seizure susceptibility or circuit
hyperexcitability may affect the reversibility of certain deficits in heterozygous female models,
particularly after seizure onset. In the future, it will be necessary to extend these experiments to
aged (seizing), heterozygous female mouse models of CDD, determine the minimum and
maximum levels of CDKL5 expression required for safe phenotypic reversal, and define the latest
time window allowable for rescue, at least in mouse models. In the subsequent chapter, we
expand upon this analysis of heterozygous female models of CDD, and provide promising
insights into the treatability of these seizure-like phenotypes specifically.

Materials and Methods
Regulatory approval. Experiments were conducted in accordance with the ethical guidelines of
the National Institutes of Health and with the approval of the Institutional Animal Care and Use
Committee of the University of Pennsylvania. Mice were group-housed in cages of two to five in a
twelve-hour light/dark cycle with food and water provided ad libitum.

Mouse strains and genotyping. Cdkl5STOP mice were generated in collaboration with
Biocytogen using CRISPR-mediated genomic editing techniques. A selected gRNA
(TGCAACTACAGCATTAGCTCTGG) was chosen upon screening of 12 candidates for targeting
specificity and efficacy at intron 3 of the Cdkl5 locus. The DNA repairing template constituted a
loxP-flanked transcriptional STOP cassette, flanked by 817bp of DNA as the 5’ homologous arm
and 1453bp of DNA as the 3’ homologous arm. Synthesized gRNA, purified and linearized DNA
repairing template, as well as Cas9 mRNA were co-injected into a one-cell zygote of C57BL/6
background to allow for homology-directed repair, followed by implantation. PCR primers specific
to the 5’ and 3’ integration sites flanking the gRNA sequence at Cdkl5 intron 3 were used to
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screen for positively targeted pups. Southern blotting was finally conducted to confirm the correct
targeting of the F1 generation, followed by establishment a Cdkl5 floxed-STOP (STOP) colony in
a C57BL/6J genetic background.
Cdkl5FLEX mice were generated in collaboration with Biocytogen using CRISPR-mediated
genomic editing techniques. A pair of gRNAs (TGCAACTACAGCATTAGCTCTGG &
TTTCACAGTAGGTTACCCAGGGG) were chosen upon screening of 22 candidates for targeting
specificity and efficacy at introns 3 and 4 of the Cdkl5 locus. The DNA repairing template
constituted the endogenous Cdkl5 exon 4 flanked by a pair of mloxP and loxP sites, all flanked by
888bp of DNA as the 5’ homologous arm and 1800bp of DNA as the 3’ homologous arm.
Synthesized gRNA, purified and linearized DNA repairing template, as well as Cas9 mRNA were
co-injected into a one-cell zygote of C57BL/6 background to allow for homology-directed repair,
followed by implantation. PCR primers specific to the 5’ and 3’ integration sites flanking the gRNA
sequence at Cdkl5 exon 4 were used to screen for positively targeted pups. Southern blotting
was finally conducted to confirm the correct targeting of the F1 generation, followed by
establishment a Cdkl5 FLEX (FLEX) colony in a C57BL/6J genetic background.
UBC-CreER (Stock No. 007001) mice and CAG-CreER (Stock No. 004682) mice were
obtained from the Jackson Laboratories. All lines have been maintained in the C57BL/6J
background.
Experimental cohorts were all weaned at 3 weeks of age and littermates housed
together. For genotyping of UBC-CreER and CAG-CreER transgenics, primers and genotyping
strategy were identical to that used by Jackson Laboratories. Cdkl5STOP and Cdkl5FLEX mice were
genotyped using a qPCR based strategy optimized by Transnetyx to detect the presence of a
loxP-flanked STOP cassette within intron 3 of the endogenous Cdkl5 gene and the inversion of
exon 4 of the endogenous Cdkl5 gene, respectively.

Tamoxifen preparation and administration. Tamoxifen (Sigma, T5648) was dissolved in corn
oil (Sigma, C8267) at a concentration of 20mg∙ml-1 by vortexing and slowly heating the solution at
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40°C for approximately one hour. Freshly prepared tamoxifen was protected from light by
aluminum foil and stored at 4°C for a maximum of one week. Animal feeding needles from Roboz
Surgical Store (20 gauge, 1.5” length, curved; FN-7910) were used for oral gavage delivery of
0.3mg∙kg-1 of tamoxifen every other day for a total of five doses. For adult restoration of Cdkl5, a
slower dosage timeline was introduced to avoid the lethality associated with rapid reintroduction
of CDKL5: Cdkl5+/y; CreER/+, Cdkl5STOP/y; +/+, and Cdkl5STOP/y; CreER/+ cohorts all received
0.3mg∙kg-1 of tamoxifen once a week for a total of three weeks, and then two subsequent booster
deliveries every other day after the third dose (total of 5 doses). See schematic in Figure 3a for
details. All genotypes received tamoxifen within each experimental cohort.

Behavioral assessments. All animal behavioral studies were carried out blinded to genotype.
Mice were allowed to habituate to the testing room for at least 1 hr before the test, and testing
was performed at the same time of day. All animal behaviors were performed on adult male and
female mice between postnatal days 120-160, and the analysis of behavioral data was carried out
by a researcher blinded to genotype.
Elevated zeromaze. The elevated zeromaze (San Diego Instruments; California, USA) consists of
a circular-shaped platform elevated 3 feet above the floor. Two opposite quadrants of the maze
are enclosed (wall height, 12 inches), whereas the other two are open (wall height, 0.5 inches).
Mice were placed in one of the closed quadrants and their movement traced over the course of 5
min. Analysis, including the quantification of percent of time spent in open arms and the number
of entries, was performed manually using a stopwatch. An entry was defined as a transition from
a closed to open arm, or vice versa, that involves all four paws. Total distance traveled over the
entire assay was measured by a ceiling-mounted camera coupled to a video-tracking software
(SmartScan 3.0), allowing for real-time analysis of all movements.
Open-field test. Locomotor activity was measured via an open-field test where mice were
individually placed into, and allowed to explore, a 15” x 15” arena for a total of 60 min. A ceilingmounted camera allowed for a video-tracking software (SmartScan 3.0) to real-time analyze the
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total distance traveled as well as the percent time spent in the center of the arena (defined as the
central 25% of the total area).
Y-maze. Spontaneous alternation behavior was measured on a Y-maze apparatus (San Diego
Instruments; California, USA), composed of three arms (Arm A: 8in. x 5in. x 3in.; Arms B and C:
6in. x 5in. x 3in.). For testing, the mouse was placed in Arm C, facing the center, and allowed to
freely explore the maze for 5 min. A spontaneous alternation was defined an entry into the arm
less recently explored. Percent spontaneous alternation was calculated as the number of
spontaneous alternations over the total number of entries. For example, the sequence
C,B,A,B,C,B,A,C (starting in arm C) resulted in a percent spontaneous alternation of 4/6 = 67%.
Three-chambered social approach assay. The social choice test was carried out in a threechambered apparatus that consisted of a center chamber and two end chambers. Before the start
of the test and in a counter-balanced sequence, one end chamber was designated the social
chamber, into which a stimulus mouse would be introduced, and the other end chamber was
designed the nonsocial chamber. Two identical, clear Plexiglas cylinders with multiple holes to
allow for air exchange were placed in each end chamber. In the habituation phase of the test
(Phase I), the test mouse was placed in the center chamber and allowed to explore all three
chambers for 10 min. During this acclimation period, baseline measurements of how much time
the mouse spent in each of the three chambers and the distance traveled by the test mouse were
collected. In the social choice phase of the test (Phase II), an age-matched stimulus mouse
(adult, gonadectomized A/J mice) was placed in the cylinder in the social chamber while a novel
object was simultaneously placed into the other cylinder in the nonsocial chamber. During the
subsequent 10 min social choice period, chamber times and numbers of transitions among
chambers were again recorded as well as the percent time spent sniffing the social cylinder. In
the direct social interaction test, the cylinders were removed simultaneously following the social
choice test, and the amount of time test and stimulus mice spent in direct contact (sniffing,
allogrooming) was measured for a total of 5 min. If fighting persisted for more than several
seconds, the mice were removed from the apparatus and excluded from the study.
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Accelerating rotarod assay. Mice were placed on an accelerating rotarod apparatus (Harvard
Apparatus) for 16 trials (four trials a day for four consecutive days) with at least 15 min of rest
between the trials. Each trial lasted for a maximum of 5 min, during which the rod accelerated
linearly from 4 to 40 rpm. The amount of time for each mouse to fall from the rod was recorded for
each trial.
Context- and cue-dependent fear conditioning. For the training day, mice were placed in
individual chambers (Med Associates) for 2 min followed by a loud tone (85 dB, 2 kHz) lasting 30
s that coterminated with a 2-s, 1.25-mA foot shock. Mice were left undisturbed for an additional
30 s in the chamber and then immediately placed back into their home cage. Freezing behavior,
defined as no movement except for respiration, was determined before and after the tone-shock
pairings and scored by FreezeScan NI version 2.00. To test for context-dependent learning, we
placed mice back into the same testing boxes 24 hr later for a total of 5 min without any tone or
shock, and again measured the total time spent freezing. After 4 hrs, we tested for cuedependent fear memory by placing the mice into a novel chamber consisting of altered flooring,
wall-panel inserts, and vanilla scent. After 2 min in the chamber, the cue tone (85 dB, 2 kHz) was
played for a total of 3 min, and the total time spent freezing during the presentation of this cue
tone was recorded.
Olfaction. Mice were tested for whether they could detect and differentiate odors in a habituationdishabituation protocol modified from Yang and Crawley(Yang & Crawley, 2009). Mice were
presented with cotton-tipped wooden applicators dipped in either water, vanilla, or swiped across
the bottom of an unfamiliar social cage. Each stimulus was presented for 2 min with a 1-min intertrial interval. Time spent sniffing was defined as when the animal was oriented with its nose 2 cm
or closer toward the cotton tip.
Repetitive behavior. Mice were individually placed into a clean, home-cage like environment lined
with bedding. After allowing 5 min for habituation, 10 min of activity was videotaped for each
mouse. The duration of repetitive behavior, defined as grooming or digging, was scored manually
using a stopwatch.
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Hindlimb clasping. Mice were suspended by the base of their tail at least 6 inches above a flat
surface for up to 1 min. If the hindlimbs were consistently splayed outward, away from the
abdomen, the mouse was assigned a score of 0. If one hindlimb was retracted towards the
abdomen for more than 50% of the time, the score was 1. If both hindlimbs were partially
retracted for greater than 50% of the time, the score was 2. Finally, if both hindlimbs were entirely
retracted and touching the abdomen for more than 50% of the time suspended, the mouse
received a score of 3.

Brain microdissection. To assess CDKL5 protein expression in various brain regions, adult
male mice were sacrificed by cervical dislocation. After decapitation, brains were removed and
sectioned into 1mm coronal slices using a mouse brain matrix. Tissue was dissected from the
somatosensory cortex, striatum, hippocampus, and cerebellum and homogenized in RIPA lysis
buffer (150mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate [DOC], 0.1% sodium dodecyl
sulfate [SDS], 25mM Tris [pH7.4] with protease inhibitors [Roche, cOmplete, EDTA-free protease
inhibitor cocktail tablets; 5056489001]). To prepare protein extracts, homogenized lysates were
incubated on ice for 15 min, and then centrifuged at 21,000 x g for 15min at 4°C. The supernatant
fraction was removed and sonicated using a Biorupter for 3 alternating session at max frequency
for 15 sec, each followed by a 60 sec cooldown period. The lysate was then centrifuged at 21,000
x g for 15min at 4°C, and the top aqueous layer carefully removed and collected as the total
protein fraction.

Postsynaptic density protein purification. We adapted a widely used protocol for the
preparation of PSD fractions that we previously reported on(Bermejo et al., 2014; Tang et al.,
2019). Mice were sacrificed via cervical dislocation, and their brains quickly extracted. Forebrain
cortical tissues were microdissected and Dounce-homogenized in 10mL of homogenization buffer
(0.32M sucrose, 4mM HEPES, pH 7.4 with protease inhibitors [Roche, cOmplete, EDTA-free
protease inhibitor cocktail tablets; 5056489001]). The homogenate was centrifuged at 1000 × g
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for 10 min at 4°C to pellet cellular debris and nuclei (P1), and the subsequent supernatant (S1)
was centrifuged for another 15 min at 10,000 × g at 4°C. The resulting pellet (P2, “crude”
synaptosomes) was re-suspended in another 10mL of homogenization buffer and centrifuged at
10,000 × g for 15 min at 4°C. The supernatant was discarded, and the resulting pellet (P2’) was
re-suspended in 10mL of 4mM HEPES (pH 7.4) then homogenized on ice. The lysate was
incubated at 4°C for 30 min while shaking to hypo-osmotically lyse the synaptosomes, and then
centrifuged for 20 min at 25,000 × g at 4°C. The resultant pellet (LP1) was re-suspended in 1 mL
of homogenization buffer and layered on top of a discontinuous sucrose gradient (bottom to top:
1.5mL of 1.2M sucrose, 1mL of 1.0M sucrose, and 1mL of 0.8M sucrose). The gradient was
ultracentrifuged at 150,000 × g for 1.5hr at 4 °C. The turbid layer between the 1.0/1.2 M sucrose
interphase containing the synaptic plasma membranes (~1mL) was collected and re-suspended
in 5mL of 4mM HEPES to dilute out the sucrose. This fraction was ultracentrifuged again at
200,000 × g for 30 min at 4°C. The resulting pellet was re-suspended in 1mL of 50mM HEPES
with 2mM EDTA (pH 7.4), and the membrane proteins extracted by adding Triton X-100 at a final
concentration of 0.5% and incubating at 4°C while rotating for 15 min. The proteins were
centrifuged at 32,000 × g for 20 min at 4°C, and the resulting pellet re-suspended in 75µL of
50mM HEPES with 2 mM EDTA.

Western blot. Protein concentration was measured using a Bradford assay. Purified synaptic
density membrane proteins or protein lysates were prepared for gel electrophoresis by adding 4X
LDS Sample Buffer (NuPAGE, NP0008) to a final concentration of 1X and β-mercaptoethanol to
a final concentration of 5%. Samples were heat-denatured at 75°C for 20 min, and 7.5µg or 25 µg
of protein was loaded into each well of a 4–12% Bis-Tris gradient gel (Invitrogen, 10-well, 1.5mm;
NP0335) for PSD protein or brain lysate quantification, respectively. Protein gels were run for 2hr
at 125V at room temperature on a XCell SureLock mini-cell electrophoresis box (ThermoFisher;
EI001) using a PowerPac HC High-Current Power Supply (BioRad; 1645052), then transferred
onto a polyvinylidene fluoride (PVDF) membrane (0.45µm pore-size; Biorad 162–0115) at 27V for
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1hr and 10min at room temperature. The resulting membrane was blocked with a 1:1 solution of
Odyssey blocking buffer (LICOR; 927-40100) and 1X PBS for 1hr at room temperature.
Primary antibodies used were rabbit anti-N-terminal CDKL5 (in house; diluted 1:500),
mouse anti-β-Actin (Abcam; ab8226; diluted 1:10,000), rat anti-EB2[K52] (Abcam, ab45767;
diluted 1:10,000), and rabbit anti-phospho-EB2[S222] (generously shared by Dr. Sila Ultanir at
the Francis Crick Institute; London, UK; diluted 1:1000). For postsynaptic density studies, the
primary antibodies used were rabbit anti-N-terminal CDKL5, mouse anti-GluN1 (ThermoFisher,
OMA1–04010; diluted 1:1000), rabbit anti-GluN2A (Frontier Institute, AB_2571605; diluted 1:200),
rabbit anti-GluN2B (Frontier Institute AB_2571761; diluted 1:200), rabbit anti-GluA1 (Abcam,
ab31232; diluted 1:5000), rabbit anti-GluA2 (Abcam, ab133477; diluted 1:5000), and anti-β-Actin.
Secondary antibodies (LI-COR) used were goat anti-rabbit IgG IRDye800CW, rabbit anti-mouse
IgG IRDye680LT, and goat anti-rat IRDye680LT, all incubated for 50min at room temperature at
dilutions of 1:10,000. Standard protocols were used for the Odyssey Infrared Imaging System (LICOR) for protein visualization and quantification.

NMDA-induced seizure scoring. Seizures were induced in postnatal day 180 mice by
intraperitoneal administration of 90 mg∙kg-1 NMDA (Sigma-Aldrich; M3262) in sterilize, 0.9% PBS.
Seizure progression was scored using a modified Racine scale as previously described: (0) no
abnormality; (1) exploring, sniffing, and grooming ceased, animal becomes motionless; (2)
forelimb and/or tail extension, appearance of rigid posture; (3) myoclonic jerks of the head and
neck, with brief twitching movement, or repetitive movements with head bobbing or “wet-dog
shakes”; (4) forelimb clonus and partial rearing, or rearing and falling; (5) forelimb clonus,
continuous rearing and falling; (6) tonic-clonic movements with loss of posture tone, often
resulting in death(Okuda et al., 2017). After drug injection, max seizure scores were recorded
within a 30 min observation period.
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Electrophysiology recordings. Mice were deeply anesthetized using isoflurane and perfused
transcardially with ice-cold ACSF (pH 7.3 – 7.4) containing (in mM): 124 NaCl, 2.5 KCl, 1.2
NaH2PO4, 24 NaHCO3, 5 HEPES, 12.5 glucose, 1.3 MgSO4, 7H2O, 2.5 CaCl2. The brain was
rapidly removed, and transverse sections (400 uM) were cut on a vibratome (VT 1200s, Leica).
Slices were incubated in a holding chamber for 12-15 minutes at 32-34°C in a NMDG-based
recovery solution (pH 7.3-7.4, pH adjusted with HCl) (in mM): 92 NMDG, 2.5 KCl, 1.2 NaH2PO4,
30 NaHCO3, 20 HEPES, 25 glucose, 5 sodium ascorbate, 2 thiourea, 3 sodium pyruvate, 10
MgSO4, 7H2O, 0.5 CaCl2. Osmolarity for the NMDG-based solution and ACSF was kept between
300-310 mOsm. Following incubation, slices were moved to a second holding chamber
containing ACSF at room temperature (20-22°C) for at least 1 hr. prior to recording. For
recording, slices are transferred to the recording chamber (Scientifica) fully submerged in
oxygenated (95% O2, 5% CO2) ACSF at a perfusion rate of 1.4-1.6 mL/min, bath temperature of
29-30°C, and secured using a slice anchor (Warner Instruments). Electrophysiology data were
acquired using custom-built Recording Artist software version (Rick Gerkin), Igor Pro 6.37
(Wavemetrics). All recordings were sampled at 20kHz, filtered at 2.8kHz.

Evoked AMPA/NMDA currents. CA1 pyramidal neurons were visualized using differential
interference contrast (DIC) video microscopy on an upright microscope (Olympus, BX51).
Somatic whole-cell recordings were performed using borosilicate glass (World Precision
Instruments, TW150-3) that had a tip resistance of 3-5 MΩ, filled with cesium-based internal for
voltage-clamp recordings (in mM): 115 CsMeSO3, 20 CsCl, 10 HEPES, 0.6 EGTA, 2.5 MgCl, 10
Na-Phosphocreatine, 4 Na-ATP, 4 Na-GTP, 0.1 Spermine, 1 QX-314 (pH adjusted to 7.3-7.4 with
CsOH). A bipolar theta glass electrode backfilled with ACSF was positioned in the Schaffer
collaterals for electrical stimulation. Stimulation intensity was adjusted to evoke single component
EPSCs with a frequency of 0.1Hz. Voltage-clamp traces were recorded at a holding potential of 70 mV (for AMPA-EPSCs) or +40 mV (for NMDA-EPSCs) in the presence of 100μM picrotoxin
(Sigma-Aldrich). For each cell, at least 15 traces were averaged to obtain a representative
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response at each holding potential. The peak EPSC amplitude at -70 mV was taken as the
magnitude of the AMPA-EPSCs. To isolate the NMDA-mediated current, 10 μM NBQX (Abcam)
was bath-applied and was blockade of AMPA-mediated currents was confirmed at -70mV. To
calculate the NMDA/AMPA ratio, the amplitude taken at +40mV in the presence of NBQX was
divided by the peak amplitude of the AMPA-EPSC at -70mV. The access resistance was
monitored throughout the experiment and data was excluded if access resistance increased
above 20 MΩ. The decay time constant of NMDAR-mediated EPSCs was calculated with a
single-exponential fit in Igor 7.

Statistical Analysis. For behavioral assays, we chose similar sample sizes for all behavioral
experiments based on previous published studies of Cdkl5 constitutive knockout mice and Cdkl5
conditional knockout mice(Tang et al., 2019; Tang et al., 2017; I. T. Wang et al., 2012).
Importantly, the number of mice used was pre-determined prior to the start of each experiment.
Statistical analyses were performed using Prism (GraphPad). All data sets were analyzed using
the Shapiro-Wilk test for normality. For one-sample comparisons, data sets with normal
distributions were analyzed for significance using the one-sample t-test, whereas data sets with
non-normal distributions were analyzed using the Wilcoxon signed-rank test. For two-sample
comparisons, data sets with normal distributions were analyzed for significance using the
unpaired Student’s t-test, whereas data sets with non-normal distributions were analyzed using
the Mann-Whitney test. Two-way repeated measures ANOVA or the Kruskal-Wallis test was
conducted for the appropriate data sets with post hoc Sidak’s or Dunn’s multiple-comparisons
tests. All one-sample, two-sample, and multiple-comparison tests were two-tailed.
For NMDA seizure induction experiments, we tested a pilot cohort of wild-type and Cdkl5
knockout animals at various doses of NMDA to establish an effect size in our own hands on this
reported phenotype. This enabled proper power analysis to determine the appropriate sample
size for our experimental cohorts (n=10 at 90 mg∙kg-1). Max seizure scores were statistically
analyzed using the Kruskal-Wallis test and post hoc Dunn’s multiple comparisons test for
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significance. Similarly, we referenced reported effect sizes for NMDA/AMPA ratio phenotypes
reported in mouse models of CDD and related models of neurodevelopmental disorders in order
to determine proper sample sizes for our physiology experiments. To analyze significance, we
conducted One-way ANOVA with post hoc Tukey’s multiple-comparisons test.
All graphs are plotted using Prism (GraphPad). Bolded center lines reflect the mean, and
all error bars indicate s.e.m. For boxplots, the limits indicate the minimum and maximum with
boxplot center line indicating the median. In our figures, p-values between 0.05 and 0.1 are
shown explicitly, * is used to denote all 0.01 < p < 0.05, ** for 0.001 < p < 0.01, *** for 0.0001 < p
< 0.001, and **** for p < 0.0001.
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Figures

Figure 1: Adult restoration of Cdkl5 expression rescues CDD-associated behavioral
deficits.
(a) Top: schematic of conditional rescue approach in Cdkl5STOP mice where a loxP-flanked
transcriptional STOP cassette can be removed in the presence of Cre; Bottom: tamoxifen
administration scheme and experimental schedule. (b) Left: representative western blot
demonstrating restored CDKL5 protein expression in Cdkl5STOP/y; CreER/+ (Res) mice, but not
Cdkl5STOP/y; +/+ (STOP) mice, to nearly Cdkl5+/y; CreER/+ (Cre) levels with tamoxifen
administration concomitant with significant rescue of phosphorylation of EB2 at Ser222 but no
change in total EB2 levels; Right: quantification of CDKL5 and EB2 pSer222 protein levels in
forebrain tissues of all genotypes demonstrates significant rescue of both in Res mice upon
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tamoxifen administration. (c) STOP mice, but not Res mice, spend significantly more time than
Cre littermates in the open arm of the elevated zeromaze assay suggestive of decreased anxiety
that is rescued in Res animals. (d) STOP mice travel significantly more distance in the open-field
assay than Cre and Res littermates, demonstrating rescued hyperactivity in Res animals. (e)
STOP mice spent significantly less time sniffing and (f) directly interacting with a stimulus mouse
during the 3-chambered social choice test compared to Cre and Res littermates, highlighting
rescued sociability phenotypes in Res animals. (g) STOP mice, but not Res mice, spend
significantly more time grooming and digging in a home cage-like environment, demonstrating
aberrant repetitive behaviors that are rescued in Res animals. (h) STOP mice take significantly
less time to fall from an accelerating, rotating rod, suggestive of impaired motor coordination,
whereas Res mice fall at a similar latency to Cre littermate controls demonstrating rescue of
motor coordination. (i) STOP mice present with hindlimb clasping behaviors, whereas no Cre or
Res mice were observed to carry hindlimb clasping phenotypes. (j) STOP and Res mice freeze in
response to a mild footshock similarly to Cre littermates, but STOP mice show decreased percent
time freezing compared to Cre and Res littermates when returned to the testing chamber
(contextual) and upon hearing the testing tone (cue), demonstrating impaired learning and
memory selectively in STOP mice that is restored in Res mice. For all panels: Cre, n=23; STOP,
n=20; Res, n=17 where all genotypes received tamoxifen; Kruskal-Wallis test with Dunn’s multiple
comparisons test (except Rotarod: 2-way repeated measures ANOVA with Sidak’s multiple
comparisons test). *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. Bars represent mean ± SEM.
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Figure 2. STOP mice are behaviorally similar to Cdkl5 germline knock-in mice by postnatal
day 42.
(a) STOP and KO mice move significantly more in the open-field test compared to Cre controls
suggestive of hyperactivity. (b) STOP and KO mice show a trending decrease in percentage of
spontaneous alternations during the Y-Maze assay compared to Cre controls suggestive of
impaired working memory. STOP and KO mice also (c) travel significantly more and (d) make
more total alternations compared to Cre controls in the Y-Maze assay. (e) STOP mice spend less
time directly interacting with a novel stimulus mouse during a dyadic social test, demonstrating
decreased sociability as reported for other Cdkl5 knockout and knock-in lines. For all panels:
n=14 Cre (Cdkl5+/y; CreER/+); n=7 STOP (Cdkl5STOP/y; +/+); n=7 KO (Cdkl5R59X/y) all at postnatal
day 42. Kruskal-Wallis test with Dunn’s multiple comparisons test (except dyadic social: MannWhitney test); *p<0.05, **p<0.01. Bars represent mean ± SEM.
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Figure 3. Rapid, but not gradual, reversal of Cdkl5 expression is associated with
significant lethality.
(a) Top: tamoxifen administration schematic (rapid); Bottom: survival curve demonstrating
significant lethality in Cdkl5STOP/y; CreER/+ mice, exclusively, with tamoxifen delivery suggesting
rapid Cdkl5 reintroduction could be detrimental (n=8 Cdkl5+/y; +/+; n=11 Cdkl5+/y; CreER/+; n=8
Cdkl5STOP/y; +/+; n=6 Cdkl5STOP/y; CreER/+). (b) Top: tamoxifen administration schematic
(gradual); Bottom: survival curve demonstrating no significant difference in lethality between
Cdkl5STOP/y; CreER/+ mice and other genotypes with tamoxifen delivery, suggesting that gradual
Cdkl5 reintroduction mitigates lethality associated with its re-expression (n=23 Cdkl5+/y; CreER/+;
n=20 Cdkl5STOP/y; +/+; n=17 Cdkl5STOP/y; CreER/+). For all panels: all genotypes received
tamoxifen; Mantel-Cox (log-rank) test; *p<0.05, **p<0.01, ***p<0.001.
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Figure 4. Additional behavioral domains analyzed upon adult rescue of Cdkl5.
(a) Total distance traveled during the elevated Zeromaze assay was similar between Cre, STOP,
and Res mice. (b) STOP, but not Res, mice traveled significantly more in an open-field assay
relative to Cre littermates over the course of one hour (distance traveled binned in 5min intervals)
suggestive of rescued hyperactivity in Res mice. (c) STOP and Res mice show a significant
decrease in percentage of spontaneous alternations in a Y-Maze assay compared to Cre
littermates, suggestive of impaired working memory. (d) STOP, but not Res, mice make
significantly more total number of alternations and (e) travel more distance during the Y-Maze
when compared to Cre littermate controls further highlighting rescued hyperactivity in Res
animals. (f) Cre, STOP, and Res mice all spent equal time exploring chamber 1 and chamber 2
during Phase I of the 3-chambered social choice test (prior to any social/non-social stimulus
presentation). (g) Cre, STOP, and Res mice all spent significantly more time in the chamber
containing a social stimulus (S; novel mouse) over a non-social stimulus (NS; rock) during Phase
II of the 3-chambered social choice test. (h) Cre, STOP, and Res mice all spent significantly more
time sniffing a social scent over either water or almond scents, with STOP mice spending
significantly less time than Cre or Res animals sniffing the social scent. For all panels: Cre, n=23;
STOP, n=20; Res, n=17 where all genotypes received tamoxifen; Kruskal-Wallis test with Dunn’s
multiple comparisons test (except open field & olfaction: two-way, repeated measures ANOVA
with Dunnett’s multiple comparisons test & social choice test: paired t test); *p<0.05, **p<0.01,
***p<0.001, ****p<0.0001. Bars represent mean ± SEM.
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Figure 5. Partial restoration of CDKL5 protein is capable of rescuing multiple behavioral
domains.
All panels reference data from Figure 1 with four partial rescue (Res) animals highlighted in blue.
(a) Quantification of western blot results for CDKL5 protein levels in forebrain tissues of all
genotypes demonstrates significant rescue of CDKL5 protein to nearly Cre-only levels in most
Res, but not STOP, mice upon tamoxifen administration except for four animals (highlighted in
blue) demonstrating between 20-60% CDKL5 protein restoration. Results from the (b) elevated
zeromaze assay, (c) open-field assay, (d-e) 3-chambered social choice test, (f) repetitive
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behavior assay, and (g) fear conditioning paradigm highlight that the four Res animals not
showing full CDKL5 protein restoration (blue diamond) still cluster with the remaining Res animals
versus STOP mice, demonstrating rescue on most behavioral domains evaluated. For all panels:
Cre, n=23; STOP, n=20; Res, n=17; partial rescue Res, n=4 where all genotypes received
tamoxifen; Kruskal-Wallis test with Dunn’s multiple comparisons test; *p<0.05, **p<0.01,
***p<0.001, ****p<0.0001. Bars represent mean ± SEM.
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Figure 6: Adult restoration of CDKL5 abrogates aberrant NMDAR-mediated synaptic
responses.
(a) Representative western blots showing several major ionotropic glutamate receptor subunits
from postsynaptic density membrane fractions in Cre, STOP, and Res mice. (b-e) STOP, but not
Res, mice show a selective increase in levels of GluN2B, a major subunit of the NMDA receptor
compared to Cre littermate controls (n=8 per genotype). (f) STOP, but not Res, mice show a
significantly increased susceptibility to NMDA-induced seizures compared to Cre littermate
controls (Cre, n=9; STOP, n=10; Res, n=9). (g-i) STOP, but not Res, mice show an increased
ratio of NMDA-mediated to AMPA-mediated synaptic responses in the hippocampal CA1 (g)
concomitant with a significantly larger decay time constant of NMDAR-mediated EPSCs (i),
suggestive of a higher contribution of GluN2B-containing NMDARs (representative traces shown
in (h)) and demonstrating an attenuation of aberrant NMDAR signaling deficits in Res mice. For
all panels: Kruskal-Wallis test with Dunn’s multiple comparisons test (except for (g) and (i): oneway ANOVA with Tukey’s multiple comparisons test). *p<0.05, **p<0.01, ***p<0.001. Bars
represent mean ± SEM.
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Figure 7: Adult restoration of Cdkl5 expression ameliorates several CDD-associated
behavioral deficits in heterozygous female CDD mice
(a) Cdkl5FLEX mice carry an inverted exon 4 of the endogenous Cdkl5 locus, flanked by two pairs
of loxP sites that allow for proper cassette re-orientation and gene expression upon tamoxifen
delivery. All female mice received tamoxifen beginning at postnatal day 90, and behavioral
analysis was performed 3 months later. (b) Open-field test demonstrating significant hyperactivity
in heterozygous female Cdkl5 knockout mice (Cdkl5FLEX/+; +/+, or FLEX), but no significant activity
change between Cre-only controls (Cdkl5+/+; CreER, or Cre) and rescue mice (Cdkl5FLEX/+;
CreER, or Res) suggesting reduced hyperactivity. (c) Examination of sociability behaviors during
a 3-chambered social choice test demonstrates reduced sociability in FLEX females mice
compared to Cre littermate controls indicated by reduced (c) time spent sniffing and (d) directly
interacting with a novel stimulus mouse. Res mice spent similar amounts of time sniffing and
directly interacting with a stimulus mouse as their Cre littermate controls, demonstrating rescued
sociability. (e) FLEX heterozygous females carry impaired context-dependent memory retrieval in
a Pavlovian fear-conditioning paradigm highlighted by reduced time spent freezing upon return to
the foot-shock chamber. Res mice show significantly increased time freezing compared to FLEX,
suggesting improved memory retrieval. Relevant statistical details are embedded in each graph.
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CHAPTER 5 – X-LINKED CELLULAR MOSAICISM UNDERLIES AGE-DEPENDENT
SEIZURE OCCURRENCE IN MOUSE MODELS OF CDKL5 DEFICIENCY DISORDER

Contributions: Barbara Terzic, Yolanda Cui, and Andrew C. Edmondson co-led this
study with help from Nicolas Sarmiento and Dasha Zaitseva for data analysis, Erin
Nugent for seizure monitoring, and Zhaolan Zhou for the review and interpretation of
data. Yue Cui and Erin Nugent managed all mouse husbandry, genotyping, and
breeding. Barbara Terzic wrote this chapter with input from all authors.
Abstract
CDKL5 Deficiency Disorder (CDD) is an infantile epileptic encephalopathy presenting
with early-onset seizures, intellectual disability, motor impairment, and autistic features. The
disorder has been linked to mutations in the X-linked CDKL5, and mouse models of the disease
recapitulate several aspects of CDD symptomology including learning and memory impairments,
motor deficits, and autistic-like features, but not spontaneous seizures. Here, we report the first
observation of disturbance-associated and spontaneous seizure-like events in heterozygous
female mice across two independent mouse models of CDD: Cdkl5 knockout mice and CDKL5
R59X knock-in mice. We find that both the prevalence and severity of this phenotype increase
with aging, with a median onset around 28 weeks of age. Similar seizure-like events are not
observed in hemizygous knockout male or homozygous knockout female littermates, suggesting
that X-linked cellular mosaicism is a driving factor underlying these epileptic events. Furthermore,
we successfully demonstrate significant prevention of seizure activity upon early (pre-epilepsy)
Cdkl5 expression restoration, and a significant abatement of seizure activity upon late (postepilepsy) Cdkl5 expression restoration across 2 independent, conditional rescue mouse lines.
Together, these findings not only contribute to our understanding of the effects of CDKL5 loss on
seizure susceptibility, but also strengthen the face validity of current CDD mouse models for
future therapeutic development.
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Introduction
Pathogenic variants in the X-linked gene encoding cyclin-dependent kinase-like 5
(CDKL5) have been associated with the severe childhood epileptic encephalopathy known as
CDKL5 Deficiency Disorder (CDD)(Bahi-Buisson & Bienvenu, 2012; Fehr et al., 2013; Kalscheuer
et al., 2003; Tao et al., 2004; Weaving et al., 2004). CDD is characterized by a heterogeneous
array of clinical symptoms including early-onset seizures, marked hypotonia, autistic features,
and severe neurodevelopmental impairment(S. Demarest et al., 2019; H. E. Olson et al., 2019).
The disorder predominantly affects young females heterozygous for mutations in the X-linked
CDKL5, with an overall incidence of one per forty-two thousand live births, making it one of the
most common genetic causes of epilepsy in children(S. Demarest et al., 2019; Symonds et al.,
2019). Despite the constellation of phenotypes presented in CDD, the severe, early-onset
seizures in particular drastically impact quality of life, with ninety percent of patients displaying
seizures by three months of age. Eighty percent of children with CDD have daily seizures, and
fewer than half report more than two months of seizure freedom(H. E. Olson et al., 2019).
Furthermore, children with epilepsy that presents before 3 years of age have been shown to carry
a high burden of behavioral and cognitive comorbidities, and this risk increases with increased
seizure incidence(Berg et al., 2008; Berg, Zelko, Levy, & Testa, 2012). This high burden of
refractory seizures in CDD make it a particularly debilitating aspect of the disorder for both
patients and their families, highlighting the pressing need to develop effective therapeutics for
seizure management.

Several mouse models of CDD have been established and exhibit many of the cardinal
phenotypes of the disorder, including autistic-like behaviors, impaired motor control, and poor
learning and memory(Zhou, Han, & Zhou, 2017; Y.-C. Zhu & Z.-Q. Xiong, 2019). The first Cdkl5
knockout mouse was generated and characterized in 2012, mimicking a reported CDD splice-site
mutation resulting in skipping of exon 6 and loss of CDKL5 function(Archer et al., 2006; I. T.
Wang et al., 2012). Although hippocampal electroencephalographic (EEG) recordings in postnatal
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day (P) 70-90 male mice of this line demonstrated disruptions in event-related neuronal
oscillations in response to auditory stimuli, chronic video-EEG recordings revealed no
spontaneous seizure activity. Furthermore, basal EEG patterns and power distribution across
various oscillation frequencies were unchanged in hemizygous knockout male mice compared to
littermate controls. In 2014, Amendola et al. developed and characterized another Cdkl5 knockout
mouse (exon 4 deletion) in which EEG recordings also revealed no spontaneous epileptiform
activity in hemizygous male knockouts(Amendola et al., 2014). More recently, an exon 2 deletion
mouse of Cdkl5 as well as the CDKL5 R59X knock-in, mimicking a CDD-associated nonsense
mutation resulting in loss of CDKL5 function, were created. Although these animals display an
increased sensitivity to NMDA-induced seizures, no overt spontaneous seizure activity was
initially reported(Okuda et al., 2017; Tang et al., 2019). Recently, aged heterozygous female mice
from the first Cdkl5 knockout (exon 6 deletion) and CDKL5 R59X knock-in mouse lines were
reported to exhibit spontaneous epileptic spasms (Mulcahey, et al. 2020)

The lack of a robust seizure phenotype in CDD mouse models has so far been attributed
to neural network differences between human and mouse brains(Zhou et al., 2017). EEG
recordings in loss-of-function models of CDD have not revealed spontaneous seizures, but the
majority of these studies have been limited to hemizygous male mice(Amendola et al., 2014; I. T.
Wang et al., 2012). Despite the lack of overt, behavioral seizures in animal models of CDD
reported to date, several groups have observed synaptic and circuit-level hyperexcitability in
various brain regions as well as altered sensitivity to specific chemoconvulsants. CDKL5 is most
highly expressed in neurons of the forebrain, and selective loss of CDKL5 from forebrain
excitatory neurons results in increased frequency of miniature excitatory post-synaptic currents
(mEPSC) in the hippocampal CA1 region(Tang et al., 2017). Interestingly, selective loss from
GABAergic forebrain neurons also recapitulates this increased mEPSC frequency coupled with
circuit hyperexcitability in the form of aberrant paired-pulse facilitation(Tang et al., 2019). In this
same region, loss of CDKL5 was found to result in enhanced long-term potentiation by a
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misregulation of postsynaptic GluN2B-containing NMDA receptor localization, and in line with
this, knockout mice exhibit significant hyperexcitability to NMDA(Okuda et al., 2017; Tang et al.,
2019). Although high-dose kainic acid induces overt seizures in Cdkl5 hemizygous knockout
males at similar latency to wild-type littermates, the mean duration of the resultant epileptic EEG
bursts is reported to be longer(Amendola et al., 2014). Cdkl5 knockout mice have also been
reported to display decreased latency to the first stages of seizure progression upon low-dose
pentylenetetrazol administration(Yennawar et al., 2019). These findings suggest that seizure
susceptibility may in fact be altered in the absence of CDKL5, but perhaps only under certain
environmental conditions or specific periods of development and aging.
Here, we report the occurrence of overt, myoclonic and tonic-clonic behavioral seizurelike events in two distinct mouse models of CDD: a Cdkl5 knockout carrying a deletion of exon 6
and the CDKL5 R59X knock-in, both resulting in loss of CDKL5 function. These events are
specific to female mice heterozygous for mutations in Cdkl5, and not seen in hemizygous
knockout males, homozygous knockout females, or wild-type littermates. Both the frequency and
severity of this seizure-like activity increased with aging, with a median age of onset around 28
weeks of age. The lack of overt similar seizure-like events in hemizygous male knockout and
homozygous female knockout mice suggests that X-linked mosaicism of Cdkl5 deficiency likely
drives the seizure phenotype in mouse models of CDD. Importantly, we demonstrate for the first
time that these seizure-like events in CDD mouse models are preventable and reversible with
restoration of Cdkl5 expression, providing a positive outlook for seizure management and
treatment in CDD patients.

Results
Female mice heterozygous for mutations in Cdkl5 exhibit seizure-like events in an agedependent manner
The severity and prevalence of seizures in patients with CDD has motivated numerous
efforts to model and examine seizure-related phenotypes in Cdkl5-deficient mice(Amendola et al.,
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2014; Okuda et al., 2018; Tang et al., 2019; Tang et al., 2017; I. T. Wang et al., 2012; Yennawar
et al., 2019). Initial reports in several mouse models of CDD failed to recapitulate the
spontaneous seizure phenotype commonly presented in CDD patients. However the majority of
these studies, including our own, have focused on hemizygous knockout male mice. Furthermore,
the majority of these behavioral or functional assays have been confined to young adult mice
(postnatal days (P) 50-90).
Given that Cdkl5 is X-linked, we maintain and generate experimental mice by crossing
wild-type males to females heterozygous for Cdkl5 mutations (e.g., R59X). In the process of
breeding R59X heterozygous females (Cdkl5R59X/+ or R59X/+), we observed that numerous aged
(>P200) females displayed abnormal movements following cage opening/disturbance. Upon
observing these abnormal movements, which we felt resembled seizure-like behaviors, we
sought to establish a methodology to consistently and quantitatively score these events. We
modified the Racine scale widely used to describe the progress and severity of chemoconvulsantinduced seizures (Table 1), and set up a process of regular monitoring (3 minutes per cage, 2-3
times a week) and seizure scoring along this scale for our R59X/+ breeder and non-breeder
females as well as wild-type littermate controls(Velíšková, Velíšek, Mareš, & Rokyta, 1990). Over
the span of fourteen months, upon cage opening or handling, we have documented behavioral
events that we believe resemble seizures beginning as early as 17 weeks of age.
The most frequent seizure-like events observed consisted of myoclonic jerks involving
sudden and repetitive movement of the head and neck with or without tail stiffening (Racine
Stage 1, Supplementary Video 1A, 1B, 1C). Tonic-clonic seizures with an initial appearance of
wild running followed by loss of the righting reflex (Racine Stage 4, Supplementary Video 4A, 4B,
4C) were the second most frequent seizure type observed. On rare occasions, the tonic-clonic
seizures would progress into extension of fore- and hind-limbs, reaching Racine Stage 5
(Supplementary Video 5). Clonic seizures with forelimb clonus and rearing were also relatively
rare (Racine Stage 3, Supplementary Video 3A, 3B, 3C). To streamline data collection, analysis,
and presentation, all seizures ranging from Racine stages 1 to 2 were termed ‘myoclonic
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seizures-like events’ and events resembling Racine stages 3 to 5 were grouped as ‘severe
seizure-like events.’ Mice were defined as being epileptic only after a second seizure-like event
had been observed (typically Racine Stage 1). By 20 weeks of age, we found that 12% of R59X/+
females had displayed a second seizure-like event, and this increased to 70% of R59X/+ females
exhibiting at least 2 seizures-like events by 40 weeks of age. We never observed similar events
(or similar behaviors of any type) in wild-type (+/+) females, hemizygous knockout male mice
(R59X/y), or wild-type male mice (+/y) across any of the age groups (Figure 1A).
As no laboratory had previously documented seizures in any CDD mouse model at the
time, we attempted to confirm our findings in an independent Cdkl5 knockout line lacking Cdkl5
exon 6 (hereafter referred to as KO). Indeed, by 12 weeks of age we had observed at least two of
these similar events in 8.7% of KO/+ females, and this increased to 65% of KO/+ females by 40
weeks of age. Again, no seizure-like activity was observed in wild-type (+/+) females, hemizygous
knockout male mice (KO/y), or wild-type male mice (+/y) across any of the age groups (Figure
1B).
To rule out the possibility that this epilepsy phenotype is exclusive to the CDKL5 colonies
we have maintained in our laboratory, we obtained additional R59X/+ females (Stock No. 028856)
and KO/KO females (Stock No. 003724) from the Jackson Laboratory, crossed them to newly
obtained C57BL/6J males (Stock No. 000664), and subsequently monitored their progeny twice a
week for seizure-like events as described above. 10 out of 13 R59X/+ females (77%), but no +/+
female or R59X/y male littermates, were observed to have at least one seizure-like event by 30
weeks of age. Similarly, KO/+ females, but no +/+ female or KO/y male littermates, displayed
seizure-like events by 30 weeks of age. We therefore concluded that the phenotype we had
detected was indeed due to loss of Cdkl5 function.
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Seizure-like event frequency and severity in Cdkl5 heterozygous females increases with
age with a concomitant reduced life span
While monitoring R59X/+ female mice, we observed that several mice reaching Racine
Stage 5 seizures would die after reaching the tonic phase of the seizure. We found that on
average, R59X/+ females have a significantly decreased lifespan compared to their wild-type
littermate (+/+) females with significantly more R59X/+ females dying between 40-50 weeks of
age (Figure 1C), possibly as a result of infrequent but lethal seizures. In contrast, no significant
change in life span was found between R59X/y males and their wild-type (+/y) littermates (Figure
1D). These results suggest that the seizure-like events occurring in R59X/+ females may
decrease life span.
Of the R59X/+ females observed starting at 12 weeks of age, the median age of onset of
a second observed myoclonic seizure-like event (Racine Stages 1 to 2) was 28 weeks. More
severe seizure-like events (Racine Stages 3 to 5) also occurred more frequently with increasing
age, with a median onset of 47 weeks of age (Figure 2A). In addition to this increasing seizurelike event severity, the frequency of all observed seizure-like events also increased with age
(Figure 2B).
It should be noted that there is significant individual variability within R59X/+ females for
both the onset and the frequency of these seizure-like events. During our observations, some
females displayed their first disturbance-associated seizure-like event as early as 17 weeks of
age while others did not display an overt seizure-like event until 49 weeks of age or ever. For
some R59X/+ mice, disturbance-associated seizure-like events occurred every week for a time
span of a few months, while for other mice no events were observed after two initial seizure-like
events. A summary of 20 R59X/+ females monitored from 12 to 45 weeks of age for all seizurelike events demonstrates this trend of age-dependency and variability (Figure 2C).
We similarly tracked the age-dependent development of seizure-like events in our second
Cdkl5 knockout line to validate our findings. In KO/+ females, the median age of onset of a
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second observed myoclonic seizure-like event (Racine Stages 1 to 2) was 32 weeks, with a first
seizure-like event observed as early as 16 weeks of age in some mice. More severe seizure-like
events (Racine Stages 3 to 5) occurred in KO/+ females with a median age of onset of 57 weeks
(Figure 3A). Similar to the R59X/+ females, the likelihood of both myoclonic seizure-like events
and a severe seizure-like events in KO/+ females increased with age (Figure 3B). We monitored
17 KO/+ females from 12 weeks until 42-45 weeks of age and recorded all seizure-like events,
and found similar individual variability in both age-of-onset and seizure frequency as reported
above for R59X/+ (Figure 3C).
We recognize that this variability may also be a result of our sampling method of only
observing seizure-like events 2-3 times a week upon cage disturbance, and that our incomplete
reported penetrance of ~70% may not accurately reflect the actual incidence of seizure-like
events amongst heterozygous female carriers of Cdkl5 mutations. To investigate whether the
seizure-like events we were observing only occur with cage opening/disturbance, we continuously
video recorded R59X/+ females mice that had previously displayed a disturbance-associated
seizure-like event for >72 hours to determine whether events can also occur spontaneously. Both
myoclonic seizure-like events (Supplementary Video 6A, 6B) and tonic-clonic seizure-like events
(Supplementary Video 7) were observed during this recording session. These events occurred
spontaneously without any disturbances or environmental changes, suggesting that loss of
CDKL5 leads to spontaneous seizure-like events as well as the disturbance-associated seizurelike events we reported above.
In an attempt to capture EEG correlates of these seizure-like events, we performed EEG
implantation surgery utilizing 2 cortical surface electrode and video monitoring in R59X/+ female
mice as described in the methods section (n=13). Mice under EEG surveillance with time-locked
video were mildly disturbed by a gentle touch of the hand at varying times and intervals
throughout the monitoring period to mimic the seizure monitoring interactions. No Racine stage 4
or 5 handling-provoked generalized tonic-clonic seizures were evoked. We also watched the
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recorded video and analyzed the EEG tracing using integrated seizure detection software without
observing any unprovoked Racine stage 4 or 5 seizures. Over 1,574 hours of video-EEG data
across 13 R59X/+ female mice (roughly 121 hours/mouse) we were only able to observe one
female displaying a stage 1 handling-associated seizure-like event (Supplemental Videos 8A,
8B), characterized by brief movements involving neck extension and body stiffening temporally
associated with bilaterally synchronous slow-wave discharges on EEG. We also recorded over
145 hours of video-EEG data across 4 wild-type female and wild-type male mice without
detection of similar seizure-like events as reported prior to surgery and implantation. Using this
technique, we did detect epileptic spasms as recently described in the same mouse
lines(Mulcahey et al., 2020).
Given the concern that inability to observe these seizure-like behaviors could be due to a
possible blunting effect from the surgery itself, we utilized a different EEG implantation technique
with 2 cortical surface electrodes and a double-depth electrode in right hippocampus in 7 R59X/+
and 9 KO/+ heterozygous females mice, as well as 8 wild-type female mice. Each mouse
underwent video-EEG recording for at least 11 days as described in the methods. Over the entire
duration of over 2,300 hours of video-EEG monitoring for all 24 mice, the technicians who
handled the mice observed no Racine stage 4 or 5 handling-provoked generalized tonic-clonic
seizures. We also utilized a third EEG implantation technique with 8 electrodes (hippocampal,
bilateral parietal, bilateral motor, bilateral visual electrodes) and failed to detect any Racine stage
4 or 5 handling-provoked generalized tonic-clonic seizures while working with these mice.
Interestingly, a recent publication reported spontaneous epileptic spasms, associated with
generalized, slow-wave activity on EEG, in identical strains of KO/+ and R59X/+ female mice at
similar ages(Mulcahey et al., 2020). Our findings of disturbance-associated myoclonic and tonicclonic seizure-like events, therefore, complement the previous findings and suggest that multiple
seizure semiologies exist in mouse models of CDD.

148

Heterozygous mosaic, but not homozygous or hemizygous, loss of CDKL5 underlies
spontaneous seizure development
We were intrigued by the sex-specificity of our observed seizure-like phenotype and
wanted to dissect the contributing factors that may underlie this segregation of seizure
presentation to R59X/+ and KO/+ females but not R59X/y or KO/y hemizygous male knockouts.
Since sex hormones are well known to affect the seizure threshold of both epileptic humans and
mice, we examined whether estrous cycle or androgen hormones may be contributing to the sexspecificity of this phenotype(Tauboll, Sveberg, & Svalheim, 2015). We collected vaginal lavage
samples from R59X/+ and KO/+ females immediately upon observing disturbance-associated
seizure-like events in order to test for estrous cycle stage at the time of seizure occurrence. We
identified seizing females in all four stages of the mouse estrous cycle (Figure 4A), suggesting
that the levels of sex hormones or estrous cycle stage are unlikely to be triggering factors for the
seizure-like events we observed. We also compared the median age of seizure onset between
breeder and nulligravid R59X/+ females and did not observe any significant differences (Figure
4B).
An additional factor that differs between our seizing heterozygous knockout females and
hemizygous males is the X-linked mosaicism exclusively present in heterozygous female
knockouts. To investigate whether mosaicism may be underlying the seizure-like phenotype
segregation between our male and female CDD mice, we have been generating a cohort of mice
by breeding R59X/+ females to +/y and R59X/y males. To date, we have monitored 14
homozygous knockout females (R59X/R59X) together with 16 heterozygous knockout females
(R59X/+) and 9 wild-type (+/+) littermate controls beginning at 12 weeks of age. 12 out of 16
(75%) R59X/+ females have been observed to display at least two disturbance-associated
seizure-like events with a median age-of-onset of 32 weeks, while no seizure-like events have
been seen in +/+ littermate controls and only one seizure-like event being observed in a single
R59X/R59X female littermate (Figure 4C). This supports the idea that X-linked mosaicism of
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Cdkl5 deficiency may be a driving factor of the disturbance-associated and spontaneous seizurelike events observed in female models of CDD.

Restoration of Cdkl5 expression prevents and reverses the evolution of seizure-like
events in heterozygous female models of CDD
Our unexpected seizure phenotype finding provoked a unique insight into genetic models
of CDD, and led us to examine the reversibility of this epileptic phenotype in our Cdkl5STOP and
Cdkl5FLEX heterozygous female mice. We began by examining Cdkl5STOP heterozygous females
(Cdkl5STOP/+, hereafter referred to as STOP/+) for the occurrence of any seizure-like events
similar to what we reported in R59X/+ and KO/+ females. STOP/+ females developed agedependent seizure-like events by a median age of 31 weeks, confirming our seizure phenotype in
an independent Cdkl5 knockout model (Figure 5). Similar events were not detected in UB-CreERonly control littermates (Cdkl5+/+, CreER/+). We first tested the potential for prevention or
mitigation of this epilepsy phenotype with early Cdkl5 expression restoration (i.e. prior to epilepsy
onset).
We subsequently raised up a cohort of STOP/+; +/+ and STOP/+; CreER/+ female
littermates, and administered tamoxifen to all genotypes beginning at P90 (13 weeks of age)
using the same regiment applied in our conditional knockout experiments in Chapter 3 (0.3mg∙kg1

every other day for a total of 5 doses). This regiment restores Cdkl5 expression in STOP/+;

CreER/+ mice, but not STOP/+ mice, prior to the onset of any seizure phenotype. Using the same
bi-weekly-monitoring method as described in previous sections, we noticed that STOP/+, but not
STOP/+; CreER/+ mice, developed seizure-like behaviors by 31 weeks of age. These results
demonstrate a successful prevention (or at least significant mitigation) of seizure-like events with
early Cdkl5 restoration (Figure 5), and align with our previous behavioral rescue studies in
females (Chapter 4, Figure 7).
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We next tested whether late Cdkl5 expression restoration (i.e. after epilepsy onset) was
also capable of mitigating the occurrence of seizure-like events in heterozygous Cdkl5 knockout
female models. In an independent cohort, we report that STOP/+ mice and their STOP/+;
CreER/+ littermates all develop seizure-like events by a median age of 28.5 weeks (Figure 6). We
subsequently delivered tamoxifen (0.3mg∙kg-1 every other day for a total of 5 doses) to all animals
beginning at 33 weeks of age in order to test the reversibility of this epileptic phenotype. While
STOP/+ mice continued to present with seizure-like events even after tamoxifen administration,
no subsequent seizure-like events were detected in STOP/+; CreER/+ littermates (Figure 6).
These results suggest that Cdkl5 expression restoration can reverse or significantly mitigate the
occurrence of seizure-like events even in mice that were previously seizing. Importantly, we
corroborated these findings in our independent conditional rescue line, the Cdkl5FLEX/+ (FLEX/+)
crossed to a distinct inducible Cre (CAG-CreER). We demonstrate that FLEX/+ females and their
FLEX/+; CreER/+ littermates all develop seizure-like events at a median age of onset of 37 and
28.5 weeks, respectively (Figure 7). Importantly, late Cdkl5 expression restoration (33 weeks of
age) using our same tamoxifen regiment successfully mitigated the occurrence of seizure-like
events in FLEX/+; CreER/+ females, but not FLEX/+ littermates (Figure 7). Together, these
results demonstrate the potential for seizure prevention and reversal in heterozygous female
mouse models of CDD.

Discussion
Despite the presence of multiple behavioral and neurophysiological impairments, the
spontaneous seizures that are a hallmark feature of CDD have not been reported across four
independent Cdkl5 knockout mouse models(Amendola et al., 2014; Okuda et al., 2018; I. T.
Wang et al., 2012; Yennawar et al., 2019). It is therefore imperative to establish animal models
with stronger face validity in order to dissect the mechanisms underlying the epilepsy associated
with mutations in CDKL5 as well as to facilitate future development of targeted therapeutics. This
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is the first report of disturbance-associated and spontaneous seizure-like phenotypes in mouse
models of CDD. Both the disturbance-associated and spontaneous seizure-like activity appear to
be specific to female mice heterozygous for mutations in Cdkl5, with no hemizygous male
knockout, homozygous female knockout, or wild-type littermate control mice displaying epileptic
activity to our knowledge. In contrast to humans with CDD, we find that our female CDD mice
display a delayed seizure phenotype onset, at a median age around 30 weeks (averaged across
our two independent loss-of-function lines). We speculate that this delayed-onset as well as the
variable presentation between individual animals (Figures 2C and 3C) may account for the
absence of previous reports of seizures across various heterozygous female models of CDD.
Our initial observations in R59X/+ females led us to investigate and validate our seizurelike findings across three additional, independent Cdkl5 knockout lines (KO/+, STOP/+, and
FLEX/+) with similar age-of-onset and incidence, suggesting that this phenotype is indeed linked
to mutations in Cdkl5 and will likely be shared across additional mouse models of CDD.
Myoclonic seizures, as well as generalized tonic-clonic seizures, have been widely described in
CDD patients, reflecting a potential similarity between human CDD epilepsy and the events we
observe in our mice(H. E. Olson et al., 2019). Furthermore, we find that the segregation of this
seizure-like phenotype exclusively to heterozygous female knockouts (and not hemizygous males
or homozygous females) highlights X-linked mosaicism as a potential driving factor for seizure
presentation in mouse models of CDD.

Late-onset of epilepsy phenotype in female CDD mouse models
The delayed onset of seizure-like events in our CDD mice reflects a key distinction
between the human CDD patient seizure phenotype and that of our models. The median age of
onset for a second observed seizure-like event in our R59X/+ and KO/+ females was 28 weeks
and 32 weeks of age, respectively; considered well into the middle-aged stage of the lifespan of
C57BL/6 mice(Flurkey et al., 2007). In contrast, CDD patients display early-onset seizures with a
median age of onset at six weeks of age and with 90% developing seizures by three months of

152

age(Fehr et al., 2013; H. E. Olson et al., 2019). As previously discussed, one factor that could be
underlying this variability between human and mouse CDD seizure onset in this study is the
behavioral method of observation for seizure-like events. By sampling events in our mouse
models 2-3 times a week, it is possible we may have missed any spontaneous seizure-like events
occurring at earlier ages, especially given the frequency of seizure-like events appears to
increase with age. It is also plausible that earlier-occurring seizures in our mice may not have had
recognizable behavioral correlates. The prevalence, frequency, and semiology of spontaneous
epileptic spasms are characterized in a recent publication using chronic video-EEG recording in
aged, Cdkl5 mutant mice(Mulcahey et al., 2020). In future studies, a more detailed
characterization of seizure progression and onset in younger animals via chronic, video-EEG will
allow for a more fine dissection of the temporal progression of this seizure phenotype.
In CDD patients, typical seizure progression appears to follow a pattern progressing from
early onset and at times pharmacoresponsive seizures (Stage I; onset 1-10 weeks), to epileptic
encephalopathy with infantile spasms (Stage II; onset 6 months to 3 years), and subsequently
refractory, multifocal and myoclonic epilepsy (Stage III; onset 5-7 years)(Bahi-Buisson, Kaminska,
et al., 2008). This final stage of refractory epilepsy appears to continue long-term in most
patients, highlighting an increasing seizure severity with age that human CDD patients also
appear to display. Developmental differences between human and mouse brains may underlie
these phenotypic differences in age of onset. As such, a more in-depth focal analysis of the cell
type or circuit of origin for these epileptic events in the future will provide clarity on the nature of
this delayed-onset phenotype in mice. Our findings of a second seizure type in addition to the
recently described epileptic spasms complements the previous findings and suggest that similar
to CDD patients, mouse models of CDD exhibit multiple seizure semiologies(Mulcahey et al.,
2020).
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Disturbance-associated nature of CDD mouse seizure phenotypes
Seizures are known to be precipitated by a myriad of factors including stress, menses,
photic stimulation, etc.(Engel Jr., 2012). Our initial observances of seizure-like events in our aging
CDD female mice occurred upon cage opening or disturbance, suggesting that specific
environmental triggers may precipitate seizure presentation in our model. Although mice were
often gently separated by hand for easier observation, disturbance by touching was not required
for seizure-like events to occur. These events may have been invoked by the movement of the
cage during transfer to the changing station, sound from the ventilation of the changing station
hood, brighter light, exposure to human odor, or a combination of multiple of the above factors.
Even though it remains unclear what aspects of cage disturbance specifically trigger the
associated seizure-like events we observed in our R59X/+ and KO/+ females, it is important to
note that we have also observed spontaneous seizure-like events during chronic video
monitoring, in the absence of any discernible external stimuli (Supplementary Videos 7A, 7B, 7C,
8), highlighting that this environmental disturbance is not required for seizure onset. Interestingly,
some CDD patients have been reported to have reflex seizures, or seizures that are predictably
triggered by specific stimuli, suggesting a precedence for this phenotype in humans(Peikes,
Hartley, Mhanni, Greenberg, & Appendino, 2019; Solazzi et al., 2018). While we are convinced
these observed events are seizures, we were unfortunately unable to electrographically capture
these events despite using three different EEG implantation techniques since the nature of the
behavioral phenotype changed upon EEG electrode implantation. Failing to capture these events
could be due to the rarity and unpredictability of the events in individual mice, a possible blunting
effect from the surgery itself, altered semiology of seizure-like events, or inability to replicate a
more consistent environmental trigger while in our video-EEG system. The unpredictability of
seizure events in chronic epilepsy is cited as a major factor affecting quality of life, thus, further
work into the potential triggering factors for CDD-associated seizures could provide valuable
insight into environmental influences on seizure development and potential avenues for
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mitigation(Devinsky et al., 1995). Our findings, together with those of Mulcahey et al., suggest
that multiple seizure semiologies likely exist in mouse models of CDD(Mulcahey et al., 2020).

Mosaic loss of CDKL5 drives the overt presentation of spontaneous seizures
CDD affects both male and female patients, albeit at varying frequencies, and
hemizygous male Cdkl5 knockout mice have been able to recapitulate several of the cardinal
phenotypes presented in CDD patients(Akamine et al., 2018; Amendola et al., 2014; Liang et al.,
2019; Mirzaa et al., 2013; Okuda et al., 2018; Sartori et al., 2009; Szafranski et al., 2015; Van
Esch, Jansen, Bauters, Froyen, & Fryns, 2007; I. T. Wang et al., 2012; Yennawar et al., 2019).
However, in our study, no overt seizure-like activity was observed in either R59X/y or KO/y male
mice, at least at the ages we focused on, and previously reports in various hemizygous CDD
knockout males have also not observed spontaneous seizures(Amendola et al., 2014; Okuda et
al., 2018; I. T. Wang et al., 2012; Yennawar et al., 2019). Both of our loss-of-function CDD lines
(Cdkl5R59X and Cdkl5 knockout) have been generated and maintained in the C57BL/6 strain for at
least 10 generations – an inbred strain of mouse known to confer increased seizure resistance,
thus potentially occluding the presentation of spontaneous seizures in other Cdkl5 knockout
mice(Ferraro et al., 2010; McKhann, Wenzel, Robbins, Sosunov, & Schwartzkroin, 2003). Despite
this, previous attempts by our group and others at backcrossing our Cdkl5 lines to less seizureresistant strains (e.g., DBA/2J, FVB, 129) have not precipitated the manifestation of any
spontaneous seizure events in hemizygous Cdkl5 knockout males (data not shown)(Amendola et
al., 2014). This suggests that genetic background is likely not causal to the lack of overt
behavioral seizures in hemizygous male CDD models.
We propose the differences we observe between hemizygous male and heterozygous
female mouse models of CDD may be due to the mosaicism of CDKL5 loss caused by Xchromosome inactivation in R59X/+ and KO/+. This hypothesis is supported by the lack of an
overt seizure-like phenotype in either hemizygous male knockout (R59X/y; KO/y) or homozygous
female knockout (R59X/R59X; KO/KO) mice. Furthermore, estrous cycle and androgen hormone
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levels appear to be unrelated to event incidence across seizing female mice. Interestingly,
another epileptic encephalopathy, caused by mutations in the X-linked PCDH19, is well known for
causing seizures predominantly in heterozygous females and mosaic males(Kolc et al., 2019).
The mechanism underlying PCDH19-related epilepsy has been traced to abnormalities in cellular
adhesion and consequent cell sorting in animal models(Bartnik et al., 2011; Pederick et al.,
2018). While it remains unclear whether epilepsy in CDD is definitively related to mosaicism,
mosaic exon deletions and mosaic de novo point mutations have been reported in both male and
female CDD patients and may be an underappreciated phenomenon(Stosser et al., 2018).

Seizure treatment in mouse models of CDD
Collectively, our gene rescue findings successfully demonstrated significant prevention of
seizure activity upon early (pre-epilepsy; Figure 5) Cdkl5 expression restoration and a significant
abatement of seizure activity upon late (post-epilepsy; Figure 6 & Figure 7) Cdkl5 expression
restoration across 2 independent rescue lines. These results highlight the potential not only for
inhibition of CDD-associated seizure onset with early gene replacement or treatment, but also
demonstrate the reversibility of seizure occurrence with late Cdkl5 restoration. Again, due to a
possible blunting effect from the surgery itself, altered semiology of seizure-like events, or inability
to replicate a more consistent environmental trigger while in our video-EEG system, the nature of
this seizure-like phenotype changes upon EEG implantation, making it difficult to
electrographically capture these events. However, as mentioned, a recent study in collaboration
with our group also identified epileptic spasms that were associated with generalized slow-wave
activity on EEG specific to heterozygous female CDD mice(Mulcahey et al., 2020). Our current
endeavors include attempting to capture correlates of these distinct epileptic spasms using videoEEG in STOP/+ and FLEX/+ mice, and subsequently evaluating their evolution upon early and
late Cdkl5 restoration. Early-onset epilepsy is a cardinal phenotype within CDD, therefore, these
seminal results are a critical development for future examinations into the reversibility, treatment,
and pathogenesis of epilepsy associated with CDD. Our results also highlight the potential for
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mouse models of CDD, especially our novel, conditional reversal line, to serve as a valuable tool
to dissect the circuit and EEG progression of childhood epilepsy more generally.
Together, our findings demonstrate the first report of overt, disturbance-associated and
spontaneous seizure-like events in Cdkl5 deficient mice, a second, distinct seizure phenotype,
and provide the community with newfound face validity for existing CDD models. Although we
were not able to capture the events described in this study on video-EEG, our video records
suggest that they closely resemble the spectrum of behavioral seizure phenotypes described by
the Racine scale. Our current and future work aim to more extensively dissect both the focal
circuits (or multi-focality) and continuum of severity underlying seizures presented in these CDD
mouse models as well as the mechanism of seizure reversal with late gene restoration.
Investigating the circuit origin/nature of this epilepsy phenotype in mice will continue to highlight
mechanisms by which loss of CDKL5 drives network imbalance and circuit hyperexcitability, and
will provide the CDD community with crucial insights towards the development of seizure
therapeutics.

Materials and Methods
Mouse strains. The CDKL5 R59X knock-in(Tang et al., 2019) and Cdkl5 knockout(I. T. Wang et
al., 2012) lines were generated as previously described, and have since been deposited at
Jackson Laboratories (R59X: Stock No. 028856; Cdkl5 KO: Stock No. 021967). UBC-CreER
(Stock No. 007001) mice and CAG-CreER (Stock No. 004682) mice were obtained from the
Jackson Laboratories. Cdkl5STOP and Cdkl5FLEX mice were generated as described in Chapter 4
(‘Materials and Methods’). All lines have been maintained in the C57BL/6J background.

Animal husbandry. Experiments were conducted in accordance with the ethical guidelines of the
National Institutes of Health and with the approval of the Institutional Animal Care and Use
Committee of the University of Pennsylvania. Mice were group-housed in cages of two to five in a

157

twelve-hour light/dark cycle with food and water provided ad libitum. Each breeding cage
contains one male (C57BL/6J or Cdkl5R59X/y, R59X/y) and one to two females (Cdkl5R59X/+,
R59X/+, or Cdkl5KO/+, KO/+). All progeny were genotyped either with the previously reported PCR
strategies or with qPCR by Transnetyx, Inc(Tang et al., 2019; I. T. Wang et al., 2012). Male
littermates (Cdkl5R59X/y with Cdkl5+/y; Cdkl5KO/y with Cdkl5+/y) and female littermates (Cdkl5+/+
and/or Cdkl5R59X/R59X with Cdkl5R59X/+; Cdkl5KO/+ with Cdkl5+/+) were weaned at 3 weeks of age
and housed together.

Seizure monitoring. Mice were monitored for disturbance-associated seizures two to three times
over the course of each week (every other day), during varying times between 8AM to 7PM.
Times of day with no extra disturbances occurring (such as cage changing) were chosen. Cages
were swiftly and gently pulled out of the rack and moved onto the cage changing station, one
cage at a time. Cage lids were immediately removed and mice were mildly disturbed by a gentle
touch of the hand. Mice in the cage were then closely observed for 3 minutes for the occurrence
of any seizure events and scored according to the modified Racine scale (see Table 1, adapted
from Velíšková et al., 1990). Stage 0: no changes in behavior; Stage 1: myoclonic jerks with
sudden and repetitive movement of the head and neck with or without tail stiffening; Stage 2:
atypical (unilateral or incomplete) clonic seizure; Stage 3: clonic seizure with forelimb clonus and
rearing; Stage 4: tonic-clonic seizure with an initial wild run and subsequent loss of righting reflex;
Stage 5: tonic-clonic seizure with full extension of fore- and hind-limbs. To streamline data
collection, analysis, and presentation, all seizures ranging from Racine stages 1 to 2 were termed
‘myoclonic seizures’ and events resembling Racine stages 3 to 5 were grouped as ‘severe
seizures.’

Determination of estrous cycle stage. Mice observed having disturbance-associated seizures
underwent vaginal lavage immediately after they resumed normal activities to check for estrous
cycle stage. Each mouse was picked up by the base of the tail and 20ul of saline was gently
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expelled into the vaginal cavity using a pipette, aspirated back five times, and then dispensed
onto a microscopic slide. Dry smears were then evaluated under the microscope and scored for
the estrous cycle stage according to the presence/absence and percentage of neutrophils,
nucleated epithelial cells and cornified epithelial cells(Caligioni, 2009). Proestrus stage:
predominance of nucleated epithelial cells; Estrus stage: predominance of cornified epithelial
cells; Metestrus stage: predominance of leucocytes with a small amount of nucleated and/or
cornified epithelial cells; Diestrus stage: predominance of leucocytes.

Two-Channel EEG implantation surgery. Experiments were conducted in accordance with the
approval of the Institutional Animal Care and Use Committee of the University of Pennsylvania.
Mice were stereotaxically implanted with an electrode assembly under continuous isoflurane
anesthesia. The electrode assembly consisted of 4 leads: 2 surface electrodes attached to
miniature skull screws placed over the left and right frontal cortices (from Bregma: A/P + 1.0 mm,
M/L ± 1.5 mm); and a reference and a ground electrode also attached to miniature skull screws
directly behind Lambda on either side of midline (from Bregma: A/P − -5.2 mm, M/L ± 1.5 mm);.
Silver wires (0.13 mm diameter) were attached to each electrode and connected to an 8-pin
headmount (Pinnacle Technology Inc, Lawrence, KS). The entire assembly was secured on the
skull with dental cement (Ortho-Jet, Lang Dental, Wheeling, IL). Mice were given at least 72
hours post-surgery to recover prior to being placed in a Plexiglas recording cage (Pinnacle
Technology Inc, Lawrence, KS). EEG waveform was amplified by a preamplifier with a gain of 10
μV (Pinnacle Technology Inc, Lawrence, KS) at the head of the animal before being passed
through a low-torque communtator to the Sirenia Acquisition system (Pinnacle Technology Inc,
Lawrence, KS) for final-stage amplification and filtering. EEG was sampled at 2000 Hz in a 12hour light/dark cycle with food and water provided ad libitum. Mice in the monitoring cages were
mildly disturbed by a gentle touch of the hand at varying times and intervals throughout the
monitoring period to mimic the seizure monitoring interactions as described above. Video was
watched by a reviewer familiar with the appearance of the disturbance-associated seizures. EEG
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traces were also processed with the application of a 1 Hz high-pass filter, 500 Hz low-pass filter,
and 60 Hz notch filter and analyzed within Serenia Basic (Pinnacle Technology Inc, Lawrence,
KS) using amplitude and line length individually to identify potential seizure event. For each
potential seizure event, time-locked video was used to assess for the presence of motor behavior
typical of disturbance-associated seizures.

Four-Channel EEG implantation surgery. EEG recordings were performed as previously
described in Mulcahey et al.(Mulcahey et al., 2020). All experiments were conducted in
accordance with the approval of the Institutional Animal Care and Use Committee of the
Children’s Hospital of Philadelphia. Mice were stereotaxically implanted with an electrode
assembly under continuous isoflurane anesthesia. The electrode assembly consisted of 6 leads:
2 surface electrodes attached to miniature skull screws placed over the left and right frontal
cortices (from Bregma: A/P −1.2 mm, M/L ±1.1 mm); a double-depth electrode in right
hippocampus (A/P −2.2 mm, M/L +1.2 mm, D/V −1.3 mm); and finally a reference and a ground
electrode directly behind Lambda on either side of midline. Teflon-coated silver wires (0.13 mm
diameter) were attached to each electrode and connected to a 6-pin pedestal (Plastics One,
Roanoke, VA). The entire assembly was secured on the skull with dental cement (Ortho-Jet, Lang
Dental, Wheeling, IL). All surgeries were performed by an experimenter blinded to genotype.

Video-EEG recording. Video-EEG recording was conducted as previously described in
Mulcahey et al.(Mulcahey et al., 2020). A flexible cable connected each animals headcap
assembly to a commutator thus allowing the mouse to move freely during the recordings. Mice
were given at least 72 hours post-surgery to recover prior to being placed in a recording cage and
were acclimatized for at least 72 hours before recording initiation. Video-monitored EEG
recordings of awake and behaving mice were performed in custom-made Plexiglas cages using a
Stellate Harmonie acquisition interface (Natus Medical, Pleasanton, CA) and sampled at 200 Hz
in a 12-hour light/dark cycle with food and water provided ad libitum. As previously described
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(Mulcahey et al.), each mouse underwent video-EEG recording for at least 11 days across 8 wild
type mice, 7 R59X/+ mice, and 9 KO/+ mice. During this period, each mouse underwent a routine
cage cleaning each week at approximately 9:00-11:00 AM (lights out at 1:00 PM). Cage cleanings
alternated between “deep” cleans (mouse is removed from recording cage while recording cage
is cleaned) and “quick” cleans (mouse is lifted, a temporary floor is placed in the recording cage,
a clean floor and clean bedding are placed in the cage). In addition to cage cleanings, veterinary
staff checked each recording cage each morning before 11:00 AM. Veterinary staff only opened
the cages (1) if the mouse needed food or water or (2) if the mouse appeared unhealthy. At the
conclusion of video-EEG recording, the mice were removed from the recording apparatus.

Eight-channel EEG implantation surgery. Electroencephalographic mouse studies were
performed as previously described using 8 electrodes (hippocampal, bilateral parietal, bilateral
motor, bilateral visual electrodes) using the following coordinates (from Bregma – Bilateral motor:
0.5 mm Anterior-Posterior (A-P) and 1.0 mm medial-lateral (M-L); bilateral parietal: −0.7 mm A-P,
3.0 mm M-L; bilateral visual −3.5 A-P, 2.0 mm M-L; hippocampus: −2.2 mm A-P, 2.0 mm M-L,
and 1.7 mm ventral). (Marsh et al., 2009; Simonet et al., 2015). All experiments were conducted
in accordance with the approval of the Institutional Animal Care and Use Committee of the
Children’s Hospital of Philadelphia. After 24–48 h of recovery in their home cage the animals
were transferred to the monitoring cage and recorded using a 32- channel Intan extracellular
amplifier (RHD2000 USB Interface Board, Intan Technologies) using either DataWave software or
importing the raw data into Matlab. The recordings were sampled at 2000 Hz, with no on-line
filtering. Electrode impedances were tested prior to all recordings. All animals were recorded for
at least 72 h. Other than when being placed in the chambers or removed, mice were not handled
during the monitoring.

Statistical analyses. Similar sample sizes for all seizure monitoring across genotypes was
chosen. Statistical analyses were performed using Prism (GraphPad). All data sets were
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analyzed using the Shapiro-Wilk test for normality. All survival curves were compared using a logrank (Mantel-Cox) test to test for significance. All graphs are plotted using Prism (GraphPad). In
our figures, * is used to denote all 0.01<p<0.05, ** for 0.001<p<0.01, *** for 0.0001<p<0.001, and
**** for p<0.0001.
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Figures

Table 1. Modified Racine scale used for behavioral seizure scoring
Seizure
Stage
0
1
2
3
4
5

Behavioral Expression
No changes in behavior
Myoclonic jerks with sudden and repetitive
movement of the head and neck with or
without tail stiffening
Atypical (unilateral or incomplete) clonic
seizure
Clonic seizure with forelimb clonus and
rearing
Tonic-clonic seizure with an initial wild run and
subsequent loss of righting reflex
Tonic-clonic seizure with full extension of foreand hind-limbs
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Grouping
for analysis

Video
Example

Myoclonic

Suppl Video
1A-C, 6A-B, 8

Myoclonic

Suppl Video 2

Severe

Suppl Video
3A-C
Suppl Video
4A-C, 7
Suppl Video 5

Severe
Severe

Figure 1. Disturbance-associated seizure-like events in heterozygous CDD female mice.
(A) Percentage of Cdkl5R59X (R59X) mice and littermates demonstrating seizure-like events at 20,
30, and 40 weeks of age. Cdkl5R59X/+ (R59X/+): 12% at 20 weeks (n=31); 53% at 30 weeks
(n=28); 70% at 40 weeks (n=20). Cdkl5+/+ (+/+): 0% at 20 weeks (n=21); 0% at 30 weeks (n=19);
0% at 40 weeks (n=12). Cdkl5R59/y (R59X/y): 0% at 20 weeks (n=33); 0% at 30 weeks (n=24); 0%
at 40 weeks (n=10). Cdkl5+/y (+/y): 0% at 20 weeks (n=34); 0% at 30 weeks (n=22); 0% at 40
weeks (n=10). (B) Percentage of Cdkl5KO (KO) mice and littermates displaying seizure-like events
at 20, 30, and 40 weeks of age. Cdkl5KO/+ (KO/+): 8.57% at 20 weeks (n=35); 39.39% at 30
weeks (n=33); 65.22% at 40 weeks (n=23). Cdkl5+/+ (+/+): 0% at 20 weeks (n=34); 0% at 30
weeks (n=9); 0% at 40 weeks (n=5). Cdkl5KO/y (KO/y): 0% at 20 weeks (n=18); 0% at 30 weeks
(n=8); 0% at 40 weeks (n=5). Cdkl5+/y (+/y): 0% at 20 weeks (n=20); 0% at 30 weeks (n=8); 0% at
40 weeks (n=7). (C) Longevity of R59X/+ (gray, dotted line; n=123) and +/+ (black, solid line;
n=54) females. Mantel-Cox (log-rank) test, p=0.0007. (D) Longevity of R59X/y (gray, dotted line;
n=36) and +/y (black, dotted line; n=34) males. Mantel-Cox (log-rank) test, ns. *p<0.05, **p<0.01,
***p<0.001, and ****p<0.0001.
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Figure 2. Prevalence and severity of disturbance-associated seizure-like events in R59X/+
females increases with age.
(A) Percentage of Cdkl5R59X/+ (R59X/+) females presenting with any seizure-like event (Racine
Stages 1 to 5; black line) and percentage of R59X/+ females presenting with at least one severe
seizure-like event (Racine Stages 3 to 5; blue line) between 12 weeks to 45 weeks of age (n=20).
Median age of onset for second observed seizure-like event was 28 weeks; median age of onset
for severe seizure-like events was 47 weeks of age. (B) Percentage of R59X/+ females observed
having at least one seizure-like event (Racine Stages 1 to 5; black line) and percentage of
R59X/+ females observed having at least one severe seizure-like event (Racine Stages 3 to 5;
blue line) any given week between 12 to 52 weeks of age (n=25).
(C) Event record of 20 Cdkl5R59X/+ females observed from 12 weeks to 45 weeks of age. Gray: no
seizure-like events observed during that week. Blue: at least one myoclonic seizure-like event
(Racine Stages 1 to 2), but no severe seizure-like event, observed during that week. Black: at
least one severe seizure-like event (Racine Stages 3 to 5) observed during that week.
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Figure 3. Prevalence and severity of disturbance-associated seizure-like events in KO/+
females increases with age.
(A) Percentage of Cdkl5KO/+ (KO/+) females presenting with any seizure-like event (Racine
Stages 1 to 5; black line) and percentage of KO/+ females presenting with at least one severe
seizure-like event (Racine Stages 3 to 5; green line) between 12 weeks to 45 weeks of age
(n=10). (B) Percentage of KO/+ females observed having at least one seizure-like event (Racine
Stages 1 to 5; black line) and percentage of KO/+ females observed having at least one severe
seizure-like event (Racine Stages 3 to 5; green line) any given week between 12 to 50 weeks of
age (n>=10 at any given time point). Median age of onset for second observed seizure-like event
was 32 weeks; median age of onset for severe seizure-like events was 57 weeks of age. (C)
Event record of 17 KO/+ females observed from 12 weeks to 45 weeks of age. Gray: no seizurelike event observed during that week. Green: at least one myoclonic seizure-like event (Racine
Stages 1 to 2), but no severe seizure-like event, observed during that week. Black: at least one
severe seizure-like event (Racine Stages 3 to 5) observed during that week.
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Figure 4. Seizure-like events are confined to Cdkl5 heterozygous female knockout mice
and are independent of estrous cycle and parity.
(A) Estrous cycle stages of females displaying disturbance-associated seizures. Proestrus:
19.35% (n=6); estrous: 9.68% (n=3); metestrus: 29.03% (n=9); diestrus: 41.94% (n=13). (B)
Percentage of breeder (gray, dotted line; n=16) and nulligravid (black, solid line; n=23) R59X/+
females not exhibiting seizure-like events between 12 to 45 weeks of age. Mantel-Cox (log-rank
test), ns. (C) Percentage of R59X/+ females (gray, dotted line; n=16), R59X/R59X females (gray,
solid line; n=14), and +/+ females (black line; n=9) not exhibiting seizure-like events between 12
to 42 weeks of age. Mantel-Cox (log-rank) test, p<0.0001. *p<0.05, **p<0.01, ***p<0.001, and
****p<0.0001.
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Figure 5: Prevention of seizure phenotype in heterozygous Cdkl5 knockout female mice
with early gene restoration.
Survival curve demonstrating the latency to a second seizure-like event in all mice monitored,
plotted as percentage of mice without seizures. Cdkl5STOP/+ (STOP/+) heterozygous female mice
exhibit seizure-like events at a median age of 31 weeks. Tamoxifen delivery (and Cdkl5
expression restoration) at 12 weeks of age (before seizure onset) prevented the development of
seizure-like events in STOP/+; CreER/+ females, but not STOP/+; +/+ littermate controls. Creonly littermate controls exhibit no similar seizure-like events. This demonstrates the potential for
seizure prevention with early Cdkl5 expression restoration. n=7 CreER/+, n=12 STOP/+, n=14
STOP/+; CreER/+ where all mice received tamoxifen. Mantel-cox (log-rank) test, ****p<0.0001.
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Figure 6: Reversal of seizure phenotype in heterozygous Cdkl5 knockout female mice with
late gene restoration.
Cdkl5STOP/+ (STOP/+) and STOP/+; CreER/+ heterozygous female mice exhibit seizure-like
events by a median age of 28.5 weeks (prior to tamoxifen delivery). Tamoxifen delivery (and
Cdkl5 expression restoration) at 33 weeks of age (after seizure onset) abrogates the occurrence
of any subsequent seizure-like events in STOP/+; CreER/+ females, but not STOP/+; +/+
littermate controls, suggesting a rescued seizure phenotype. Top: survival curve demonstrating
latency to a second seizure-like event in all observed mice between 10-52 weeks of age. Bottom:
survival curve demonstrating latency to a second seizure-like event in all observed mice after
tamoxifen administration (33-52 weeks of age). This demonstrates the potential for seizure
phenotype rescue with Cdkl5 expression restoration even in mice that were previously displaying
seizures. n=8 STOP/+; n=20 STOP/+; CreER/+ where all mice received tamoxifen. Mantel-cox
(log-rank) test, ****p<0.0001.
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Figure 7: Reversal of seizure phenotype in heterozygous females of an independent Cdkl5
knockout mouse line with late gene restoration.
Cdkl5FLEX/+ (FLEX/+) and FLEX/+; CreER/+ heterozygous female mice exhibit seizure-like events
by a median age of 37 and 28.5 weeks, respectively (prior to tamoxifen delivery). Tamoxifen
delivery (and Cdkl5 expression restoration) at 33 weeks of age (after seizure onset) abrogates
the occurrence of any subsequent seizure-like events in FLEX/+; CreER/+ females, but not
FLEX/+; +/+ littermate controls, suggesting a rescued seizure phenotype. Top: survival curve
demonstrating latency to a second seizure-like event in all observed mice between 10-52 weeks
of age. Bottom: survival curve demonstrating latency to a second seizure-like event in all
observed mice after tamoxifen administration (33-52 weeks of age). This demonstrates the
potential for seizure phenotype rescue with Cdkl5 expression restoration in an independent
conditional rescue line, even in mice that were previously displaying seizures. n=6 CreER/+, n=9
FLEX/+, n=8 FLEX/+; CreER/+. All mice received TAM. Mantel-cox (log-rank) test, ****p<0.0001.
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Supplemental Videos
Supplemental Video 1. Disturbance-associated seizure-like events of Racine stage 1 in
Cdkl5R59X/+
(a) Cdkl5R59X/+ female at 70 weeks of age displaying a seizure-like event of Racine stage 1.
(b) Cdkl5R59X/+ female at 59 weeks of age displaying a seizure-like event of Racine stage 1.
(c) Cdkl5R59X/+ female at 26 weeks of age displaying a seizure-like event of Racine stage 1.
Supplemental Video 2. Disturbance-associated seizure-like event of Racine stage 2 in
Cdkl5R59X/+
Cdkl5R59X/+ female at 56 weeks of age displaying a seizure-like event of Racine stage 2.
Supplemental Video 3. Disturbance-associated seizure-like events of Racine stage 3 in
Cdkl5R59X/+
(a) Cdkl5R59X/+ female at 71 weeks of age displaying a seizure-like event of Racine stage 3.
(b) Cdkl5R59X/+ female at 63 weeks of age displaying a seizure-like event of Racine stage 3.
(c) Cdkl5R59X/+ female at 50 weeks of age displaying a seizure-like event of Racine stage 3.
Supplemental Video 4. Disturbance-associated seizure-like events of Racine stage 4 in
Cdkl5R59X/+
(a) Cdkl5R59X/+ female at 60 weeks of age displaying a seizure-like event of Racine stage 4.
(b) Cdkl5R59X/+ female at 71 weeks of age displaying a seizure-like event of Racine stage 4.
(c) Cdkl5R59X/+ female at 58 weeks of age displaying a seizure-like event of Racine stage 4.
Supplemental Video 5. Disturbance-associated seizure-like event of Racine stage 5 in
Cdkl5R59X/+
Cdkl5R59X/+ female at 26 weeks of age displaying a seizure-like event of Racine stage 5.
Supplemental Video 6. Spontaneous seizure-like events of Racine stage 1 in Cdkl5R59X/+
females
(a) Cdkl5R59X/+ female at 31 weeks of age with a Racine stage 1 seizure-like event.
(b) Cdkl5R59X/+ female at 31 weeks of age with a Racine stage 1 seizure-like event.
Supplemental Video 7. Spontaneous seizure-like event of Racine stage 4 in Cdkl5R59X/+
female
Cdkl5R59X/+ female at 43 weeks of age with a Racine stage 4 seizure-like event starting at 8:02:52
PM
Supplemental Video 8. Video-EEG recording of disturbance-associated seizure in
Cdkl5R59X/+
(a) Cdkl5R59X/+ female at 75 weeks of age displaying a Racine stage 1 seizure. Real-time playback
of a video-EEG recording clip demonstrating myoclonic jerks with time-locked EEG.
(b) Manual frame-by-frame viewing of the corresponding myoclonic event captured on video-EEG
in Supplemental Video 8A. Note that the onset of the behavioral spasm occurs immediately after
the onset of spike-wave activity.

171

CHAPTER 6 – EXTENDED DISCUSSION AND FUTURE DIRECTIONS

Cellular Origins of CDKL5 Deficiency Disorder-Related Phenotypes
The findings presented in Chapter 2 on Cdkl5 conditional knockout mice (Dlx-cKO)
complement a previous report characterizing behavioral and circuit phenotypes in Nex-cKO
animals(Tang et al., 2017). Together, these results demonstrate the behavioral segregation of
Cdkl5 constitutive knockout phenotypes between forebrain glutamatergic (Nex-cKO) and
GABAergic (Dlx-cKO) Cdkl5 conditional knockout mice, where impaired learning and memory is
selectively recapitulated in Nex-cKO mice and autistic-like features are selectively recapitulated in
Dlx-cKO mice. This suggests that CDKL5 is necessary in each of these forebrain neuronal
populations in order to development and/or maintain proper learning and memory and social
behaviors, respectively.
Interestingly, the anxiety-related behaviors, hyperactivity, and motor coordination deficits
reported in germline Cdkl5 knockout mice were not impaired in either Dlx- or Nex-cKO mouse
line(Tang et al., 2019; Tang et al., 2017). These phenotypes may be regulated by CDKL5 action
in cell types and/or brain regions not targeted by either NEX-Cre or Dlx5/6-Cre drivers.
Alternatively, their disruption may arise via a synergistic disruption across multiple cell types and
circuits upon loss of CDKL5 that cannot be modeled by conditional knockout. Either way, these
results present an interesting future avenue to further dissect the cell types and circuits
underlying these specific CDD-related phenotypes.
We also highlight aberrant NMDAR signaling as contributing to the autistic-like features of
Dlx-cKO animals, and selectively rescue these aberrant behaviors in constitutive knockout mice
using a competitive NMDAR antagonist, memantine(Tang et al., 2019). Together, these findings
emphasize the importance of further dissecting cell-type-specific functions of CDKL5 within the
heterogeneous brain, especially in regards to targeted therapies for the constellation of
phenotypes comorbid in CDD.
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Given that CDKL5 is a kinase, the identification of CDKL5 substrates and interacting
proteins remains key to illuminating the etiology of CDD. However, CDKL5 is expressed across
multiple heterogeneous circuits and cell-types, confounding the identification of reliable targets in
vivo(Zeisel et al., 2015). Furthermore, the difficulty to date in generating a specific antibody for
CDKL5 has impeded the visualization and sub-cellular localization of this kinase in the brain. To
bypass these confounds, we generated genetically modified mice wherein CDKL5 can be labeled
with biotin in a Cre-dependent manner for future molecular investigations into cell-type-specific
signaling targets.

Generation of CDKL5-TAVI knock-in mice for the investigation of CDKL5 molecular
targets and signaling pathways
As part of a future direction, we develop and characterize a novel genetic tool, CDKL5TAVI, that allows for cell-type-specific biotin tagging of CDKL5 in vivo. We inserted a short affinity
tag immediately upstream of the endogenous Cdkl5 stop codon, termed TAVI, which comprises a
TEV protease cleavage site and a 15 amino acid biotinylation consensus motif that can be posttranslationally labeled with biotin by Escherichia coli biotin ligase BirA (Figure 1a). To control
biotinylation of CDKL5 in a cell-type-specific manner, we crossed these mice to transgenic mice
carrying a conditional BirA allele (R26cBirA) that allows for Cre-dependent expression of BirA.
Upon crossing these mice to mice carrying a cell-type-specific Cre allele (e.g., NEX-Cre), we are
able to restrict BirA expression (and CDKL5 biotinylation) to select cell-types (Figure 1b).
We crossed our Cdkl5TAVI (hereafter referred to as CDKL5-TAVI) mice to mice carrying
the conditional BirA allele and NEX-Cre (Cdkl5Tavi/y; BirA/+; NEXCre). These mice carry CDKL5TAVI in every cell, but only NEX+ neurons will express Cre, and therefore have BirA-mediated
biotinylation of CDKL5. We confirmed this result in forebrain cortices of Cdkl5Tavi/y; BirA/+; NEXCre
mice, demonstrating selective biotinylation of CDKL5, but no biotinylation of CDKL5-TAVI in
Cdkl5Tavi/y; BirA/+; +/+ littermate controls or wild-type littermates (Figure 1c). The strong affinity
between biotin and avidin/streptavidin can be harnessed to visualize a biotin-tagged protein (e.g.,
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with streptavidin-conjugated antibodies), or to purify a biotin-tagged protein using streptavidinconjugated beads(Deal & Henikoff, 2010). We attempted the latter in order to evaluate the extent
to which our CDKL5-TAVI tool allowed for successful purification of CDKL5 in vivo. We
subsequently optimized a condition to successfully enrich biotinylated CDKL5 protein from brain
tissue extracts of Cdkl5Tavi/y; BirA/+; NEXCre mice via immunoprecipitation with streptavidinconjugated beads, but not Cdkl5Tavi/y; BirA/+; +/+ control littermate brain tissues (Figure 1d). The
details of this immunoprecipitation protocol are outlined in the ‘Materials and Methods’ section
below. In the future, this novel genetic tool can serve as an invaluable resource for cell-typespecific in vivo visualization of CDKL5, purification and identification of co-interactors, and sorting
of biotin-labeled cells for further proteomic or transcriptomic analyses. This advancement
provides the CDD and CDKL5 research community with a valuable tool for future dissection of
cell-type-specific CDKL5 interactomes and signaling cascades throughout the brain. This will be
particularly relevant when considering the cell-type-specific effects and overall efficacy of any
CDD-targeting drugs or therapeutics.

Synaptic Convergence of CDKL5 Loss-of-Function Phenotypes
Several studies to date have highlighted disrupted neuronal arborization and/or dendritic
spine stability with loss of CDKL5(Amendola et al., 2014; Della Sala et al., 2016; Lupori L, 2019;
Okuda et al., 2018; Ricciardi et al., 2012; Tang et al., 2017; Zhu et al., 2013). The direct impact of
CDKL5 loss on pyramidal neuron morphology has been contentious, likely due to contextdependent variability and confounds of mixing cell and non-cell autonomous cellular effects.
Interestingly, we find that adult deletion of Cdkl5 can lead to similar behavioral deficits without
concomitant effects on neuronal morphology or dendritic arborization, bringing into question the
necessity of these reported arborization phenotypes to CDD-related behavioral deficits.
Alternatively, we find that both post-developmental and sparse deletion of CDKL5 in mice
increased dendritic filipodia-like structures suggestive of a morphologically immature spine state
that, when combined with the absence of changes in overall spine density, reflects a greater
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proportion of morphologically immature spines on hippocampal CA1 pyramidal neurons(Harris
KM, 1989).
These findings are in line with the observation that CDKL5 is responsible for the
phosphorylation of EB2, a member of the microtubule end-binding protein family. End-binding
proteins are plus-end-tracking proteins that accumulate at the growing microtubule end, and play
pivotal roles in microtubule dynamics that mediate cellular architecture, cargo trafficking, and
spine stability(Akhmanova & Steinmetz, 2015; Komarova et al., 2009). In Chapter 3, we
demonstrate that EB2 phosphorylation is developmentally regulated and correlates with the
expression pattern of CDKL5. The known roles of end-binding proteins in microtubule dynamics
align with the cellular and synaptic phenotypes we report upon loss of CDKL5 in mice (e.g.,
disrupted NMDA receptor subunit trafficking and spine morphology). Importantly, we also
demonstrate that restoration of Cdkl5 expression in adulthood is capable of restoring EB2
phosphorylation to wild-type levels (Chapter 4), highlighting the dynamic regulation by CDKL5 of
this microtubule-associated substrate. Thus, CDKL5 may play a role in regulating microtubule
dynamics, particularly those related to spine morphology and receptor trafficking at the postsynaptic density, via its continual regulation of microtubule-associated proteins such as EB2. An
EB2-related family member, EB3, has previously been implicated in regulating dendritic spine
morphology within hippocampal neurons(Leterrier et al., 2011). However, the extent to which
CDKL5-mediated phosphorylation of EB2 may play similar roles remains undetermined.
Interestingly, it has been reported that EB2 suppresses neurite outgrowth and attenuates the
microtubule growth mediated by EB1 activity, but how phosphorylation of EB2 at Ser222
specifically modulates this action is untested(Laketa, Simpson, Bechtel, Wiemann, & Pepperkok,
2006).
We also demonstrate that CDKL5 plays a critical role in maintaining the post-synaptic
composition of NMDA receptor subunits, namely GluN2B. During development, the canonical
switch from predominantly GluN2B-containing to predominantly GluN2A-containing NMDA
receptors across the CNS is thought to be a regulatory mechanism involved in shaping circuits
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and constraining synaptic plasticity during the critical period of synaptogenesis for several brain
regions(Paoletti et al., 2013). Interestingly, the peak expression of CDKL5 in mouse forebrain
appears to coincide with this subunit composition switch during a time window also associated
with circuit refinement and acquisition of learning abilities. Loss of CDKL5 may therefore result in
an elongated or unconstrained critical period that ultimately leads to maladaptive plasticity across
multiple neural circuits and the subsequent heterogeneous collection of symptomology
associated with CDD(H. E. Olson et al., 2019). Surprisingly, post-developmental restoration of
CDKL5 expression reverses this elevation of GluN2B expression and NMDA hyperexcitability
phenotype observed in germline knockout mice, arguing that CDKL5 may persistently regulate
NMDA receptor composition beyond the early stages of development. Interestingly, CDKL5 has
been reported to target EB2 pS222 via an NMDAR-dependent mechanism, providing a potential
link between disrupted NMDAR signaling, microtubule dynamics, and CDKL5 loss-of-function
phenotypes(Lucas L. Baltussen et al., 2018). Nonetheless, the causal relationship among the
molecular, cellular, and behavioral domains examined in this study requires further examination.

Temporal Dissection of CDKL5 Deficiency Disorder Pathophysiology
Several mouse models of CDD have been characterized to date, and although they
recapitulate many of the hallmark phenotypes of the human disorder, it remained unclear whether
these phenotypes were a consequence of detrimental changes exclusively accumulating in the
developing nervous system or are similarly inducible upon loss of CDKL5 in mature neurons.
Furthermore, from a therapeutic perspective, it remained imperative to determine the reversibility
of CDD-related deficits particularly after the early stage of brain development, and to delineate
the temporal requirement of CDKL5 action needed to establish as well as maintain proper
neurological function. Prior to this dissertation, it remained unknown if CDD symptomology was
treatable and whether a critical developmental time window was required for treatment. Our
temporal knockout and temporal rescue experiments highlighted in Chapters 3-4 address these
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questions, and constitute a seminal foundation for future endeavors to dissect the pathogenic
origins and design effective therapeutic strategies for CDD.
Our findings demonstrate that multiple behavioral and circuit phenotypes in knockout
mouse models of CDD are recapitulated following adult deletion of Cdkl5. In parallel, postdevelopmental restoration of Cdkl5 expression ameliorates most of these loss-of-function deficits
in mice, suggesting that the underlying circuitry critical for many of the behavioral domains
disrupted upon loss of CDKL5 are amenable to later kinase restoration. Thus, CDKL5 appears to
be required not only during development, but also in adulthood, suggesting that chronic, lifelong
treatment of CDD will likely be required.
Notably, working memory, as measured via spontaneous alternations in a Y-Maze assay,
was not significantly affected by adult loss or restoration of CDKL5 expression, demonstrating
that CDKL5 does function critically in early development. It remains relevant to dissect the
emergence of this working memory phenotype in developing animals, and to examine the circuit
and cellular mechanisms that drive its perturbation early in life. In parallel, adult knockout of Cdkl5
resulted in significantly enhanced motor learning in contrast to the impaired motor learning and
coordination reported in germline knockout animals. How loss of CDKL5 in adulthood leads to
improved motor coordination and learning remains uncertain, but also represents an interesting
future avenue to investigate temporally-distinct influences of CDKL5 loss on the same behavioral
output.
Through genetic manipulation of endogenous Cdkl5 expression in a temporal manner, we
uncover for the first time that CDKL5 is required to maintain proper spine morphology, sensoryinformation processing, and behavioral output in the adult brain. Consistent with this, postdevelopmental restoration of Cdkl5 expression is sufficient to ameliorate NMDAR-related synaptic
deficits, and leads to significant reversal of multiple behavioral domains related to CDD. Together,
our findings highlight the promise of disease reversal in CDD across a broader than expected
time window, and present an exciting and pressing development for therapeutic treatment of
CDD.

177

Therapeutic Insights for CDKL5 Deficiency Disorder
Previous studies have applied the concept of late gene reversal in rodents to attempt
phenotypic rescue in various models of neurodevelopmental disorders(Creson et al., 2019; Guy
et al., 2007; Y. Mei et al., 2016). Late restoration of Mecp2 expression in knockout mice has been
reported to alleviate impairments associated with Rett syndrome, and adult restoration of Shank3
is capable of rescuing selective autistic-like phenotypes(Guy et al., 2007; Y. Mei et al., 2016).
Meanwhile, a recent finding reported that adult restoration of the SynGAP protein selectively
improved electrophysiological measures of memory and seizures(Creson et al., 2019). CDD,
however, is distinct from these and other autism spectrum and neurodevelopmental disorders in
that it is characterized by early-onset features within the first few weeks after birth as opposed to
a developmental regression after the first few years of life(Ozonoff, Heung, Byrd, Hansen, &
Hertz-Picciotto, 2008; Zoghbi & Bear, 2012). Thus, our temporal reversal findings provide a novel
development over these previous studies, and demonstrate the potential for treatment of
neurological symptoms despite the lack of a relatively stable early-postnatal period. We also
found that post-developmental restoration of Cdkl5 expression significantly ameliorated multiple
behavioral deficits related to CDD, rather than a few behavioral domains as was reported in
previous reversal studies, arguing a uniquely critical role for CDKL5 in the maintenance of various
neurological functions throughout life.
Surprisingly, we observed that a relatively rapid reversal of Cdkl5 expression led to
significant lethality in rescue mice, in line with previous findings from a Mecp2 re-expression
study(Guy et al., 2007). As with MeCP2, a gradual restoration of CDKL5 expression alleviated
this lethality issue, and resulted in significant phenotypic reversal. Thus, the time course and
dosage of CDKL5 re-introduction need to be carefully considered in future gene replacement
trials to avoid contravening outcomes, particularly in a system that may have partially
compensated for its loss(Benke & Kind, 2020). Additionally, post-hoc examination of CDKL5
restoration revealed that several rescue mice showed only 20-50% of wild-type protein
expression. The rescue of numerous behavioral domains in these mice underscores the potential
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that even partial restoration of CDKL5 expression may show notable therapeutic benefit, at least
in mice.
We acknowledge that many of our findings are limited to studies in male mice in order to
avoid potential confounding effects of mosaic Cdkl5 expression in females from random Xchromosome inactivation. However, our preliminary behavioral rescue data in heterozygous
Cdkl5 knockout female mice (Chapter 4) presents a promising outlook for the reversal of
additional CDD-related cellular and circuit deficits in female models. In the future, it will be
necessary to extend these experiments to heterozygous female mouse models of CDD,
determine the minimum and maximum levels of CDKL5 expression required for safe phenotypic
reversal, and define the latest time window allowable for rescue, at least in mouse models(Benke
& Kind, 2020). Finally, the potential for seizure mitigation with Cdkl5 re-expression also highlights
promising outcomes for seizure management and phenotypic reversal for the pervasive epilepsy
in CDD.

Materials and Methods
Regulatory approval. Experiments were conducted in accordance with the ethical guidelines of
the National Institutes of Health and with the approval of the Institutional Animal Care and Use
Committee of the University of Pennsylvania. Mice were group-housed in cages of two to five in a
twelve-hour light/dark cycle with food and water provided ad libitum.

Mouse strains and genotyping. Cdkl5TAVI mice were generated using CRISPR-mediated
genomic editing techniques. A specific gRNA was chosen upon screening for targeting specificity
and efficacy just upstream of the Cdkl5 stop codon. The DNA repairing template constituted a
TAVI sequence containing a TEV protease cleavage site and a 15 amino acid biotinylation
consensus sequence (ENLYFQGLNDIFEAQKIEWHE), flanked by 100bp of DNA as the 5’
homologous arm and 100bp of DNA as the 3’ homologous arm. Synthesized gRNA, single strand
DNA repairing template, as well as Cas9 mRNA were co-injected into a one-cell zygote of
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C57BL/6 background to allow for homology-directed repair, followed by implantation. PCR
primers specific to the 5’ and 3’ integration sites flanking the gRNA sequence at the 3’ end of the
Cdkl5 locus were used to screen for positively targeted pups. Southern blotting was finally
conducted to confirm the correct targeting of the F1 generation, followed by establishment
a CDKL5-TAVI colony in a C57BL/6J genetic background.
R26cBirA (BirA) mice were generated as previously described, and Nex-Cre mice (RRID:
MGI: 4429523), generously shared by Klaus-Armin Nave (Max Planck Institute of Experimental
Medicine, Göttingen, Germany) and Lazzerini Denchi (The Scripps Research Institute)(Goebbels
et al., 2006; Johnson et al., 2017). All lines have been maintained in the C57BL/6J background.
Experimental cohorts were all weaned at 3 weeks of age and littermates housed
together. Mice were genotyped using a qPCR based strategy optimized by Transnetyx.

Brain microdissection. To assess protein expression in various brain regions, adult male mice
were sacrificed by cervical dislocation. After decapitation, brains were removed and sectioned
into 1mm coronal slices using a mouse brain matrix. Tissue was dissected from the
somatosensory cortex, striatum, hippocampus, and cerebellum and homogenized in RIPA lysis
buffer (150mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate [DOC], 0.1% sodium dodecyl
sulfate [SDS], 25mM Tris [pH7.4] with protease inhibitors [Roche, cOmplete, EDTA-free protease
inhibitor cocktail tablets; 5056489001]). To prepare protein extracts, homogenized lysates were
incubated on ice for 15 min, and then centrifuged at 21,000 x g for 15min at 4°C. The supernatant
fraction was removed and sonicated using a Biorupter for 3 alternating session at max frequency
for 15 sec, each followed by a 60 sec cooldown period. The lysate was then centrifuged at 21,000
x g for 15min at 4°C, and the top aqueous layer carefully removed and collected as the total
protein fraction.

Streptavidin-Mediated Pull-Down. Brain tissue lysates were prepared as described above.
500μg of protein lysate was utilized for each pull-down reaction, with 10% of the lysate collected
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prior to streptavidin treatment as an “input” loading control. Protein lysates were incubated with
70μL streptavidin-conjugated magnetic beads (Dynabeads M-280 Streptavidin; Invitrogen
11205D) for 1hr at 4°C while rotating. Magnetic beads were separated away from the remaining
lysate using a DynaMag-2™ rack (Invitrogen; 12321D), and 20μL of remaining lysate collected as
“flow-through.” The lysate was then discarded and the beads subsequently washed 4X with 1%
NP-40 in 150mM NaCl wash buffer. Beads were resuspended in the appropriate amount of LDS
Sample buffer and β-mercaptoethanol, and then heat denatured at 90°C for 15min.

Western blot. Protein concentration was measured using a Bradford assay. Purified synaptic
density membrane proteins or protein lysates were prepared for gel electrophoresis by adding 4X
LDS Sample Buffer (NuPAGE, NP0008) to a final concentration of 1X and β-mercaptoethanol to
a final concentration of 5%. Samples were heat-denatured at 75°C for 20 min, and 7.5µg or 25 µg
of protein was loaded into each well of a 4–12% Bis-Tris gradient gel (Invitrogen, 10-well, 1.5mm;
NP0335) for PSD protein or brain lysate quantification, respectively. Protein gels were run for 2hr
at 125V at room temperature on a XCell SureLock mini-cell electrophoresis box (ThermoFisher;
EI001) using a PowerPac HC High-Current Power Supply (BioRad; 1645052), then transferred
onto a polyvinylidene fluoride (PVDF) membrane (0.45µm pore-size; Biorad 162–0115) at 27V for
1hr and 10min at room temperature. The resulting membrane was blocked with a 1:1 solution of
Odyssey blocking buffer (LICOR; 927-40100) and 1X PBS for 1hr at room temperature.
Primary antibodies used were rabbit anti-N-terminal CDKL5 (in house; diluted 1:500),
rabbit anti-BirA consensus sequence (Abcam; ab1400; diluted 1:1,000), and mouse anti-β-Actin
(Abcam; ab8226; diluted 1:10,000). A streptavidin-conjugated fluorophore, IRDye 680RD
Streptavidin (LI-COR; 926-68079; diluted 1:1,000), was utilized for visualization of biotinylated
proteins. Secondary antibodies (LI-COR) used were goat anti-rabbit IgG IRDye800CW and rabbit
anti-mouse IgG IRDye680LT, all incubated for 50min at room temperature at dilutions of
1:10,000. Standard protocols were used for the Odyssey Infrared Imaging System (LI-COR) for
protein visualization and quantification.
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Figure 1. Generation and characterization of CDKL5-TAVI mice.
(a) Diagram of Tavi-tagged CDKL5 showing the kinase domain and amino acid sequence of the
TAVI tag (TEV protease cleavage site plus biotinylation consensus sequence). (b) Breeding
strategy to biotinylated the TAVI tag in a Cre-dependent manner. (c) Representative western
blots showing the conditions in which the TAVI tag is biotinylated using whole-brain tissue lysates
from male mice. Top left: Blot was probed with antibody to the CDKL5 N-terminus, highlighting
the presence of CDKL5 in both wild-type and CDKL5-TAVI tissues; Top right: Blot was probed
with streptavidin for detection of biotinylated proteins, demonstrating a biotinylated CDKL5
product only in CDKL5-TAVI; BirA/+; Cre mice (asterisk denotes endogenous biotinylated
products detectable from brain lysate at 75kDa and 150kDa). Bottom: overlay of CDKL5 antibody
(green) and streptavidin (red) staining demonstrating the overlap of biotinylated CDKL5 product.
(d) Representative western blot demonstrating the enrichment of CDKL5 protein from mouse
brain tissues using streptavidin-coated beads in CDKL5-TAVI; BirA* mice, but not BirA*-only
mice.
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